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Abstract 
 
 Age-related macular degeneration (AMD) is the leading cause of blindness 
amongst the Western population, with an annual cost of 350 billion dollars worldwide. 
This disease affects a specialised region in the central retina, the macula, where 
photoreceptors and the retinal pigment epithelium (RPE) cells begin to degenerate upon the 
onset of AMD. In the more prevalent atrophic or ‘dry’ form of AMD, gradual 
photoreceptor and RPE cell death leads to the formation of an expanding retinal lesion, 
which causes irreversible blindness over time. Although AMD pathogenesis involves 
multiple genetic and environmental factors, it is well understood that inflammation is 
highly implicated in disease progression. The recruitment of retinal microglia and 
macrophages, the production of cytokines and chemokines, and the deposition of 
complement system components are key features of atrophic AMD. 
 This thesis identifies retinal microglia and macrophages as therapeutic targets for 
slowing the progression of retinal degenerations such as AMD. In these studies, a rodent 
model of photo-oxidative damage is used, which recapitulates features of atrophic AMD 
including oxidative stress, inflammation and photoreceptor cell loss. This thesis first 
provides a further understanding of the role of microglia and macrophages in contributing 
to chronic complement activation and photoreceptor death in the degenerating retina. It is 
shown that locally-derived complement component 3 (C3) is a major contributor to the 
progression of retinal degeneration, and that microglia and macrophages are the primary 
source of retinal C3, in both rodent retinal degeneration and human AMD.  
 The recruitment of microglia and macrophages in retinal diseases is caused by 
increased chemokine signalling. It is demonstrated in this thesis that the use of a broad 
spectrum chemokine inhibitor (NR58-3.14.3) is able to ameliorate the accumulation of 
vi 
 
microglia and macrophages in the outer retina, protecting the photoreceptors from further 
damage. Finally, it is shown that interleukin-1β (IL-1β), a strong pro-inflammatory 
cytokine, is primarily produced by microglia and macrophages in retinal degeneration. 
Using therapeutic strategies to neutralise or inhibit IL-1β signalling, it is found that there is 
a decrease in both macrophage recruitment and photoreceptor loss. Collectively, these 
three studies implicate a major role for retinal microglia and macrophages in contributing 
to pro-inflammatory cytokine production and complement synthesis. This thesis 
demonstrates the therapeutic value of targeting microglia and macrophages as a strategy 
for reducing inflammation and photoreceptor loss in retinal degenerations including AMD. 
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1. INTRODUCTION
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1.1. General Introduction 
 Age-related macular degeneration (AMD) is a disease of the neural retina, which 
includes the light-sensitive photoreceptors that transduce light into electrical signals, which 
can be interpreted by the brain. With the onset of AMD, photoreceptors in a localised 
region of the retina begin to degenerate and a lesion develops. This form of retinal 
degeneration is the leading cause of blindness, costing the Australian economy 5 billion 
dollars and the global economy 350 billion dollars annually [1, 2]. Although the aetiology 
of AMD involves multiple genetic and environmental factors, it is well-established that 
dysregulation of the innate immune system is highly implicated in the pathogenesis of this 
disease [3]. A key feature of AMD is the activation and recruitment of resident microglia 
and blood-borne macrophages to the site of degeneration, which are associated with 
photoreceptor loss and further progression of the disease [4, 5]. 
 In this chapter, I will provide an overview of the current understanding of the 
pathogenesis of AMD, and will introduce the immunological aspects of AMD progression, 
including the role of chemokines. I will also highlight the use of therapeutic molecules that 
target the innate immune system as a strategy for slowing the progression of retinal 
degenerative diseases such as AMD. 
 
1.2. The eye and retina 
1.2.1. The eye – gateway to vision 
Most people, when questioned, regard vision as being the most important of their 
special senses. The eye (Figure 1.1) comprises an outer protective layer, the sclera, which 
together with the transparent cornea at the anterior surface, form a continuous external  
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Figure 1.1. Anatomy of the eye and retina (adapted from Kolb, 1995 [6]). Light passes 
through the pupil of the eye and is focused onto the retina, a multi-layered structure at the 
posterior of the eye. The photoreceptors are contained in the outer nuclear layer (ONL). 
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barrier around the globe [6]. Internally there is an anterior and a posterior chamber. Light 
passes through the anterior chamber and into the eye through the pupil, the size of which is 
adjusted by the iris, to allow more or less light to enter the eye. The lens focuses the light 
onto the retina, a sensory structure that lines the posterior surface of the eye. The light 
passes through the vitreous chamber, is absorbed by opsins in the photoreceptor outer 
segments, and is transduced into electrical signals. Photoreceptors feed this signal via the 
bipolar cells, to ganglion cells whose axons project to the brain via the optic nerve [6, 7].  
1.2.2. Organisation of the retina 
The human retina is made up of ten distinct layers which differ in both structure 
and function [8]. The inner retina consists of the inner limiting membrane (ILM), nerve 
fibre layer (NFL), ganglion cell layer (GCL), inner plexiform layer (IPL), inner nuclear 
layer (INL), and outer plexiform layer (OPL). The INL houses multiple cell types 
including bipolar cells, amacrine cells and horizontal cells, as well as the Müller cell 
bodies [8]. Müller cells are radial glial cells that span the whole retina providing structural 
support [9]. They also functionally support neurons by recycling neurotransmitters, and 
promote the survival of photoreceptors through a range of homeostatic signalling 
mechanisms to control neuronal activity, metabolism and outer segment recycling 
(reviewed in [9-12]). Müller cells also function as ‘light guides’, directly contributing to 
vision [13]. Upon retinal injury, Müller cells can undergo gliosis and proliferation to fill 
gaps in the photoreceptor layer [10, 14, 15], and may even proliferate to generate retinal 
neurons [16, 17] and photoreceptors [18, 19]. 
The outer retina is made up of the outer nuclear layer (ONL), the outer limiting 
membrane (OLM), and the inner and outer segments (IS and OS) of the photoreceptors in 
the sub-retinal space [8]. A monolayer of retinal pigment epithelium (RPE) cells - which 
are part of the neural retina - form the outer blood-retinal barrier (BRB), between the retina 
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and the underlying Bruch’s membrane. Transporters and tight junctions of the RPE cells 
allow for the selective movement of ions, proteins and water in and out of the retina, whilst 
maintaining the immune privilege of the eye by inhibiting the passage of immune cells into 
the retina [20, 21]. The choroid is a network of blood vessels under the Bruch’s membrane 
which delivers nutrients and oxygen to the outer retina, and removes waste and heat from 
the retina [22].  
1.2.3. Photoreceptors 
 Photoreceptors are made up of three major parts: cell bodies which make up the 
ONL, inner segments (IS), which act as the powerhouse for the photoreceptors, and outer 
segments (OS), which contain one of four different light-sensitive opsins (in humans) that 
absorb light of specific frequencies to provide for phototransduction [6, 23]. There are two 
types of photoreceptor cells: rods and cones. The outer segments of rod cells comprise 
membranous disks of opsin and retinal, which combine to form rhodopsin. Rods are very 
light sensitive, and are useful only in dim light conditions. Cone photoreceptors contain 
one of three different opsins which combine with retinal to form cone opsins, having a 
particular range of spectral sensitivities (short, medium and long wavelengths) that both 
broadens the range of visible frequencies as well as allows for the processing of ‘colour-
coded’ signals, and colour vision. Cone opsins do not saturate in bright light, and mediate 
virtually all of our useful vision [6, 23]. 
The human retina comprises approximately 120 million rods and 6 million cones 
[24]. Cones are dominant in the macular region of the retina, the centre of the visual field. 
Cones, but not rods, provide input into retinal circuits which are highly adapted to extract 
information that provides for high spatial resolution (acuity) as well as colour. The fovea 
centralis within the macula is a rod-free and vessel-free area where light scattering is 
minimal, allowing for the maximum amount of light to be absorbed by the cones [6]. 
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However, most likely due to the unique and highly specialised design and 
microenvironment of the macula, where blood supply is limited and there is high density of 
oxygen-demanding photoreceptors, the macula is subject to degeneration over time [25]. 
 
1.3. Degeneration of the retina 
1.3.1. Ageing and retinal disease 
Tissue homeostasis is a key element to preserving the health of the retina. Under 
basal conditions, the immune system in the retina can maintain homeostasis, and low levels 
of tissue stress are regulated by the microglia, the resident immune cells of the retina [5]. 
However, constant exposure to noxious conditions, such as overload with reactive oxygen 
species (ROS) over time may lead to chronic tissue stress, in which para-inflammation may 
occur [26]. Para-inflammation is an intermediate inflammatory response that returns the 
stress levels in the retina back to homeostasis [27]. If para-inflammation persists, such as in 
ageing, this may result in release of pro-inflammatory cytokines, that can propagate a full 
inflammatory response [26]. Ageing is defined as the accumulation of temporal changes 
that increase susceptibility to disease with increasing lifespan [28]. Para-inflammation in 
ageing can contribute to the onset of many retinal degenerative diseases later in life, 
including diabetic retinopathy, glaucoma and age-related macular degeneration (AMD) 
[26]. Onset and progression of retinal degenerative diseases including AMD, glaucoma, 
retinitis pigmentosa, diabetic retinopathy and retinal detachment share several features in 
common, including increases in both oxidative stress and inflammation [8, 29-31]. 
1.3.2. Age-related macular degeneration 
Age-related macular degeneration (AMD) is the leading cause of blindness in the 
Western World, primarily affecting the population aged over 65, with the projected number 
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of people with the disease estimated to be 288 million worldwide by 2040 [32]. AMD 
poses a significant economic burden, with an annual global cost of 350 billion dollars for 
the treatment and healthcare of visually impaired patients [2]. Early/intermediate AMD is 
clinically diagnosed by the presence of drusen surrounding the macular region (Figure 1.2). 
Drusen are yellow deposits of debris that form between the RPE and Bruch’s membrane 
[33, 34]. The presence of drusen, which may coalesce over time, can lead to the 
degeneration of RPE cells overlaying the drusen deposits [35, 36]. At this stage, the 
photoreceptor layer is still largely intact, and there is an absence of neovascularisation. 
There are two types of late-stage AMD (Figure 1.2). Neovascular or “wet” AMD, 
accounts for 10% of all cases, and can lead to sudden loss of vision due to choroidal 
neovascularisation (CNV). In wet AMD, new blood vessels derived from the choroid enter 
the subretinal space near the photoreceptors. Prolonged leakage of blood, serum and lipids 
into the outer retina from these fenestrated, or non-barriered blood vessels disrupts 
photoreceptor alignment and alters the neural microenvironment, promoting Müller cell 
gliosis, scarring and visual impairment [34, 37].  
Atrophic or “dry” late-stage AMD is characterised by the emergence of geographic 
atrophy (GA), in which a lesion in the RPE, photoreceptors and choriocapillaris of the 
macula develops and progressively expands over time [34]. This is in part due to drusen 
deposition around the macula, which may cause the degeneration of RPE and 
photoreceptor cells in these areas, leading to the development of a focal outer retinal lesion 
[38]. This atrophy is usually accompanied by reduced blood flow in the choroid and 
thinning of the choriocapillaris [39, 40]. The progressive loss of outer retinal cells and the 
expansion of the atrophic lesion results in a large drop in visual function in patients with 
the disease [41]. Development of a two millimetre lesion in the foveal region can result in 
legal blindness [25].  
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Figure 1.2. The pathogenesis of AMD (from Ambati et al. 2013 [3]). There are two forms 
of late-stage AMD that can develop from early or intermediate dry AMD; geographic 
atrophy (dry AMD), where photoreceptors and RPE deteriorate, and neovascular AMD 
(wet AMD), where the growth of new blood vessels can cause oedema and cell death. 
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1.3.3. Pathogenesis of AMD 
 The pathogenesis of AMD is multifactorial and the precise causes of onset and 
progression of this disease remain unclear. However, several factors are strongly 
implicated in increasing the risk of developing AMD, including a range of genetic and 
environmental factors [34, 42]. Advancing age remains the highest risk factor for all forms 
of the disease [43-46]. Genetic predispositions regarding the immune system are heavily 
linked to the development of the disease, especially the dysregulation of complement 
system genes, which strongly increases the risk of developing AMD [47, 48]. There is 
some evidence suggesting that autoimmunity may also contribute to the progression of the 
disease, as autoantibodies have been detected in the blood of AMD patients [49, 50].  
A key component of AMD onset and progression has been linked to mechanisms 
that cause oxidative stress and retinal damage, which can be initiated by a number of 
environmental factors [29, 30]. The retina is subject to oxidative stress over time, due to 
the generation of ROS from high light exposure and oxygen consumption, as well as the 
continual inhibitory mechanisms of the RPE against immune cells in the choroid [22, 51, 
52]. Environmental factors including cigarette smoking [45, 53-56] and systemic 
hypertension [57, 58] have also been linked to the prevalence of AMD.  
Additionally, photo-oxidative damage resulting from excessive exposure to light 
causes lipid peroxidation of the outer segments, and may be a factor in AMD pathogenesis 
[59]. Continual phagocytic activity of the RPE cells generate lipofuscins, which are 
pigment granules containing remnants of lysosomal digestion [60]. Lipofuscin 
accumulation in the RPE is also thought to cause RPE cell degeneration and photoreceptor 
loss adjacent to the degenerating RPE [61].  
Analysis of drusen composition has identified over 100 different proteins [62], 
many of which were covalently cross-linked with carboxyethylpyrrole (CEP), a by-product 
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of docosahexaenoic acid (DHA) oxidation, in which fragmentation occurs under oxidative 
stress conditions [63]. The generation and accumulation of CEP-adducted proteins in the 
outer retina is heavily implicated in the pathogenesis of AMD [64, 65]. Another oxidative 
stress by-product found in drusen is malondialdehyde (MDA), produced through the 
oxidation of phosphatidylcholine [66]. MDA is known to interact with complement factor 
H (CFH), a critical regulator of the complement system [67]. Induction of the innate 
immune system following oxidative stress is known to contribute to the progression of 
AMD [68-70]. 
Although there are a wide range of factors that may contribute to AMD 
pathogenesis, the significance of immunological processes in AMD has been well 
established. Dysregulation of the immune system is critically linked to the development of 
geographic atrophy, including the recruitment of activated resident microglia to the outer 
retina, and the persistent accumulation of subretinal macrophages [4, 5, 71-75]. Under 
normal conditions, the eye has an ocular immune privilege, and is protected from 
inflammation by separation from the choroidal vasculature by the BRB, as well as through 
the production of immune system inhibitors in the eye [76, 77]. However, once damage 
occurs to the RPE and photoreceptors in retinal diseases such as AMD, the BRB is 
breached which may remove this immune privilege and allow inflammation to occur [31]. 
 
1.4. Inflammation and AMD 
1.4.1. Cytokine production in AMD 
 Cytokines are a large family of inflammatory molecules that are involved in many 
aspects of both the innate and adaptive immune system, including leukocyte activation and 
recruitment, antigen presentation, bone marrow differentiation and adhesion molecule 
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expression [78]. Cytokines can be classified as either pro-inflammatory (e.g. tumour 
necrosis factor (TNF), interleukin-1 (IL-1), IL-6, IL-12) or anti-inflammatory (e.g. IL-4, 
IL-10, IL-13) [79]. A specialised sub-group of cytokines that are primarily involved in 
leukocyte migration are the chemokines, a group of small chemoattractant molecules that 
form chemotactic gradients for the activation and recruitment of leukocytes expressing the 
appropriate chemokine receptors [80]. Chemokines and their receptors are classified into 
four sub-groups depending on their characteristic cysteine motifs; C (γ chemokines), CC (α 
chemokines), CXC (β chemokines) and CXC3 (δ chemokines) [81]. In the central nervous 
system, chemokines are produced by neurons, astrocytes and microglial cells at lower 
levels [82]. Upon activation of stress or inflammatory signalling pathways, higher levels of 
chemokines are expressed, leading to recruitment of blood-borne leukocytes to areas of 
damage [81]. These leukocytes are primarily monocytes (precursors of macrophages), 
neutrophils, lymphocytes and eosinophils [83].  
 In AMD, chemokines attract leukocytes to areas of outer retinal tissue damage [84]. 
A genome-wide association study (GWAS), involving 68 human donor eyes from normal 
and AMD patients, demonstrated that several chemokines involved in leukocyte 
recruitment (CCL2, CXCL1 and CXCL10) were upregulated in both wet and dry AMD 
eyes [47]. Studies involving animal models of retinal degeneration have demonstrated that 
expression of Ccl2, Cxcl1 and Cxcl10 is coordinated by RPE and Müller cells to activate 
resident microglia and recruit blood-borne macrophages to the degenerating retina [85-87]. 
In addition, it has been shown that culturing RPE and Müller cells with lipopolysaccharide 
(LPS)-stimulated microglia can induce the expression of Ccl2 and Il-6, indicating that 
prolonged chemokine expression may occur through the continual expression of 
chemokines by these retinal cells [86, 88]. Upregulation of a suite of chemokines and pro-
inflammatory cytokines, which includes CCL2 [85, 89-92], CCL3 [93, 94], CCL4 [95] and 
IL-6 [96, 97] are strongly implicated in the progression of retinal diseases. 
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 Interleukin-1β (IL-1β) is a pro-inflammatory cytokine primarily produced through 
the activation of the inflammasome [98, 99]. The inflammasome is an oligomer protein 
complex that leads to the maturation and secretion of IL-1β and IL-18 into the extracellular 
environment [100]. The assembly and activation of the inflammasome is stimulated by 
several mechanisms, including toll-like receptor signalling and purinergic receptor 
signalling, the latter which is activated by extracellular ATP released by dying cells [100, 
101]. Although inflammasome signalling is thought to play both detrimental and protective 
roles in atrophic and neovascular AMD due to the production of IL-18 [102-109], the 
synthesis of mature IL-1β is known to be involved in the pathogenesis of central nervous 
system (CNS) diseases [110], including both forms of AMD [111, 112]. This has also been 
supported in several studies involving animal models of retinal degenerations, 
demonstrating that IL-1β is secreted by activated microglia [113-117]. 
1.4.2. Microglia and macrophages in AMD 
 Microglia are the resident immune cells of the CNS, existing in a ramified immune 
surveillance state in the normal brain and retina [118]. Microglia are derived from 
primitive yolk sac macrophages in development [119], and have a distinct phenotype from 
blood-borne macrophages [120]. In the healthy retina, microglia are highly motile, which 
allows them to constantly sense the microenvironment and interact with other retinal cells 
such as Müller cells and photoreceptors, using highly mobile processes [121, 122]. As well 
as monitoring the inflammatory environment, microglia have a key role in neurogenesis, 
neuronal survival and synaptic maintenance in CNS development [123-125], as well as 
maintaining synaptic function in the mature retina [126]. Under normal retinal conditions, 
mechanisms to inhibit microglial activity are in place, including the CD200:CD200R 
signalling axis [127, 128] and the CX3CL1:CX3CR1 signalling axis [129, 130]. Microglia 
normally reside in the plexiform layers of the inner retina [5], however, upon receiving 
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inflammatory cues such as chemokine signalling or purinergic signalling from damaged 
photoreceptors, RPE and Müller cells, microglia can migrate to sites of tissue damage 
[131]. During ageing, there are higher numbers of microglia in the retina, which begin to 
accumulate in the outer retina with age [132, 133].  
In age-related retinal diseases such as AMD, the accumulation of leukocytes in the 
outer retina is a well-established feature of disease pathogenesis [4, 71-75]. This outer 
retinal leukocyte population primarily consists of activated microglia and infiltrating 
blood-borne macrophages from the retinal vasculature [5]. Microglial activation and 
macrophage recruitment are strongly implicated in the pathogenesis of several retinal 
diseases, including AMD [4, 47, 75, 134, 135], glaucoma [136, 137], retinitis pigmentosa 
[134], and diabetic retinopathy [138]. There are two types of macrophages, M1 (pro-
inflammatory) macrophages that are involved in the clearance of cell debris, pathogens and 
apoptotic cells [116, 134, 139], and M2 (anti-inflammatory) macrophages, which are 
involved in wound healing and angiogenesis [113]. However, phagocytosis by these cells 
has also been found to contribute to the degeneration of living photoreceptors adjacent to 
damaged photoreceptors [116, 134]. Additionally, retinal microglia and macrophages are 
known to express complement system components [140-144]. The role that these cells play 
in contributing to prolonged disease progression is not fully understood. 
 
1.5. Complement system and AMD 
1.5.1. The complement system 
 The complement system is a key component of the innate immune system. It 
comprises a cascade of over 30 proteins circulating in the plasma and on cell surfaces 
[145], that are sequentially lysed to form a terminal complex initiating the destruction of a 
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pathogen or foreign body, which has been associated with cell debris [145, 146]. It is an 
ancient system that is evolutionarily conserved as a critical mechanism for host defence 
[147, 148]. The complement system consists of three pathways of activation (Figure 1.3); 
classical, lectin and alternative pathways [149].  
The classical pathway of the complement system is activated through the binding of 
foreign antibodies on pathogenic surfaces, which initiates activation of the complement 
component 1 (C1) complex. This complex is comprised of a C1q hexamer molecule bound 
to C1r and C1s, which together when activated form a serine protease which goes on to 
cleave the next proteins in the pathway, C4 and C2. Two fragments generated during this 
interaction, C4b and C2a, form the C3 convertase enzyme (C4b2a) that facilitates the 
hydrolysis of C3, a central molecule of all pathways of the complement system. C3 
hydrolysis generates smaller C3 fragments that are used up further downstream for several 
complement system functions. These C3 convertase enzymes are attached to the 
pathogenic cell surfaces, largely limiting complement activity to these bound surfaces. The 
lectin pathway consists of a similar chain of proteins, whereby the C1 complex is replaced 
with a mannose-binding lectin (MBL) protein, which binds specifically to mannose 
residues on pathogenic cell surfaces. MBL-associated serine proteases 1 and 2 (MASP-1 
and MASP-2) cleave the C4 and C2 proteins, generating C4b and C2a fragments necessary 
for the formation of the C3 convertase [145-147, 149]. 
 The alternative pathway operates under a spontaneous hydrolysis mechanism. The 
constant hydrolysis of C3 allows for C3 convertases to be formed at lower levels. C3 
convertase (C3bBb) formation via this pathway is regulated by a number of factors. 
Complement factor B (CFB) and complement factor D (CFD) are positive regulators of C3 
hydrolysis, whereas complement factor H (CFH) and complement factor I (CFI) negatively  
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Figure 1.3. Schematic representation of the complement system (adapted from Murphy et 
al. 2008 [149]). There are three pathways of complement activation; classical, lectin and 
alternative. These pathways all lead to the hydrolysis of C3, which triggers the downstream 
formation of the membrane attack complex (MAC). This marks the destruction of 
pathogens, apoptotic cells and debris. 
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regulate this pathway and inhibit the hydrolysis of C3. Properdin (factor P) may bind to the 
C3 convertase and enhance its stability upon binding to pathogenic cell surfaces [149]. 
Upon C3 hydrolysis by each of the three complement pathways, a number of fragments are 
produced including C3a, C3b and C3d (inactive component). The larger fragment C3b 
forms part of a C5 convertase which lyses C5 into C5a and C5b. This C5b fragment 
combines with C6, C7, C8 and 16 molecules of C9 to form the membrane attack complex 
(MAC, C5b-9) terminal complement product, which assembles on the pathogenic cell 
surface and essentially forms a membrane pore in the surface, facilitating the destruction of 
pathogens, foreign bodies or cell debris via lysis [145-147, 149]. 
 This key function of the complement system not only plays a vital role in host 
defence against pathogens, but also clears debris as well as dead, damaged and apoptotic 
cells, which may protect against autoimmunity [149]. Complement may also lead to a 
prolonged activation of the innate immune system via several mechanisms. Complement 
contributes to the opsonisation of pathogens for phagocytic destruction, by coating the 
cells in C3b (short-lived) or C3d (inactive long-lasting) molecules. The hydrolysis of C3 
and C5 also generate C3a and C5a anaphylatoxins, which propagate local inflammation by 
recruiting phagocytic cells to the site of injury [145-147, 149]. Additionally, C1q is 
thought to activate the inflammasome, another component of the innate immune system, by 
affecting the phagolysosomal process to trigger inflammasome activation [106]. Increases 
in MAC are also associated with activation of the inflammasome [150]. 
1.5.2. Complement activation and AMD 
Under normal conditions, the complement system pathways are under tight 
regulation. However, in neurodegenerative diseases such as age-related macular 
degeneration (AMD), complement activation is uncontrolled, leading to the continuous 
production of complement which can contribute to disease onset and progression [3, 151, 
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152]. Genetic factors are strongly implicated in the pathogenesis of AMD, especially those 
involving the innate immune system. In 2005, multiple studies revealed that a single 
nucleotide polymorphism (Y402H variant) in CFH, a negative regulator of the alternative 
complement pathway, was responsible for the onset of almost 50% of all cases of AMD 
[48, 153-156]. Additionally, polymorphisms in C2, CFB and C3 have also been associated 
with disease onset [157, 158]. GWAS analysis indicated that there is a link between 
complement activation and the progressive expansion of the macular lesion in geographic 
atrophy, demonstrating that there was a global upregulation of a suite of complement genes 
in the neural retina, including C3, C4, C1s, CFI and SERPING1 [47]. 
Numerous histopathological investigations have shown that a large range of 
complement components and factors (e.g. CFH, CFB, C3, C5, C5b-9) are present in drusen 
that have accumulated in the outer retinas of AMD retinas [62, 153, 157, 159-162]. 
Furthermore, although the terminal membrane attack complex (MAC, C5b-9) is present in 
the choriocapillaris as early as three years of age, the significantly increased presence of 
MAC in the choriocapillaris of AMD retinas may be indicative of the contribution of 
complement to outer retinal cell loss [163-165]. However, even though it is well 
established that complement system dysregulation is linked to chronic lesion expansion in 
human atrophic AMD, the cellular events mediating this process are unclear. 
1.5.3. Complement as a gateway to adaptive immunity 
Complement component C1q is often considered to be the bridging molecule 
between the innate and adaptive immune system [146, 147, 166]. C1q provides the link to 
the adaptive immune response through the binding of antibodies complexed to antigens, 
which is part of the classical pathway [167-169]. In addition, the activation of complement 
may increase the efficiency of the adaptive immune system [146, 147]. In retinal 
degenerative diseases, adaptive immune system cells including T-cells and neutrophils 
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may contribute to RPE degeneration [170, 171]. The anaphylatoxin protein fragment C5a 
mediates recruitment of pro-inflammatory T-cells into the eye in a model of neovascular 
AMD [172], and C5a increases production of pro-inflammatory cytokines IL-17 and IL-22 
by T-cells in AMD patient sera [173]. In neovascular AMD human tissue and animal 
models, it is thought that IL-17 is produced primarily by γδT-cells [172, 174, 175]. 
However, further studies are needed to elucidate the role of the adaptive immune system in 
contributing to the progression of retinal degenerations. 
 
1.6. Therapeutic targeting of inflammation 
1.6.1. Strategies to manage inflammation in AMD 
 Therapeutic strategies involved in the treatment of AMD have so far been only 
effective in patients with the neovascular ‘wet’ form of the disease. Vascular endothelial 
growth factor A (VEGFA)-targeted therapies have proven highly beneficial for 
neovascular AMD, with market compounds available to inhibit abnormal blood vessel 
growth such as Ranibizumab (Lucentis; Genentech/Novartis) [176], and Aflibercept 
(VEGF Trap-Eye/Eylea; Regeneron/Bayer) [177]. However, there are currently no 
effective treatments for atrophic ‘dry’ AMD, the most prevalent form of the disease. 
Immune-based therapies are being explored as the most likely drug candidates for clinical 
trials, including a number of complement system inhibitors [3, 178]. Several clinical trials 
are currently underway involving the use of C5 inhibitors [179, 180] and a complement 
factor D inhibitor (Lampalizumab, Genentech) [178]. However, the complement system 
has a high degree of redundancy, comprising more than 30 different protein components 
[145]. Therefore inhibition of specific complement components, especially those involved 
in the activation phase of the complement cascade (e.g. C1, C4, C2 components) is likely 
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to be challenging, since blocking one pathway may result in the activation of other 
pathways that lead to terminal membrane attack complex formation [178]. 
 Therefore, strategies that inhibit production of complement system components 
may be more beneficial. Both RPE cells and macrophages are known to synthesise 
complement in the retina [140, 141, 144, 181] and drug treatments that inhibit the 
activation and production of complement by these cells may hold therapeutic potential in 
slowing the progression of AMD. Novel therapeutic strategies such as microRNAs 
(miRNAs), known as ‘master gene regulators’, are being explored as therapeutic molecules 
for retinal degenerations, and have been employed experimentally to reduce the expression 
of inflammatory genes [182]. Chemokine inhibitors have also been used to regulate the 
activation and recruitment of macrophages in experimental models of retinal detachment, 
diabetic retinopathy, retinitis pigmentosa, and in a model of atrophic AMD primarily 
concerning inhibition of the CCL2-CCR2 axis [89, 183, 184]. However, the issue of 
redundancy again plays a role in chemokine signalling, as the inhibition of specific 
chemokines or their receptors may actually lead to an increased production of other 
chemokines to compensate, of which there are over 50 chemokine ligands and associated 
receptors [78, 93, 185]. 
1.6.2. Broad spectrum chemokine inhibition (BSCI) 
 Addressing the issue of redundancy, a novel broad spectrum chemokine inhibitor 
(BSCI) NR58-3.14.3 has been shown to suppress the entire CCL- and CXCL-signalling 
pathways. One of the first BSCIs tested was Peptide 3, which was only effective in vitro 
[186]. As a result, NR-58.3.14.3 was synthesised as a cyclic 13 amino acid retroinverso 
analogue of Peptide 3, which is 1000 times more potent than Peptide 3 [187]. The new 
cyclic structure of the BSCI NR-58.3.14.3 does not affect its broad pan-chemokine 
inhibiting ability [188]. The exact mechanism of action of BSCI is not fully understood, 
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however, it is known to act as a blocker for chemokine signalling cues so that leukocyte 
recruitment is hindered [187].  
NR58-3.14.3 has been promising in a number of different tissue types and disease 
models, including skin inflammation [187], cerebral ischemia-reperfusion (IR) injury 
[189], obliterative bronchiolitis [190], lung ischemia [191], atherosclerosis [192], 
intraperitoneal adhesions [193], endometriosis [194] and pulmonary graft-versus-host 
disease (GVHD) [195]. These studies have reported that treatment with NR58-3.14.3 was 
able to reduce the accumulation of inflammatory cells in the tissue, and ameliorate tissue 
damage. While BSCIs have proven to be effective in reducing inflammation and tissue 
degeneration in these disease models, their use in the eye has not been documented. 
 
1.7. In vivo models of retinal degeneration 
1.7.1. Animal models of retinal degeneration 
 Models of wet AMD primarily focus on the use of experimental methods that 
induce choroidal neovascularisation (CNV) in the retina (reviewed in [196]). However, to 
model retinal atrophy that occurs in dry AMD, several types of rodent models exist, and 
many of these models involve increases in oxidative stress and/or inflammation [196, 197]. 
Knockout models of chemokine genes or complement system genes have been utilised to 
develop retinal degeneration in mouse models, including CX3CR1-knockout mice, where a 
deficiency in the fractalkine receptor involved in the inhibition of microglial activity is 
known to cause retinal pathology [198, 199]. Complement factor H (CFH)-deficient mice 
also develop increased C3 deposition and abnormalities in the retina [200]. 
 Rodent models that induce oxidative stress in the retina have been developed to 
model features of dry AMD. A model involving the immunisation of mice with 
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carboxyethylpyrrole (CEP)-adducted mouse serum albumin induced retinal degeneration, 
where mice developed C3 deposition in the outer retina, macrophage recruitment and 
photoreceptor cell death [63, 68, 69]. Retinal photo-oxidative damage (or light damage) 
models have been utilised for over 50 years [201] to induce photoreceptor degeneration in 
the rodent retina (reviewed in [202, 203]). Although the effect of photo-oxidative damage 
in the retina is affected by circadian rhythm and light history of the animals [204, 205], 
photo-oxidative damage has been used to initiate photoreceptor death and extensive retinal 
remodelling in the rodent retina [206, 207]. This occurs primarily in the superior retina 
where the area centralis, an area analogous to the human macula, is located [208].  
 Our laboratory has demonstrated the use of photo-oxidative damage models of 
retinal degeneration using both rats and mice, to investigate the immunological 
mechanisms of atrophic AMD pathogenesis [209, 210]. By producing several features of 
the disease in the rodent retina, we have demonstrated that oxidative damage and 
photoreceptor cell death is induced during exposure to photo-oxidative damage [209, 210]. 
Damaging light induces ROS production and lipid peroxidation in the retina, which can 
initiate photoreceptor loss and upregulate stress mechanisms. Chemokines such as CCL2 
are expressed by RPE, Müller cells and activated microglia [85, 87], leading to the 
migration of retinal microglia and the recruitment of blood-borne macrophages from the 
retinal vasculature and underlying choroid to the damaged photoreceptors [113, 141, 209]. 
Additionally, these microglia and macrophages have been found to express complement 
activation markers such as C3 in the outer retina [141, 211]. These inflammatory 
components are associated with the progression of retinal degeneration following exposure 
to photo-oxidative damage. Substantial focal lesion development occurs in the 
photoreceptor layer, starting at the area centralis in the superior retina and eventually 
expanding over time [209, 210], modelling a key feature of atrophic AMD. 
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1.7.2. Complement activation in animal models 
 Models of photo-oxidative damage show that complement activation is facilitated 
by microglia and macrophages in the damaged retina, and indicate that complement 
expression may be associated with further photoreceptor damage [141, 211, 212]. The 
expression of retinal complement by microglia and macrophages is also observed in 
models of ageing [143, 144]. However, further studies are needed to elucidate the role of 
these cells in contributing to complement activation and prolonged retinal remodelling, 
using a protracted time course of progressive retinal degeneration. Additionally, the 
cellular contribution of complement-expressing cells in the retina is not fully understood. 
RPE cells were initially reported to be major producers of complement in the retina [140, 
181, 213, 214]. However, emerging evidence indicates that microglia and macrophages are 
the more likely primary mediators of complement expression in the degenerating retina 
[140-144]. Investigation of the contribution of these local retinal sources of complement to 
retinal degeneration is necessitated. 
 Furthermore, the contribution of each complement pathway upon activation is not 
fully understood, and it has been suggested that more than one complement pathway may 
be involved in the progression of retinal degeneration [215]. The activation of the 
alternative pathway is known to contribute to retinal degeneration in several animal models 
[216-220]. Recently, CFH has been described to have a non-canonical role in mononuclear 
phagocyte clearance in the degenerating retina, where CFH mutations may result in the 
toxic accumulation of these cells, including microglia and macrophages, in the outer retina 
[309]. Novel roles for the complement pathways are continuing to be uncovered, and so 
further characterisation of complement activators and regulators in retinal degeneration is 
necessary to fully understand how complement activation can be targeted therapeutically. 
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1.8. Summary and aims 
 The activation and accumulation of microglia and macrophages in the degenerating 
retina are highly implicated in the progression of retinal diseases such as AMD. However, 
several key questions remain unanswered, regarding their contributions to complement 
activation and photoreceptor death in progressive retinal degeneration.  
The overall aims of this thesis are: 
1. To determine the contribution that microglia and macrophages have in propagating the 
inflammatory response in retinal degeneration, which may lead to further photoreceptor 
cell death and atrophic lesion development. 
2. To utilise novel therapeutic strategies to inhibit the activity of these microglia and 
macrophages in the degenerating retina.  
 Chapter 2 outlines the general methodology described throughout this thesis. 
Chapter 3 characterises the role of complement activation by microglia and macrophages 
in contributing to retinal degeneration in humans, rats and mice, with a particular focus on 
the role of C3 in atrophic lesion development. Chapter 4 describes the therapeutic potential 
of a broad spectrum chemokine inhibitor (BSCI) NR58-3.14.3 in modulating 
inflammatory-mediated cell death by macrophages in retinal degeneration. Chapter 5 
details the role of interleukin-1β (IL-1β) in promoting chemokine production by retinal 
supporting cells in retinal degeneration, and we demonstrate the use of two inhibition 
strategies to reduce IL-1β-derived macrophage recruitment. Finally, the significance of 
these findings is discussed in Chapter 6.  
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2. METHODS 
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2.1. In vitro experiments 
2.1.1. Cell cultures 
 Immortalised human cell lines for Müller cells (MIO-M1, Müller 1 Mooreﬁelds 
Institute of Ophthalmology; Dr A. Limb, Institute of Ophthalmology, University College 
London, UK) and RPE cells (ARPE-19, ATCC CRL-2302; American Tissue Culture 
Collection, VA, USA) were cultured for experiments presented in this thesis. Cell lines 
were authenticated by CellBank, Australia. Cell lines stored at -80°C were thawed and 
grown in a tissue culture flask with Dulbecco's Modified Eagle Medium (DMEM, high 
glucose with sodium pyruvate; Sigma-Aldrich, MO, USA) supplemented with 10% fetal 
bovine serum (FBS; Thermo Fisher Scientific, MA, USA) and 3mM L-glutamine (Thermo 
Fisher Scientific). Cells were incubated at 37°C in a humidified atmosphere (95% air and 
5% CO2). To passage the cells every 3 to 4 days, cells were incubated with trypsin solution 
(containing 2.5% trypsin (Thermo Fisher Scientific), 1% EDTA and 0.1M phosphate 
buffered saline (PBS)) for 3 minutes at 37°C to detach the cells from the flask. Cells were 
centrifuged then split 1:5 into a new flask and incubated at 37°C until needed for 
experiments, as detailed later in this thesis. 
 
2.2. Animal experiments 
2.2.1. Animal rearing and holding 
All animal experiments reported in this thesis were conducted in accordance with 
the ARVO Statement for Use of Animals in Ophthalmic and Vision Research, and with 
approval from the ANU Animal Experimentation Ethics Committee (Ethics ID: A2012/07, 
A2014/56). Adult Sprague-Dawley (SD) rats were utilised in these experiments, which 
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were born and reared under cyclic dim light conditions (12 hours at 5 lux, 12 hours at 0 
lux) in open-top cages. All rats were aged between 90-120 post-natal days at the time of 
use. Additionally, adult C57BL/6J mice aged 60-80 days and age-matched homozygous 
C3-knockout mice (C3-/-, 129S4-C3tm1Crr/J) were used in these experiments. Mice were 
born and reared in individually ventilated cages (IVCs) in cyclic dim light conditions (12 
hours at 5 lux, 12 hours at 0 lux) until needed for further experiments. 
2.2.2. Intravitreal injections 
Intraocular (intravitreal) injections were performed to deliver compounds of 
interest (NR58-3.14.3, C3 siRNA, Il-1β siRNA) into the eye. A total volume of 3µl was 
delivered via intravitreal injection into each rat eye, and a total volume of 1µl into each 
mouse eye. These volumes were chosen as they minimise disturbance to the pressure of the 
eye, reducing the risk of cataract formation [221]. All compounds were delivered in 
ultrapure endotoxin-free 0.1M PBS (Thermo Fisher Scientific).  
Prior to all injections, animals were restrained and anaesthetised using a mixture of 
Ketamine (100mg/kg body weight; Troy Laboratories, NSW, Australia), an anaesthetic, 
and Ilium Xylazil-20 (12mg/kg body weight; Troy Laboratories), a muscle relaxant, 
delivered through an intraperitoneal injection with an insulin syringe. Each animal was 
checked for signs of unconsciousness, including loss of movement (except for breathing), 
and loss of the corneal and toe-pinch reflexes. A heat mat was used to maintain core body 
temperature. A pupil dilator was administered to both eyes (Minims Atropine Sulphate 1% 
w/v eye drops for mice, or Minims Tropicamide 0.5% w/v eye drops for rats; Bausch and 
Lomb, NSW, Australia). Animals were then transferred to a surgery mat under a Zeiss 
OPMI 99 examination microscope (Zeiss, West Germany), or a Leica M125 stereo 
microscope (Leica Microsystems, Wetzlar, Germany), which was used to aid the 
intravitreal injection process. Following dilation of the pupil, a cotton string loop was tied 
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around the eye lifting it from the socket. 10% w/v povidone-iodine antiseptic liquid 
(Betadine; Faulding Pharmaceuticals, SA, Australia) was applied to each eye before 
injection.  
The injectable compound of interest was drawn up into a 10µl Hamilton syringe 
with an attached 34G bevelled needle (World Precision Instruments, FL, USA). Using a 
30G bevelled needle (Becton Dickinson, NJ, USA), a small puncture wound was made into 
the eye about 1mm from the limbus. The tip of the needle was inserted in a supero-
temporal direction and then removed. The 34G needle attached to the Hamilton syringe 
was inserted into the hole, and 1-3µl of solution was intravitreally injected into each eye. 
Following the injection, Chlorsig antibiotic cream (Aspen Pharma, NSW, Australia) was 
applied to the injection site. Eye gel (GenTeal; Novartis, NSW, Australia) was 
administered to both eyes to prevent dryness, and the animal was recovered on a heat mat. 
2.2.3. Photo-oxidative damage 
 Photo-oxidative damage (or light damage) has been used as a model to induce 
retinal degeneration in rodents for over 50 years [201]. The use of two photo-oxidative 
damage models have been reported throughout this thesis as previously published; a rat 
model [209] and a mouse model [210]. SD rats were placed into transparent Perspex open-
top boxes and exposed to 1000 lux white light for 24 hours (COLDF2, 2x36W, IHF; Thorn 
Lighting, Spennymoor, UK), with free access to food and water. Lighting levels were set to 
1000 lux using a light meter device (DLM2; UEi Test Instruments, OR, USA). Following 
photo-oxidative damage and post-damage live animal analysis, animals were either 
euthanized for tissue collection (0 day time point) or were held under dim lighting (5 lux) 
until required for tissue collection (3, 7, 14 or 56 days). 
 C57BL/6J and C3-/- mice were placed into Perspex boxes coated with a reflective 
interior surface, and exposed to 100 Klux of natural white light-emitting diodes (LED) for 
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up to 7 days, with free access to food and water. Lighting levels were set to 100 Klux using 
a light meter device (HD450; Extech MA, USA). During the course of photo-oxidative 
damage, each animal was administered with pupil dilator eye drops twice daily, morning 
and evening (Minims Atropine Sulphate 1% w/v eye drops; Bausch and Lomb). Following 
photo-oxidative damage and post-damage live animal analysis, animals were euthanized 
for tissue collection. Age-matched non-damaged animals were used in all rat and mouse 
experiments as dim-reared controls. 
2.2.4. Electroretinography (ERG) 
 Electroretinography (ERG) was used to measure mouse retinal function in response 
to full-field flash stimuli under scotopic conditions in dim-reared control and photo-
oxidative damaged animals in methods previously published [210]. Mice were dark-
adapted overnight prior to the measurement of retinal recordings, and all recordings were 
performed in a dark room with minimal red light sources. Animals were restrained and 
intraperitoneally anaesthetised using a mixture of Ketamine (100mg/kg body weight; Troy 
Laboratories) and Ilium Xylazil-20 (12mg/kg body weight; Troy Laboratories). A heat mat 
was used to maintain core body temperature. A pupil dilator (Minims Atropine Sulphate 
1% w/v eye drops; Bausch and Lomb) and eye gel (GenTeal; Novartis) was administered 
to both eyes prior to taking retinal recordings.  
The animal was setup on a homeothermic blanket to maintain body temperature at 
at 37°C using a rectal probe (Harvard Apparatus, MA, USA). A cotton loop was tied 
around the eye, and the head of the animal was inserted into the Ganzfeld sphere. An earth 
probe was placed on the hind foot of the animal. An Ag-AgCl reference probe was placed 
in the mouth of the animal (SDR Scientific, NSW, Australia) and a corneal probe was 
placed on the corneal surface of the eye to be examined. Eye drops or gel was administered 
to both eyes prior to commencing the recordings. A BioAmp (AD Instruments, Dunedin, 
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New Zealand) set at 2mV was used to ensure there was minimal noise in the setup. A 
single-flash paradigm was used to elicit mixed (rod and cone) responses. Mice were 
exposed to flash stimuli over the intensity range of -4.4-1.9 Log cd.s/m2 using an LED-
based system (FS-250A Enhanced Ganzfeld; Photometric Solutions International, VIC, 
Australia). The interstimulus interval was increased from 2 seconds for the lowest 
intensities to 4 minutes for the highest intensities to allow complete recovery of the b-wave 
between stimuli. Following the retinal recordings, eye gel (GenTeal; Novartis) was 
administered to both eyes of the animal to maintain hydration upon recovery of the animal.  
Measurements of the a-wave and b-wave were performed using Lab Chart 8 (AD 
Instruments). An assessment of retinal function was made by comparison of the amplitudes 
of the a-wave and b-wave between experimental groups. The amplitude of the a-wave was 
measured from the baseline to the trough of the a-wave (minimum value), and the 
amplitude of the b-wave was measured from the trough of the a-wave to the peak of the b-
wave (maximum - minimum value). The a-wave and b-wave data were fitted with a Naka-
Rushton equation [R/Rmax = I/(I + K)] using the Solver function in Microsoft Excel 2013 to 
determine Rmax (maximum amplitude) and K (semi-saturation constant) from the response 
amplitude (R) and the flash intensity (I).  
2.2.5. Optical Coherence Tomography (OCT) 
Optical coherence tomography (OCT) is a technique used to assess morphology of 
the retinal layers. Cross-sectional retinal and fundus images were undertaken in live rats 
using a Spectralis HRA+OCT device (Heidelberg Engineering, Heidelberg, Germany). 
Animals were anaesthetised with an intraperitoneal injection of Ketamine (100 mg/kg body 
weight; Troy Laboratories) and Ilium Xylazil-20 (12 mg/kg body weight; Troy 
Laboratories). A heat mat was used to maintain core body temperature. Following 
anaesthesia, a pupil dilator (Minims Tropicamide 0.5% w/v eye drops; Bausch and Lomb) 
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and hypromellose 0.3% eye drops (GenTeal; Novartis) was administered to both eyes. A 
rodent contact lens was placed on the eye (PMMA lenses, radius of curvature of the central 
optic zone of 2.70mm and diameter of 5.20mm; Cantor + Nissel, Brackley, UK) [222]. 
Animals were restrained on a custom-made platform attached to the Spectralis 
HRA+OCT imaging device, adapted for rat eyes according to the manufacturer’s 
specifications (Heidelberg Engineering). Eyes were kept well-hydrated using the 
hypromellose eye drops to maintain corneal hydration and improve OCT image quality. 
Using the Heidelberg Eye Explorer software (Heidelberg Engineering) with a C-Curve 
setting of 7.7mm (radius of the curvature of the anterior corneal surface), the camera was 
switched on and confocal scanning laser ophthalmoscopy (cSLO) was used to take fundus 
images of the retina. A custom glass 25 diopter lens optimised for rodent cSLO was fitted 
to the device over the 30 degree lens (Heidelberg Engineering). The filter wheel was set to 
Position A or R (acquisition mode). The camera was moved left to right to line up with the 
eye, then was moved up and down until aligned with the eye. The camera was moved 
slowly towards the eye until an evenly-illuminated cSLO image was displayed. The focus 
was set to 0.00D prior to image acquisition. For OCT images, the camera was moved back 
and the custom mouse lens was removed. The camera was slowly moved back towards the 
eye using the focus knob to keep the retina in the display. Once the retina spanned the 
length of the display at a minimum imaging quality of 25dB, a line scan or volume scan 
was obtained with an automatic real time (ART) mean of 100 frames. Cross-sectional OCT 
images were taken in 1mm increments from the optic nerve (up to 3mm superior, and 2mm 
inferior to the optic nerve) to assess retinal layer thickness. Following retinal imaging, the 
contact lens was removed from the eye and eye gel (GenTeal; Novartis) was administered 
to both eyes of the animal to maintain hydration upon recovery. 
OCT and fundus images were analysed using ImageJ software (NIH, MD, USA). 
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Cross-sectional images of the retina were analysed per millimetre in duplicate, with a 
minimum of 5 measurements of individual retinal layers manually taken per cross-
sectional image. The outer nuclear layer (ONL) containing the photoreceptor cell bodies 
was measured to determine photoreceptor loss in each experimental group following 
photo-oxidative damage, and compared to control retinas. ONL thickness ratios were 
calculated as the thickness of the ONL relative to the distance between the inner and outer 
limiting membranes (ILM-OLM). Fundus images were used to detect the presence of a 
retinal lesion in areas of ONL thinning, where the fundus appeared darker. Images of the 
area of interest (2-3mm superior to the optic nerve) were converted to greyscale (8-bit), 
and contrast and brightness were optimised using the ‘curves’ function in Photoshop CS6 
using a standard approach. Images were then converted to bitmaps using controlled 
parameters (99 pixels/inch, halftone screen, 53 lines/inch, 45˚, square). ImageJ was used to 
measure the lesion size manually (arbitrary units). 
2.2.6. Tissue collection 
Following live animal experiments, rats were euthanized intraperitoneally using an 
overdose of barbiturate (Lethabarb, 60mg/kg body weight; Virbac, NSW, Australia; 2% 
Ilium Lignocaine-20; Troy Laboratories), and mice were euthanized using carbon dioxide 
(CO2). Tissue collection commenced after confirming death, indicated by the loss of 
movement, reflexes, breathing and heartbeat. To collect the retina for molecular analysis, a 
corneal incision was made along the surface of one eye, and the retina was excised from 
the eye and placed into 150µl RNAlater (Thermo Fisher Scientific) at 4°C to preserve the 
RNA until extraction. The retinas were kept at 4°C overnight prior to their long-term 
storage at -80°C until required for RNA extraction.  
For histological analysis, the superior aspect of the other eye was marked with a 
permanent marker pen for orientation. Using dissecting scissors and forceps (World 
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Precision Instruments), each eye was lifted from the socket, and was enucleated from the 
connective tissues. The eye was injected with approximately 50µl 4% paraformaldehyde 
fixative using an insulin syringe and was collected into a vial containing 4% 
paraformaldehyde for 3 hours at 4°C. Following fixation, the eyes were washed 3 times 
with 0.1M PBS for 5 minutes each wash. The eyes were then left in 15% sucrose solution 
overnight at 4°C for cryoprotection prior to embedding the following day. 
 
2.3. Histological and in situ molecular analysis 
2.3.1. Embedding 
Prior to cryosectioning the eyes for histological analysis, enucleated eyes were 
embedded in Tissue-Tek Optimal Cutting Temperature Compound (Sakura Finetek USA 
Inc., CA, USA). Dry ice was slowly added to acetone in a plastic container, until the 
temperature of the mixture had dropped to approximately -78°C. Truncated plastic 
embedding moulds (Pro Sci Tech, QLD, Australia) were filled with the Tissue-Tek 
medium. Each eye was placed into an individual mould, with the marked superior aspect of 
the eye facing the same direction for orientation. The mould was then lowered into the dry 
ice and acetone freezing mixture and the eye was snap-frozen for approximately 2 minutes, 
until the Tissue-Tek medium had frozen into a solid block with a small peak in the centre 
of the block. The mould was double-wrapped in aluminium foil and transferred to -20°C 
for long-term storage until cryosectioned. 
2.3.2. Cryosectioning 
Retinal cryosections of each eye were cut using a Leica CM 1850 cryostat (Leica 
Microsystems). Cryosections were cut at 16µm for rat eyes, and 12µm for mouse eyes, 
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where each retinal section contained approximately 2 layers of photoreceptors in the outer 
nuclear layer (ONL). Each eye was mounted onto the cryostat chuck using a small amount 
of Tissue-Tek medium, with the superior aspect of each eye facing the same direction for 
consistent sections. Para-sagittal cryosections were collected from the optic nerve (ON) 
central region of the eye, where retinal damage is primarily located in the superior retina 
following photo-oxidative damage [206, 209, 210]. Cryosections contained structures from 
the whole eye, including the sclera, lens, retina, choroid and optic nerve. For each eye, 20-
40 sections were collected onto labelled Superfrost Ultra Plus glass slides in duplicate 
(Menzel-Glaser, Braunschweig, Germany). A Leica DM 1000 light microscope (Leica 
Microsystems, Wetzlar, Germany) was used to visualise the sections. Slides were oven-
dried at 37°C overnight, and were transferred to -20°C for long-term storage. 
2.3.3. TUNEL assay 
 The terminal deoxynucleotidyl transferase dUTP nick end labelling (TUNEL) assay 
is used in situ to detect cells undergoing DNA fragmentation during apoptosis, necrosis 
and autolysis [223]. The terminal deoxynucleotidyl transferase (Tdt) enzyme adds 
biotinylated dUTP molecules onto fragmented DNA strands. Upon secondary labelling, 
cell death is visualised and can be quantified.  
 In retinal cryosections, photoreceptor cell death was investigated using the TUNEL 
assay. Retinal cryosections containing the optic nerve were equilibrated to room 
temperature, and a hydrophobic barrier was drawn around the sections on the slides with a 
pap pen (Daido Sangyo, Tokyo, Japan). Slides were immersed in 70% ethanol for 10 
minutes and then Milli-Q water (MQ H2O) for 10 minutes. 0.1% Triton X (Sigma Aldrich) 
was added to sections for 2 minutes for permeabilisation of the membranes, before rinsing 
in 0.1M PBS for 10 minutes. Slides were equilibrated in 1x Tdt buffer for 10 minutes prior 
to addition of the Tdt reaction mixture. 
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 The Tdt reaction mixture was prepared using 1060µl MQ H2O, 125µl 10x Tdt 
buffer, 3µl biotin dUTP (Roche Diagnostics, Basel, Switzerland) and 1.5µl Tdt enzyme 
(Roche Diagnostics). The mixture was added evenly across all sections, and the slides were 
incubated at 37°C for 1 hour in a humid chamber. The reaction was then stopped by 
immersing the slides in 2x saline-sodium citrate (SSC) buffer for 15 minutes. Slides were 
blocked with 10% normal goat serum (NGS; Sigma Aldrich) for 10 minutes prior to adding 
the secondary label. Streptavidin conjugated to Alexa Fluor 594 (1:500; Thermo Fisher 
Scientific) was added evenly across all sections under dim conditions. The slides were 
incubated at 37°C for 1 hour in a humid chamber. Following secondary labelling, slides 
were rinsed twice in 0.1M PBS for 5 minutes each. For visualisation of the cellular layers, 
a DNA label (Bisbenzimide or Hoechst’s stain, 1:10000; Sigma Aldrich) was added to all 
sections for 2 minutes, followed by another rinse in 0.1M PBS for 5 minutes. Slides were 
coverslipped with Aqua Poly/Mount (Polysciences, PA, USA) prior to visualisation. Slides 
were sealed with nail varnish and were stored at 4°C. 
2.3.4. Immunohistochemistry 
The detection and localisation of specific proteins in situ was determined using 
immunohistochemistry (IHC), with primary antibodies utilised throughout this thesis 
detailed in Table 2.1. Retinal cryosections containing the optic nerve were used for 
histological analysis. For comparison, a negative control slide (no primary antibody) was 
included with each immunohistochemistry run. Slides were equilibrated at room 
temperature and a hydrophobic barrier was drawn around the sections with a pap pen. 
Slides were soaked in 70% ethanol for 10 minutes, MQ H2O for 5 minutes, and 0.1M PBS 
for 5 minutes. To perform antigen retrieval, sections were incubated in Reveal-It Ag 
(ImmunoSolution, QLD, Australia) at 37°C for 1 hour. Sections were blocked with 10% 
normal goat serum (NGS) at room temperature for 1 hour. Modifications to the blocking 
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procedure are as follows: 3% bovine serum albumin (Roche Diagnostics) was used as the 
blocking solution prior to the addition of the α-C3d antibody, while Image-iT FX Signal 
Enhancer (Thermo Fisher Scientific) was used as the blocking solution for the α-C3 
antibody. Primary antibodies (Table 2.1) were then added evenly to each section. Slides 
were incubated at 4°C for approximately 16 hours overnight in a humid chamber. 
Slides were washed 4 times, each for 5 minutes in 0.1M PBS. Secondary 
antibodies, conjugated to either Alexa 594 or 488 (Thermo Fisher Scientific), were added 
evenly to the sections under dim conditions. Slides were incubated at room temperature for 
4 hours or at 37°C for 2 hours in a humid chamber. Following incubation with the 
secondary antibody, slides were washed 4 times, each for 5 minutes in 0.1M PBS. A DNA 
label (Bisbenzimide or Hoechst’s stain) was added to the sections for 2 minutes, for 
visualisation of the cellular layers. Slides were rinsed in 0.1M PBS for 5 minutes before 
coverslipping with Aqua Poly/Mount. Slides were sealed with nail varnish and stored at 
4°C. Note: For double labelling, both primary antibodies (and both secondary antibodies) 
were added simultaneously. 
Table 2.1. List of primary antibodies used for immunohistochemistry 
Primary Antibody Dilution Catalogue Number Company 
Rabbit α-C3 1:50 AB118877 Abcam, Cambridge, UK 
Goat α-C3d 1:100 AF2655 R&D Systems, MN, USA 
Rabbit α-GFAP 1:500 Z0334 Dako, Glostrup, Denmark  
Rabbit α-IBA1 1:500 019-19741 Wako, Osaka, Japan 
Goat α-IL-1β 1:500 AF501 R&D Systems, MN, USA 
Rabbit α-Rhodopsin 1:500 AB9279 Merck Millipore, MA, USA 
Mouse α-Vimentin 1:100 V6630 Sigma Aldrich, MO, USA 
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2.3.5. In situ hybridisation 
 In situ hybridisation (ISH) is a technique utilised to visualise mRNA expression in 
tissue sections, to determine the cellular source and/or expression pattern of a specific gene 
of interest. A riboprobe is synthesised with the complementary sequence to the mRNA 
being detected. In this thesis, C3, Ccl2 and Cxcl1 mRNA transcripts were detected in 
retinal cryosections using riboprobes previously synthesised [87, 141]. C3 was cloned from 
PCR products derived from human (460bp amplicon) and rat (483bp amplicon) retinal 
cDNA. Ccl2 and Cxcl1 were also cloned from PCR products (550-bp and 504-bp 
amplicons respectively) from rat retinal cDNA. These cloned templates were then 
synthesised into digoxigenin (DIG)-labelled riboprobes. In situ hybridisation was 
conducted using our established protocol [224]. All chemicals were sourced from Sigma 
Aldrich, unless specified. 
 RNAses were cleaned from the bench and wash containers with RNAse Zap 
solution (Thermo Fisher Scientific) and MQ H2O. Slides were labelled and air-dried in a 
fume hood or biological cabinet for 30 minutes. A slide for addition of the ‘sense’ probe 
was included in the run as a control. For the pre-treatment steps prior to hybridisation, 
slides were immersed in 0.1M PBS for 5 minutes then in 10% neutral buffered formalin 
(NBF) for 20 minutes. Slides were rinsed twice in 0.1M PBS for 5 minutes each, before 
being treated with 20µg/ml Proteinase K in Tris-EDTA (TE) at 37°C for 7 minutes. Slides 
were rinsed in 0.1M PBS for 5 minutes, and then were soaked in 10% NBF for 20 minutes. 
Slides were placed in 0.1M triethanolamine (TEA) containing 630µl of acetic anhydride 
for 10 minutes, followed by a 0.1M PBS 5 minute wash. Slides were washed in 0.9% NaCl 
for 5 minutes. A series of ethanol solutions were used to dehydrate the sections; 50% 
ethanol for 1 minute, 70% ethanol for 2 minutes, 90% ethanol for 1 minute, 2 washes with 
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100% ethanol for 2 minutes. The slides were then air-dried in the fume hood or biological 
cabinet for 1 hour prior to hybridisation. 
 The pre-hybridisation (pre-hyb) and hybridisation (hyb) mixes (prepared from 
NaCl, Tris-HCl, NaH2PO4, NaEDTA, Ficoll 400, dithiothreitol, poly ribo A, yeast t-RNA, 
dextran sulphate, formamide) were heated to 60°C. The pre-hyb mix was added evenly to 
the sections, and a coverslip was placed on top of the sections. The slides were placed in a 
hydrated fume box at 55-57°C for 3 hours. Following the pre-hybridisation step, the hyb 
mix containing the antisense probe was added evenly to the slides; the sense probe was 
added to the control slide, and a coverslip was placed onto the sections. The slides were 
incubated in a hydrated fume box at 55-57°C for approximately 16 hours overnight. 
 Following hybridisation, the slides were washed in a series of saline-sodium citrate 
buffers (SSC, pH 7.4). Slides were briefly dipped 2 to 3 times into 4x SSC at 60°C to 
remove the coverslips. Slides were washed in 2x SSC at 60°C for 30 minutes, 1x SSC at 
60°C for 30 minutes, twice in 0.1x SSC at 60°C for 30 minutes, and finally in 0.1x SSC at 
room temperature for 10 minutes. To prepare the slides for antibody detection, slides were 
rinsed for 1 minute in washing buffer, constituted from maleic acid, Tween-20 (Amresco, 
OH, USA) and MQ H2O. Slides were then blocked with 2x blocking solution for 30 
minutes (made from Blocking Reagent, maleic acid and MQ H2O). The anti-digoxigenin 
(DIG) antibody (1:1000; Roche Diagnostics) was added evenly to the slides, and incubated 
at room temperature for 30 minutes.  
Following addition of the antibody, slides were washed 3 times in washing buffer 
for 40 minutes each, and then washed in detection buffer (constituting Tris-HCl, NaCl, MQ 
H2O, no Mg2+) for 5 minutes. Slides were then incubated in a NBT/BCIP colour substrate 
reaction mixture in detection buffer at 4°C for 1 to 16 hours (variable) under dim 
conditions until the colour reaction had fully developed with minimal background staining 
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as checked under a Leica DM 1000 light microscope (Leica Microsystems), taking care not 
to overstain the slides. Slides were then rinsed in MQ H2O for 10 minutes to stop the 
reaction, and then placed into 10% NBF for at least 20 minutes at 4°C. Slides were rinsed 
twice in 0.1M PBS for 5 minutes. For double labelling of the sections, 
immunohistochemistry was used following the protocol described above. As an alternative 
to NBT/BCIP staining, HNPP/Fast-Red (Roche Diagnostics) was incubated for 1.5 hours 
prior to immersion in MQ H2O to stop the reaction. Slides were coverslipped in Aqua 
Poly/Mount and stored at 4°C. 
 
2.4. Molecular analysis 
2.4.1. Fluorescence-activated cell sorting (FACS) 
 Fluorescence-activated cell sorting (FACS) was utilised to isolate CD11b+ cells 
from rat retinas, which were pooled from 2 animals (4 retinas) for each sample. Retinas 
were removed from the rat eye through a corneal incision and were placed into Hank's 
balanced salt solution (HBSS with 0.1% glucose, no phenol red, Ca2+ or Mg2+; Thermo 
Fisher Scientific) at 4°C. Retinas were transferred onto a sterile petri dish and crosshatched 
using a razor blade to fragment the retinas. A pipette tip was used to transfer the retinas to 
an Eppendorf tube containing 0.5ml of chilled digestion mix, containing 2mg/ml (0.2%) 
papain (Worthington Biochemicals, NJ, USA), 660 µg/ml (5.5mM) L-cysteine (Sigma 
Aldrich), 10µg/ml gentamycin (Sigma Aldrich),   100U/ml DNAse I (Roche Diagnostics), 
5µg/ml superoxide dismutase (SOD; Worthington Biochemicals) and 5µg/ml catalase 
(Sigma Aldrich). Samples were incubated at 37°C for 7 minutes then at 8°C for 30 
minutes, during which samples were gently homogenised with a pipette to dissociate the 
cells in suspension.  
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Samples were centrifuged for 5 minutes at 1550 rpm at 4°C, and the supernatant 
was removed. Cells were resuspended and incubated for 10 minutes in 0.5ml chilled 
neutralisation mix, containing HBSS (with 0.2% glucose and 4% bovine serum albumin 
(BSA; Roche Diagnostics)), 50µg/ml antipain (Roche Diagnostics), 10µg/ml gentamycin, 
100U/ml DNAse I, 5µg/ml SOD and 5µg/ml catalase. Samples were centrifuged for 5 
minutes at 1550 rpm at 4°C, and the supernatant was removed. Cells were resuspended in 
1ml of chilled staining buffer, containing HBSS, 1mg/ml (0.1%) sodium azide (Sigma 
Aldrich) and 10mg/ml (1%) BSA. Cells were divided into multiple tubes for antibody 
staining as necessary (including an unstained control) and centrifuged for 5 minutes at 
1200 rpm at 4°C. After the supernatant was removed, the CD11b antibody conjugated to 
Alexa 647 (Biolegend, CA, USA) was diluted in chilled staining buffer, and was added to 
the samples for 30 minutes at 4°C. The unstained control sample was resuspended in 
staining buffer without an antibody.  
Samples were centrifuged for 5 minutes at 1200 rpm at 4°C and the supernatant 
was removed. The cells were resuspended and centrifuged twice in washing buffer, 
containing 1mg/ml (0.1%) sodium azide, 10mg/ml (1%) BSA and 2mM EDTA. Following 
the final spin down of the cells, samples were resuspended in chilled staining buffer and 
were ready for analysis. CD11b-stained samples were sorted through a fluorescence 
activated cell sorter at the Imaging and Cytometry Facility at JCSMR, ANU (FACSAria II; 
BD Biosciences, NJ, USA). The isolated CD11b+ cells were collected in chilled staining 
buffer and were kept at 4°C for immediate RNA extraction. 
2.4.2. RNA extraction 
 Total RNA was extracted from whole rat retinas using a combination of TRIzol 
(Thermo Fisher Scientific) and an RNAqueous Total RNA Isolation Kit (Thermo Fisher 
Scientific). For RNA extraction from whole mouse retinas, cultured cells or FACS-isolated 
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cells, an RNAqueous Micro Total RNA Isolation Kit (Thermo Fisher Scientific) was used. 
Retinas/cells were homogenised in 200µl TRIzol using a plastic pestle. Following 
homogenisation, another 400µl TRIzol (660µl for the micro kit; 1ml per 50-100mg tissue) 
was added to the samples, vortexed for 5 seconds and incubated at room temperature for 7 
minutes. 1/5 volume of chloroform was added to the samples, which were vortexed 
thoroughly for 20 seconds. Samples were centrifuged for 10 minutes at 13000g at 4°C to 
separate the layers into RNA, DNA and protein phases. Following centrifugation, the top 
aqueous phase containing the RNA was collected into a new sample tubes. An equal 
volume of 64% ethanol was added to the RNA (half volume of 100% ethanol for the micro 
kit). Samples were vortexed for 5 seconds and transferred into the appropriate filter column 
for the kit, followed by centrifugation for 10 seconds at 13000g to trap the RNA in the 
filter. The flowthrough was discarded. 
 Samples were then run through a series of wash steps to purify the RNA. 700µl of 
wash solution 1 (180µl for the micro kit) was added to the columns and centrifuged for 10 
seconds at 13000g. After discarding the flowthrough, 500µl of wash solution 2/3 (180µl 
for the micro kit) was washed through the columns twice and centrifuged for 10 seconds at 
13000g. The flowthrough was discarded, and the filter columns were air-dried in the 
centrifuge for 1 minute at 13000g. The filter columns were placed in new tubes for 
collection of the RNA. Pre-heated 75°C elution solution was added onto the filter (30µl for 
a standard sized filter, 10µl for the small filter in the micro kit) and left for 1 minute to heat 
the filter to allow the RNA to be eluted through. Columns were spun in the centrifuge for 
30 seconds at 13000g. Another 20µl of heated elution solution (10µl for the micro kit) 
were added to the filters for further elution of the RNA. Samples were analysed for RNA 
quantity and purity using an ND-1000 spectrophotometer (Nanodrop Technologies, DE, 
USA) and were stored at -80°C. 
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2.4.3. cDNA preparation 
Using 500-1000ng of extracted RNA, cDNA was prepared using a Tetro cDNA 
Synthesis Kit (Bioline, London, UK). A 14µl mixture of RNA, Oligo (dT) Primer 
(500µg/ml), dNTPs (10mM) and RNAse-free H2O was prepared for each RNA sample in 
0.2ml tubes. Using a Veriti 96-Well Thermal Cycler (Applied Biosystems, CA, USA), the 
tubes were incubated for 5 minutes at 70°C then were chilled at 4°C for 5 minutes. The 
reverse transcriptase master mix was prepared from 5x RT buffer (4µl per tube), RiboSafe 
RNAse Inhibitor (10U/µl; 1µl per tube) and Tetro Reverse Transcriptase (200U/µl; 1µl per 
tube). 6µl of master mix was added to each sample tube. For a negative control tube, no 
reverse transcriptase enzyme was added. All tubes were incubated for 30 minutes at 45°C 
on the thermocycler. The reaction was terminated by increasing the temperature to 80°C 
for 5 minutes, and then tubes were chilled at 4°C. cDNA samples were stored at -20°C. 
2.4.4. Quantitative real-time PCR 
 Quantitative real-time polymerase chain reaction (qPCR) was performed using 
synthesised cDNA. The master mix for each cDNA sample was prepared for each gene to 
be run in technical duplicate. For each reaction, 0.2-0.4µl of cDNA template (prepared 
from 500-1000ng RNA) was added to RNAse-free H2O to a total volume of 4.5µl. These 
master mixes were added to a 384-well plate (Applied Biosystems) for each cDNA sample. 
To prepare the gene master mixes for each cDNA sample in duplicate, 2x Taqman Gene 
Expression Master Mix (5µl per reaction; Thermo Fisher Scientific) was mixed with 
specific Taqman hydrolysis assays (0.5µl per reaction; Thermo Fisher Scientific) 
dependent on the gene of interest. Table 2.2 is a list of Taqman assays used throughout this 
thesis. These master mixes were added into the 384-well plate. Plates were covered with a 
MicroAmp Optical Adhesive Film (Applied Biosystems), and were run on a QuantStudio 
12K Flex instrument (Applied Biosystems). The plate was incubated at 50°C for 2 minutes, 
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and then was heated to 95°C for 10 minutes for AmpliTaq Gold DNA Polymerase 
activation. In the PCR stage (40 cycles), samples were heated at 95°C for 15 seconds to 
denature the strands, then at 60°C for 1 minute to anneal and extend; the fluorescence in 
each well was read on the instrument. The expression of all target genes was compared to 
the Gapdh and Actb housekeeping genes using the comparative cycle threshold (Ct) 
method (ΔΔCt). These reference genes do not change expression with retinal photo-
oxidative damage [225]. The QuantStudio software was used for qPCR analysis.  
Table 2.2. Taqman hydrolysis assays used for qPCR (Thermo Fisher Scientific) 
Gene Symbol Gene Name Catalogue Number Entrez Gene ID 
Actb Actin, beta Mm01205647_g1 11461 
C1s Complement component 1, s 
subcomponent 
Rn00594278_m1 192262 
Mm01625167_g1 50908 
C2 Complement component 2 Rn00597176_m1 24231 
Mm00442726_m1 12263 
C3 Complement component 3 Mm00437858_m1 12266 
C4a Complement component 4A 
(Rodgers blood group) 
Rn00709527_m1 24233 
Mm01132415_g1 625018 
Casp1 Caspase 1 Rn00562724_m1 25166 
Casp8 Caspase 8 Rn00574069_m1 64044 
Ccl2 Chemokine (C-C motif) ligand 2 Rn01456716_g1 24770 
Ccl3 Chemokine (C-C motif) ligand 3 Rn00564660_m1 25542 
Ccl4 Chemokine (C-C motif) ligand 4 Rn00587826_m1 116637 
Ccl7 Chemokine (C-C motif) ligand 7 Rn01467286_m1 287561 
Cfb Complement factor B Rn01526084_g1 294257 
Mm00433918_g1 14962 
Cfd Complement factor D (adipsin) Rn01535436_g1  54249 
Cfh Complement factor H Rn00590326_m1 155012 
Mm01299248_m1 12628 
Cfi Complement factor I Rn00577333_m1 79126 
Cntf Ciliary neurotrophic factor Mm00446373_m1 12803 
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Cxcl1 Chemokine (C-X-C) motif 
ligand 1 
Rn00578225_m1 81503 
Cxcl10 Chemokine (C-X-C) motif 
ligand 10 
Rn01413889_g1 245920 
Fgf2 Fibroblast growth factor 2 Mm01285715_m1 14173 
Gapdh Glyceraldehyde-3-phosphate 
dehydrogenase 
Rn99999916_s1 24383 
Mm99999915_g1 14433 
Il-1β Interleukin 1β Rn00580432_m1 24494 
Il-6 Interleukin 6 Rn01410330_m1 24498 
Il-12β Interleukin 12β Rn00575112_m1 64546 
Nlrp3 Nucleotide-binding domain, 
leucine-rich-containing family, 
pyrin domain-containing-3 
Rn04244620_m1 287362 
Rho Rhodopsin Mm00520345_m1 212541 
Serping1 Serpin peptidase inhibitor, clade 
G (C1 inhibitor), member 1 
Rn01485600_m1 295703 
Tnf Tumor necrosis factor α Rn00562055_m1 24835 
 
2.4.5. Standard PCR 
 Standard PCR was used to detect amplification products in samples following 
cDNA synthesis. Forward and reverse primers specific to genes of interest (Chapters 4-5) 
were designed using the Primer3 web-based design program [226]. Oligonucleotides were 
synthesised by Sigma Aldrich. The PCR reaction mixture was setup using the MyTaq 
DNA Polymerase kit (Bioline). Components included cDNA template (40ng/µl), MyTaq 
Reaction Buffer (5x), MyTaq Polymerase, forward and reverse primers (20µM), and 
DNAse-free H2O. A negative control sample had no cDNA added to the reaction mixture. 
The PCR was run via a standard amplification protocol on a Veriti 96-Well Thermal 
Cycler (Applied Biosystems); an initial phase of 95°C preceded the amplification phase. 
This was followed by 35 cycles of melting (95°C for 15 seconds), annealing (60°C for 15 
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seconds) and amplification (72°C for 10 seconds). To finish, samples were run at 72°C for 
1 minute. Following PCR, amplification products were run on a 1% agarose gel via 
electrophoresis, with Gel Red (Biotium, CA, USA) used for visualisation. Bands on the gel 
were imaged using a UV light source and camera (Vilber Lourmat, Paris, France). 
 
2.5. Imaging and statistical analysis 
2.5.1. Quantification of cell counts and ONL thickness 
 TUNEL, IBA1 and C3 positive cells were quantified along the full length of retinal 
cryosections (supero-inferior) in duplicate. Outer retinal counts (ONL-RPE) were taken for 
IBA1+ and C3+ staining. To determine photoreceptor cell death, only TUNEL+ cells in the 
ONL were quantified. To quantify the development of an outer retinal lesion, ONL 
thickness was quantified in OCT images as described earlier. To quantify photoreceptor 
loss in retinal cryosections, the number of rows of photoreceptor nuclei (visualised using a 
DNA label) was quantified at the lesion site in the superior retina (approximately 2mm 
superior to the optic nerve in rats, 1mm in mice). For each section, 5 measurements were 
taken, and each eye was counted in duplicate.  
2.5.2. Confocal imaging 
 Fluorescence in retinal cryosections was visualised and imaged using a laser-
scanning A1+ confocal microscope (Nikon, Tokyo, Japan). Images were acquired using the 
NIS-Elements AR software (Nikon). Negative control slides were visualised and imaged 
with each different immuno-label, to determine specificity of staining and the lower 
threshold of fluorescence detection for comparison to positively-stained slides. All slides 
were imaged using the same settings for each immuno-label for the comparison of positive 
staining between experimental groups. The intensity of fluorescent staining was 
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determined using ImageJ, and images were processed and assembled into figure panels 
using Photoshop CS6 software (Adobe Systems, CA, USA). 
2.5.3. Statistical analysis 
 All graphing and statistical analysis was performed using Prism 6 (GraphPad 
Software, CA, USA), using unpaired student t-tests, one-way analysis of variance 
(ANOVA) or two-way ANOVA with the appropriate post-hoc tests to determine statistical 
significance (P<0.05), as indicated throughout this thesis in Chapters 3-5. Graphs were 
generated with mean ± SEM values. 
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3. RESULTS 
 
Retinal macrophages synthesize C3 and activate complement in 
AMD and in models of focal retinal degeneration 
 
 
This chapter is presented as the following publication (* denotes equal first author): 
Natoli, R.*, Fernando, N.*, Jiao, H.*, Racic, T., Madigan, M., Barnett, N.L., Chu-Tan, 
J.A., Valter, K., Provis, J., Rutar, M. (2017) Retinal macrophages synthesize C3 and 
activate complement in AMD and in models of focal retinal degeneration. Investigative 
Ophthalmology & Visual Science. 58 (7), 2977-2990 
The candidate has made a major contribution as a first author to this study (generating 75% 
of rat data, 50% of mouse data and preparing the manuscript for publication). 
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3.1. Abstract 
Purpose: Complement system dysregulation is strongly linked to the progression of age-
related macular degeneration (AMD). Deposition of complement including C3 within the 
lesions in atrophic AMD is thought to contribute to lesion growth, although the 
contribution of local cellular sources remains unclear. We investigated the role of retinal 
microglia and macrophages in complement activation within atrophic lesions, in AMD and 
in models of focal retinal degeneration. 
Methods: Human AMD donor retinas were labelled for C3 expression via in situ 
hybridisation. Rats were subject to photo-oxidative damage, and lesion expansion was 
tracked over a 2-month period using Optical Coherence Tomography (OCT). Three 
strategies were used to determine the contribution of local and systemic C3 in mice: total 
C3 genetic ablation, local C3 inhibition using intravitreally-injected siRNA, and depletion 
of serum C3 using cobra venom factor. 
Results: Retinal C3 was expressed by microglia/macrophages located in the outer retina in 
AMD eyes. In rodent photo-oxidative damage, C3-expressing microglia/macrophages and 
complement activation were located in regions of lesion expansion in the outer retina over 
2 months. Total genetic ablation of C3 ameliorated degeneration and complement 
activation in retinas following damage, although systemic depletion of serum complement 
had no effect. In contrast, local suppression of C3 expression using siRNA inhibited 
complement activation and deposition, and reduced cell death.  
Conclusions: These findings implicate C3, produced locally by retinal 
microglia/macrophages, as contributing causally to retinal degeneration. Consequently, this 
suggests that C3-targeted gene therapy may prove valuable in slowing the progression of 
AMD. 
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3.2. Introduction 
The complement system comprises a cascade of proteins that are cleaved 
sequentially to initiate the destruction of a pathogen, foreign body, or cell debris [145, 
146]. Prolonged cleavage of C3 may lead to membrane attack complex (MAC) assembly 
and cytolysis [145, 146]. Complement activation is under tight control, including 
regulation by complement factor H (CFH), a critical inhibitor. However, in 
neurodegenerative diseases including age-related macular degeneration (AMD), regulation 
of complement activation is compromised, contributing to disease onset and progression 
(reviewed in [3, 152, 227]). 
AMD affects photoreceptors and the retinal pigment epithelium (RPE) of the 
macula, which mediates high acuity vision. Multiple factors contribute to AMD 
pathogenesis (reviewed in [42]), however, the Y402H mutation in CFH is the most highly 
associated risk factor [153, 154]. Other variants in C3, CFB, and C2 genes are associated 
with AMD susceptibility (reviewed in [152]), with complement gene variants in the 
population estimated to account for ~70% of the risk for developing AMD [152]. 
Poor understanding  of the cellular events that initiate and feed complement 
activation in the retina has been a significant obstacle in development of innovative 
approaches in the management of AMD [3]. Immunohistochemistry analyses have 
revealed that by-products of C3 catabolism are deposited in affected areas of RPE/Bruch’s 
membrane, including drusen deposits, from AMD patients [62, 153, 157, 159-162]. This 
deposition, however, depends upon the availability of C3 within the retinal 
microenvironment, and the sources of C3 – systemic circulation or local retinal mediators – 
are unclear. Whole-transcriptome analyses of AMD donor eyes show that C3 mRNA is 
significantly increased in neural retina, but not in RPE/Choroid [47], suggesting that cells 
in the neural retina may be critically engaged in AMD pathogenesis. 
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In this study, we seek to identify the retinal modulators of complement in AMD 
and uncover their significance in the pathogenic activation of the cascade in the retina. We 
identified retinal macrophages as the local producer of C3 in both early and advanced 
forms of AMD. Using a model of outer-retinal degeneration and inflammation in rodents 
and Optical Coherence Tomography (OCT) we show that C3-expressing macrophages are 
associated with the expansion of atrophic lesions. Crucially, we demonstrate that 
intravitreal delivery of small interfering RNA (siRNA) suppresses this local expression of 
C3 and ameliorates retinal complement activation and degeneration; on the other hand, 
inhibition of serum-derived C3 has no effect on retinal complement levels or degeneration. 
Taken together, these findings inform our understanding of the role of complement in 
AMD, pinpointing macrophages as the key source of C3 that drives deleterious 
complement activation, and providing an indication for locally targeted gene therapy to 
suppress complement activation in retinal degeneration.  
 
3.3. Methods 
3.3.1. Experimental animals 
 All experiments were conducted in accordance with the ARVO Statement for Use 
of Animals in Ophthalmic and Vision Research. The study was approved by the Australian 
National University Animal Experimentation Ethics Committee (Application ID: 2014/56). 
Sprague-Dawley (SD) albino rats aged 120-150 post-natal days were used in this study. 
Additionally, C57BL/6J mice  and C3-knockout mice (C3-/-, 129S4-C3tm1Crr/J), both 
aged 60-80 days, were obtained from the Australian Phenomics Facility. For the C3 KO 
experiments, the KO mice were compared to isogenic C57BL/6J littermates. All animals 
were housed and maintained under standard laboratory conditions in 12:12hrs light:dark 
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cycle of 5lux (dim-reared). Age-matched dim-reared animals with no photo-oxidative 
damage were used as controls. 
3.3.2. Photo-oxidative damage and tissue collection 
 SD rats were placed into transparent Perspex open-top boxes and exposed to 
1000lux white light for 24hrs (COLDF2, 2x36W, IHF, Thorn Lighting, Spennymoor, UK), 
with free access to food and water [209]. Following photo-oxidative damage (PD), animals 
were euthanized with an overdose of barbiturate (60mg/kg Valabarb; Virbac, NSW, 
Australia) for tissue collection (0 days) or were held for 3, 7, 14 or 56 days under dim 
lighting (5lux), then euthanized.  
 C57BL/6J and C3-/- mice were housed in Perspex boxes coated with a reflective 
interior, and exposed to 100Klux of natural white LED for 1, 3, 5 and 7 days, with free 
access to food and water [228]. Each animal was administered with pupil dilator eye-drops 
twice daily during PD (Atropine Sulphate 1%w/v eye-drops; Bausch and Lomb, NSW, 
Australia). Following PD, electroretinography (ERG) was used to measure mouse retinal 
function in response to full-field flash stimuli under scotopic conditions in dim-reared 
control and 7-day damaged mice as described previously [228]. Animals were euthanized 
with CO2 prior to tissue collection. Eyes were collected and processed for cryosections or 
RNA extraction, as previously described in our publications [141, 228]. 
3.3.3. Optical Coherence Tomography (OCT) 
Cross-sectional and fundus images of live rat retinas were undertaken using a  
Spectralis™ HRA+OCT device (Heidelberg Engineering, Heidelberg, Germany). Animals 
were anaesthetised with an intraperitoneal injection of Ketamine (100 mg/kg; Troy 
Laboratories, NSW, Australia), and Xylazil (12 mg/kg; Troy Laboratories). Following 
anaesthesia, a pupil dilator was administered to both eyes (Tropicamide 0.5%w/v eye-
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drops; Bausch and Lomb). Animals were restrained on a custom-made platform attached to 
the imaging device, adapted for rat eyes according to manufacturer’s specifications. To 
maintain corneal hydration and improve OCT image quality to the manufacturer’s 
minimum standard (25dB), hypromellose 0.3% eye-drops (GenTeal; Novartis, NSW, 
Australia) were administered and a rodent contact lens was placed on the eye (PMMA 
lenses, radius of curvature of the central optic zone of 2.70mm and diameter of 5.20mm; 
Cantor + Nissel, Brackley, UK) [222]. Fundus and cross-sectional images were taken from 
0-3mm superior to the optic nerve (ON), and 1-2mm inferior to the ON. Eye gel (GenTeal; 
Novartis) was administered to both eyes for recovery. 
3.3.4. Treatment of mice with cobra venom factor (CVF) 
 To achieve systemic complement depletion, cobra venom factor (CVF) (Quidel, 
CA, USA) was dissolved in endotoxin-free PBS to a final concentration of 0.1µg/µl. 
C57BL/6J mice were administered with 25µg CVF intraperitoneally prior to 7 days of 
photo-oxidative damage, and on days 3 and 5 during damage to sustain complement 
depletion. To confirm an inhibition of complement activity, peripheral blood was collected 
at 7 days for a haemolytic assay. The serum of CVF-treated mice was extracted and 
incubated with sheep red blood cells (Applied Biological Products Management, SA, 
Australia) pre-sensitised with haemolysin (Sigma-Aldrich, MO, USA) as described 
previously [229]. The absorbance at 540nm was read using an Infinite-200-PRO plate 
spectrometer (Tecan, Mannedorf, Switzerland) and the percentage of haemolysis was 
calculated, and compared to serum from PBS-injected mice as a positive control, and C3-/- 
serum as a negative control. 
3.3.5. Intravitreal injections of siRNA 
 In vivo RNA interference was performed using C3 siRNA (s63165; Thermo Fisher 
Scientific, MA, USA) and negative control siRNA (12935300, Stealth RNAi Med GC; 
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Thermo Fisher Scientific), which were encapsulated using a cationic liposome-based 
formulation (Invivofectamine 3.0 Reagent; Thermo Fisher Scientific) as per the 
manufacturer’s instructions. To purify and increase the concentration of the siRNA 
formulation to a final concentration of 0.3µg/µl in endotoxin-free PBS, the samples were 
spun at 4000g through an Amicon Ultra-4 Centrifugal Filter Unit (Merck Millipore, MA, 
USA). Intravitreal injections were performed as described in our previous publication [89]; 
1µl of the C3 siRNA or negative control siRNA formulation was injected into both eyes of 
each C57BL/6J mouse on day 4 of photo-oxidative damage. Animals were recovered, and 
then returned to photo-oxidative damage for the remainder of the 7-day time-course. 
Mouse livers were collected 3 days after the siRNA injections for analysis of systemic C3. 
3.3.6. Immunohistochemistry and quantification of ONL thickness and 
microglia/macrophages in cryosections 
 All histological and immunofluorescent analyses utilised retinal cryosections that 
were cut along the para-sagittal plane (supero-inferior), described previously [209, 210]. 
These sections also included optic nerve head, in order to maintain regional consistency 
between replicates and groups.  
To detect and localise specific proteins in the retina, immunohistochemistry was 
performed using primary antibodies (Table 3.1) as described in our previous protocols with 
minor modifications [87, 141]. Mouse cryosections were immunolabelled with the α-C3 
antibody instead of α-C3d, as it achieved more optimal staining. Fluorescence in retinal 
sections was visualised under a laser-scanning A1+ confocal microscope (Nikon, Tokyo, 
Japan), and images were acquired using the NIS-Elements AR software (Nikon). Images 
were processed using Photoshop CS6 software (Adobe Systems, CA, USA). 
Immunolabelled IBA1+ cells in the outer retina (ONL-RPE) were counted across each 
whole retinal section and then averaged for each group, consistent with our prior methods 
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[210, 228]. For quantification, only the cell bodies of the IBA1+ cells were counted so as 
to prevent the occasional ambiguity of IBA1+ processes from skewing the dataset.  
Table 3.1. Primary antibodies used for immunohistochemistry 
Primary Antibody Dilution Catalogue Number Company 
Rabbit α-IBA1 1:500 019-19741 Wako, Osaka, Japan 
Goat α-C3d 1:100 AF2655 R&D Systems, MN, USA 
Rabbit α-C3 1:50 AB118877 Abcam, Cambridge, UK 
Rabbit α-Rhodopsin 1:500 AB9279 Merck Millipore, MA, USA 
Rabbit α-GFAP 1:500 Z0334 Dako, Glostrup, Denmark  
 
To assess ONL thinning on cryosections following photo-oxidative damage, the 
section were stained with Toluidine Blue and then quantified in accordance with our 
previous methodology [228]. Briefly, number of rows of photoreceptor nuclei were 
quantified within the lesion of the superior retina (1-2mm superior to the optic nerve in 
mice), and counts were subsequently averaged for each experimental group. 
3.3.7. In situ hybridisation on human and rat retinas 
To localise C3 mRNA transcripts in retinal cryosections, C3 was cloned from PCR 
products derived from human (460bp amplicon) and rat (483bp amplicon) retinal cDNA. 
These cloned templates were then synthesised into a digoxigenin (DIG)-labelled riboprobe 
that was specific to human or rat C3 mRNA, according to our published methodology 
[141].  
In situ hybridisation was performed on cryosections from either human AMD 
donor tissue or rat retinas subjected to photo-oxidative damage. AMD tissues had been 
extensively categorised and processed for cryosectioning in an earlier investigation [230]. 
In brief, human eyes were collected with informed consent through the Lions NSW Eye 
Bank, Sydney, Australia, with ethical approval from the Human Research Ethics 
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Committee of the University of Sydney and The Australian National University. Grading 
for the eyes ranged from normal to early- or late-AMD, and which was assigned by a team 
of experienced graders according to published pathological criteria [231].  
 In situ hybridisation was conducted using our established protocol [224]. Both rat 
and human C3 riboprobes were hybridised overnight at 57˚C and then washed in saline 
sodium citrate (pH 7.4) at 60˚C. The bound probe was visualised with nitro blue 
tetrazolium and 5-bromo-4-chloro-3-indolyl phosphate (NBT/BCIP), and sections were 
double-labelled using IBA1 immunohistochemistry. 
3.3.8. Quantitative real-time polymerase chain reaction (qPCR) 
 RNA extraction and purification was performed on retinas using a combination of 
TRIzol reagent (Thermo Fisher Scientific) and an RNAqueous Total RNA Isolation Kit 
(Thermo Fisher Scientific) as described in our previous publication [232]. cDNA was 
prepared from 500ng of each RNA sample using a Tetro cDNA Synthesis Kit (Bioline 
Reagents, London, UK) according to the manufacturer’s protocol.  
 Gene expression changes were measured via qPCR using Taqman hydrolysis 
probes (Table 3.2) and Taqman Gene Expression Master Mix (Thermo Fisher Scientific). 
Each qPCR was run using a QuantStudio 12K Flex instrument (Applied Biosystems) at the 
Biomolecular Resource Facility (JCSMR, ANU). Analysis was performed using the 
comparative cycle threshold method (ΔΔCt) which was normalised to the expression of 
Gapdh and Actb reference genes, as established previously [141, 144]. 
Table 3.2. Taqman hydrolysis probes used for qPCR 
Gene Symbol Gene Name Catalogue Number Entrez Gene ID 
Gapdh Glyceraldehyde-3-phosphate 
dehydrogenase 
Rn99999916_s1 24383 
Mm99999915_g1 14433 
Actb Actin, beta Mm01205647_g1 11461 
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C1s Complement component 1, s 
subcomponent 
Rn00594278_m1 192262 
Mm01625167_g1 50908 
C2 Complement component 2 Rn00597176_m1 24231 
Mm00442726_m1 12263 
C3 Complement component 3 Mm00437858_m1 12266 
C4a Complement component 4A 
(Rodgers blood group) 
Rn00709527_m1 24233 
Mm01132415_g1 625018 
Cfb Complement factor B Rn01526084_g1 294257 
Mm00433918_g1 14962 
Cfd Complement factor D (adipsin) Rn01535436_g1  54249 
Cfh Complement factor H Rn00590326_m1 155012 
Mm01299248_m1 12628 
Cfi Complement factor I Rn00577333_m1 79126 
Serping1 Serpin peptidase inhibitor, clade 
G (C1 inhibitor), member 1 
Rn01485600_m1 295703 
Cntf Ciliary neurotrophic factor Mm00446373_m1 12803 
Fgf2 Fibroblast growth factor 2 Mm01285715_m1 14173 
Rho Rhodopsin Mm00520345_m1 212541 
 
3.3.9. OCT and fundus images 
OCT and fundus images were analysed using ImageJ software (NIH, MD, USA). 
Retinal thickness, and ONL depth were measured in 5 OCT transects (superior and inferior 
to the optic nerve) spaced at 1mm intervals, with 5 points sampled across each image. ONL 
thickness ratios were calculated as the ONL thickness relative to the distance between the 
outer and inner limiting membranes. To detect fundus lesions, images of the area of interest 
(2-3mm superior to the optic nerve) were converted to grayscale, and contrast was 
optimised using the ‘curves’ function in Photoshop CS6 using a standard approach. Images 
were then converted to bitmaps using controlled parameters. ImageJ was used to measure 
the lesion size manually (arbitrary units).  
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3.3.10. Statistics 
All graphing and statistical analysis was performed using Prism 6 (GraphPad 
Software, CA, USA). Significant trends in time-course datasets were ascertained using the 
one-way or two-way analysis of variance (ANOVA) to determine statistical significance 
(P<0.05); Sidak’s or Tukey’s post-hoc tests were applied where multiple statistical 
comparisons were desired, while Fisher’s uncorrected Least Significant Difference (LSD) 
was used for instances of single comparisons. Student’s t-test was utilised for other single 
comparisons, where noted. 
 
3.4. Results 
3.4.1. Localisation of C3 mRNA in human donor retinas: A role for macrophages 
We investigated the localisation of C3 mRNA in normal aged human donor retinas 
and age-matched AMD-affected retinas using in situ hybridisation (Figure 3.1). We 
detected minimal C3 mRNA expression in normal retinas, and little-to-none within RPE 
cells or choroid (Figure 3.1A). However, in early AMD retinas, C3-expressing cells were 
detected in the nerve fibre layer (NFL), superficial retinal vasculature, and subretinal space 
in regions adjacent to RPE disturbance (Figure 3.1B-D). We detected numerous C3-
expressing cells in regions of advanced scarring (Figure 3.1E-F), at lesion edges (Figure 
1G-I), and near the optic nerve head (Figure 3.1J). In contrast, barely any labelling was 
detected in the choroid of these lesioned areas (Figure 3.1E). Counter immunolabelling 
indicated that most of the C3-expressing cells were immunopositive for the 
macrophage/microglia marker IBA1 (Figure 3.1K-N). 
  
57 
 
 
Figure 3.1. C3 expression in human AMD retinas. A: No C3-expressing cells were 
detected in the normal retina. B-D: Subretinal C3-expressing cells were present in early 
AMD retinas exhibiting RPE disturbance. C3 mRNA expression was detected near the 
inner retinal vasculature. E-J: In late AMD retinas, C3-expressing cells were detected 
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within the lesion (E-F), at the lesion edges (G-I), and at the optic nerve head (J). K-N: 
These C3-expressing cells were identified as IBA1+ microglia/macrophages. 
Representative images derived from N=2-3 per group. GCL, ganglion cell layer; INL, 
inner nuclear layer; ONL, outer nuclear layer; NFL, nerve fibre layer; OS, outer segments; 
V, vasculature. Scale bars represent 100µm in A,B,E,G,H,J; 50µm in K; 10µm in 
C,D,F,I,M. 
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3.4.2. Complement activation and macrophage recruitment within rat retinal lesions 
  Progression of lesion expansion in rat retinas following photo-oxidative damage 
was tracked in vivo using Optical Coherence Tomography (OCT) at 0, 3, 7, 14, and 56 
days (Figure 3.2). Measurements of outer nuclear layer (ONL) thickness were taken from 
cross-sectional images along 3 horizontal transects in the superior retina (Figure 3.2A), and 
2 in the inferior retina. Graphical representation of those measurements showed a gradual 
ONL thinning in the superior retina between 0 and 56 days, which was most prominent at 
2-3mm superior to the optic nerve head (Figure 3.2B). The data show a significant lesion 
detectable by 7 days (P<0.05, Figure 3.2B, D), which continued to develop further over the 
time-course. The thinnest ONL was detected in the 2-3mm transect at 56 days (P<0.05, 
Figure 3.2B, F). A retinal lesion (2-3mm superior to the optic nerve) was detected in 
fundus images from 3 days onwards (Figure 3.2G-M). The lesion size steadily increased 
from 3 to 14 days, and doubled from 14 to 56 days (P<0.05, Figure 3.2G-M). 
Expression of a suite of complement components (C1s, C2, C3 and C4a) and 
regulators (Cfb, Cfd, Serping1, Cfh, Cfi) was analysed across the time-course in whole rat 
retinas (Figure 3.3). All complement genes showed a significant trend in upregulation 
across the time-course (P<0.05), with C1s, C3 and C4a remaining significantly increased 
at 56 days post-damage compared to dim-reared controls (P<0.05, Figure 3.3B). While the 
complement regulators Cfb Cfd, Serping1, Cfh and Cfi were all highly up-regulated early 
in the time-course (0-7 days, Figure 3.3C), none were found to show any significant 
change by 56 days, compared to controls (Figure 3.3D, P>0.05). 
 Following photo-oxidative damage, there was an incursion of IBA1+ microglia and 
macrophages into the ONL and subretinal space (Figure 3.4). This persisted within the 
lesion up to 56 days (Figure 3.4A). Counts of IBA1+ cells in the ONL and subretinal space 
showed a ~7-fold increase between 0 and 7 days (Figure 3.4A, C), which decreased to  
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Figure 3.2. Outer nuclear layer (ONL) thickness ratio changes following photo-oxidative 
damage (PD) in rats. A: The regions of the superior retina imaged using OCT were from 
the optic nerve (ON) to 1mm, 1-2mm, and 2-3mm above the optic nerve. B: The ONL 
thickness ratio from ON-1mm (superior) and ON-2mm (inferior) showed minimal change 
over the time-course. The trend indicates a decrease in ONL thickness at 1-3mm superior 
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from 0 days onwards (P<0.05). A significant decrease in ONL thickness was observed at 2-
3mm (superior) up to 56 days (P<0.05). C-F: Representative OCT images of the control 
(C), in comparison to days 7-56 (D-F) at 2-3mm (superior) illustrate substantial ONL 
thinning over the time-course. G: The area (arbitrary units) of the retinal lesion as observed 
on fundus images from days 3-56 was quantified using bitmap analysis of the lesion area in 
ImageJ. A gradual increase in lesion size over time was observed, which was significant 
from 14 to 56 days (P<0.05). H-M: Representative lesion area fundus images from 2-3mm 
superior to the optic nerve (dashed box in A). No lesion was detected in control (H) and 0 
day (I) images. A retinal lesion was observed in fundus images from 3 days (J), which 
gradually increased in size at 7 days (K), 14 days (L) and 56 days (M). Statistical analysis 
was determined using one-way ANOVA with Tukey’s post-hoc test (P<0.05). GCL, 
ganglion cell layer; INL, inner nuclear layer; ONL, outer nuclear layer; IS/OS, inner and 
outer segments; S, superior; I, inferior. N=4 animals per group. 
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Figure 3.3. Complement gene expression in rat retinas following photo-oxidative damage 
(PD). All genes investigated were upregulated until 56 days post-damage compared to dim-
reared controls. A: Complement components C1s, C2 and C4a reached peak expression at 
3 days. Expression of C3 was highest at 0-7 days. B: C1s, C3 and C4a were still 
significantly increased at 56 days compared to controls (P<0.05). C: Expression of the 
complement regulator gene Cfb was highest at 0 days, whereas Cfd expression peaked at 3 
days. Serping1, Cfh, Cfi expression all peaked at 3 days. D:  Serping1, Cfh, Cfi, Cfb, and 
Cfd showed no statistically significant change after 56 days post-exposure (P>0.05). The 
trend in expression was determined using one-way ANOVA (A,C, P<0.05), and Student’s 
t-tests was used to compare controls and 56 days (B-D). N=4 animals per group. 
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Figure 3.4. Infiltration of IBA1+ microglia/macrophages into the outer rat retina following 
photo-oxidative damage (PD). A: In dim-reared controls, there were no IBA1+ cells in the 
outer retina (ONL-RPE). Upon damage, an increase in IBA1+ cell numbers in the outer 
retina reached a peak at 7 days, and remained significantly increased at 56 days (P<0.05). 
B: IBA1+ cells were detected only in the inner retinas of controls. C: IBA1+ cell numbers 
in the outer retina and subretinal space peaked at 7 days at the lesion edge. D-E: At 56 
days, there were significant numbers of IBA1+ cells in the outer retina at the lesion edges, 
even though very few photoreceptor cell nuclei remained. Statistical significance was 
determined using a one-way ANOVA. INL, inner nuclear layer; ONL, outer nuclear layer. 
N=4 animals per group. Scale bars represent 50µm. 
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approximately half the number by 14 days, but remained significantly higher than control 
animals in the outer retina at 56 days (P<0.05, Figure 3.4A, D-E).  
In situ hybridisation (ISH) to localise expression of C3 mRNA at 7, 14 and 56 days 
post-exposure was consistent with previous findings in this model at 7 days [141], showing 
C3 mRNA localisation in the neural retina and subretinal space (Figure 3.5A-F). We 
detected accumulations of C3-expressing macrophages predominantly clustered amongst 
the remnants of the ONL and at the lesion edges, and near the inner retinal vasculature up 
to 56 days (Figure 3.5A-F). Co-localisation with IBA1+ immunolabelling (Figure 3.5G-I) 
suggests the identity of these C3-expressing cells as macrophages. We did not observe C3 
expression by other cell types in retina, including RPE cells, consistent with our previous 
reports [141, 144].  
 We used immunoreactivity for C3d, a by-product of C3 cleavage and an indication 
of complement activation, to visualise the distribution of C3 following photo-oxidative 
damage (Figure 3.5J-V). C3d labelling was absent in dim-reared controls (Figure 3.5J). 
However, C3d immunoreactive deposits were prominent at 7 and 14 days post-damage in 
the ONL, amongst the photoreceptor segments and in the subretinal space, particularly at 
the lesion edges (Figure 3.5K, L). These features persisted up to 56 days (Figure 3.5M-P). 
Double immunolabelling for IBA1 and C3d showed a close association of macrophages 
with C3d deposits situated within the lesion (Figure 3.5Q-V). 
3.4.3. Suppression of local C3 inhibits retinal atrophy - mouse studies 
To better understand the role of locally-expressed C3 in complement deposition in 
the subretinal space, and its role in retinal atrophy, we used three different strategies to 
inhibit C3 in a model of retinal degeneration [228]: C3 knockout (C3-/-), local inhibition of 
C3 using siRNA, and systemic C3 depletion using Cobra Venom Factor (CVF). 
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Figure 3.5. Infiltration of C3-expressing cells and C3d protein deposition in the outer rat 
retina following photo-oxidative damage (PD). A: There was no outer-retinal C3 
expression in dim-reared controls. B-D: At 7 days post-damage, C3-expressing cells were 
detected within the lesion and at the lesion edges in the outer retina (B-C), as well as near 
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the inner retinal vasculature (D). E: C3-expressing cells were present in the outer retina at 
14 days. F: At 56 days, C3-expressing cells were still present at the lesion edges. G-I: 
These C3-expressing cells were identified as IBA1+ microglia/macrophages. J: Low levels 
of C3d were detected in the inner retinal vessels of controls. K: At 7 days post-damage, 
C3d deposition was evident throughout the outer retina (ONL and subretinal space) at the 
lesion edges. L: C3d labelling peaked at 14 days, with large amounts of protein deposition 
detected at the lesion edges. M-P: At 56 days, there was still C3d labelling present within 
the lesion (M-N) and at the lesion edges (O-P). Q-U: At 14 days (Q) and 56 days (R-U), 
there was some co-localisation of the C3d protein with IBA1+ microglia/macrophages at 
the lesion edges. V: The negative control (no primary antibodies) showed only background 
staining, with some visible autofluorescence of debris near the outer retina. Representative 
images derived from N=4 animals per group. INL, inner nuclear layer; ONL, outer nuclear 
layer; RPE, retinal pigment epithelium; C, choroid; IPL, inner plexiform layer. Scale bars 
represent 50µm in A-M,O,Q-R,V; 10µm in N,P,S-U. 
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3.4.4. C3 knockouts 
Previous reports indicate that complete ablation of C3 reduces the ERG function 
and outer-retinal integrity in 12-month old animals [233]. For this reason we carried out 
experiments on P60-80 mice, in which no functional or histological deviations were 
observed [233, 234]. Dim-reared C3-/- animals were assessed for any functional or 
histopathological changes compared to wild types (Wt). These comparisons showed no 
reduction in ERG amplitudes, changes in rhodopsin (Rhod) expression, or up-regulation of 
the stress/neuroprotective factors GFAP, Fgf-2, or Cntf (Supplementary Figure 3.1).  
C3 gene expression and immunoreactivity for C3 were confirmed as absent in C3-/-
animals and in dim-reared Wt mice (Figure 3.6A-B). Increased C3 expression in Wt retinas 
was evident after 1 day of photo-oxidative damage and was up-regulated across the 
exposure time-course, with peak expression on day 5 (P<0.05, Figure 3.6A). 
Immunoreactivity for C3 deposits in the ONL and subretinal space of Wt retinas was 
evident at 5 and 7 days (Figure 3.6C-E), and absent in C3-/- retinas over the same period 
(Figure 3.6F).  Over the time-course of photo-oxidative damage, the ONL was better 
preserved in C3-/- mice compared to Wt (Figure 3.6G-M); at 7 days ONL thickness was 
significantly greater in the C3-/- mice compared to Wt (P<0.05, Figure 3.6G, J, M).  
The a-wave and b-wave responses of the ERG reflects the differences in retinal 
morphology of Wt and C3-/- animals described above, where the ERG a-wave and b-wave 
intensity response characteristics between groups was significantly different (P<0.05, 
Figure 3.6N-O). C3-/- mice had higher a- and b-wave responses compared to Wt mice 
(Figure 3.6N-O); this difference was most pronounced at the highest flash intensity 
(P<0.05, Figure 3.6P). 
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Figure 3.6. C3 expression in C57BL/6J wild-type (Wt) and C3-/- mouse retinas. A: C3 gene 
expression following photo-oxidative damage (PD) increased to a peak at 5 days (P<0.05 
compared to control, N=8 animals). B-F: C3 protein deposition was evident at 5 and 7 days 
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in Wt retinas (C-D). C3 detection was absent in C3-/- retinas at 7 days (F), which was 
comparable to Wt controls (B). G: ONL thinning was significant in Wt retinas compared to 
C3-/- retinas at 7 days (P<0.05, N=6 animals). H-M: Toluidine blue staining of Wt and C3-/- 
retinas show no ONL disturbance in the controls (H,K), and progressive thinning at 5 days 
(I,L) and 7 days (J,M), with C3-/- retinas having a thicker ONL than Wt retinas (at the site 
of the retinal lesion, 1-2mm superior to the optic nerve). N-P: C3-/- retinas at 7 days 
demonstrated a significantly higher a-wave (N) and b-wave (O) compared to Wt retinas 
(P<0.05, N=10 animals), which was most pronounced at 1.9 Log cd.s/m2 (P, P<0.05, N=10 
animals). Statistical significance was determined using one-way (A) or two-way ANOVA 
(G, Sidak’s post-hoc test; P, uncorrected Fisher’s LSD for the 1.9 Log cd.s/m2 comparison). 
GCL, ganglion cell layer; INL, inner nuclear layer; ONL, outer nuclear layer; RPE, retinal 
pigment epithelium. Scale bars represent 50µm. 
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3.4.5. Local C3 inhibition using siRNA 
C3 siRNA significantly reduced C3 gene expression in retinas at 7 days photo-
oxidative damage (p<0.05, Figure 3.7A). Lower levels of C3 protein deposits were 
observed in C3 siRNA-injected retinas compared with those injected with negative control 
siRNA (Figure 3.7B-C). In contrast, liver expression of C3 was not affected by intravitreal 
injection of C3 siRNA, indicating that siRNA injected into the eye was largely localised 
there (Figure 3.7D).  
Quantitative analysis of retinas post-damage showed that the photoreceptor 
population was protected against cell death in C3 siRNA-injected retinas compared with 
negative control siRNA (Figure 3.7E). Comparison of retinal thickness shows that the 
ONL is significantly thicker (P<0.05) in C3 siRNA-injected animals compared with 
negative control siRNA (Figure 3.7E). Furthermore, ERG analyses showed that the mean 
a-wave and b-wave amplitudes of the ERG were significantly greater in C3 siRNA-treated 
animals compared to negative siRNA controls, which was most pronounced at the highest 
flash intensity (P<0.05, Figure 3.7H). The ERG a-wave and b-wave intensity response 
characteristics between groups was significant (p<0.05, Figure 3.7F-G). 
3.4.6. Systemic C3 depletion using Cobra Venom Factor 
To understand the possible role of serum complement components in the retina, we 
systemically depleted serum complement activity in Wt mice, using cobra venom factor 
(CVF). A haemolysis assay using serum from C3-/- animals, and animals injected with 
CVF or PBS, indicated that at 7 days damage, serum complement activity was depleted by 
CVF to a comparable level to C3-/- mouse serum, but not in PBS-injected animals, 
indicating that systemic complement was inhibited by CVF (P<0.05, Figure 3.8A).  
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Figure 3.7. Inhibition of retinal C3 expression using C3 siRNA and 7 days of photo-
oxidative damage (PD). A: Retinal C3 gene expression was significantly decreased 
following an intravitreal injection of C3 siRNA compared to the negative siRNA controls 
(P<0.05, N=11 animals). B-C: There was a reduction in C3 protein deposition in the C3 
siRNA-injected retinas compared to negative siRNA controls. D: Liver C3 gene expression 
was not affected at 3 days after the C3 siRNA intravitreal injection (N=3 animals). E: 
There was a significant reduction in photoreceptor loss in C3 siRNA-injected retinas 
compared to negative siRNA controls (P<0.05, N=13 animals). F-H: C3 siRNA retinas 
displayed a larger a-wave (F) and b-wave (G) compared to negative siRNA controls, which 
was most pronounced at 1.9 Log cd.s/m2 (H), indicating a significantly improved retinal 
function (P<0.05, N=4 animals). Statistical significance was determined by an unpaired 
student t-test (A,D,E) or a two-way ANOVA (F-G, uncorrected Fisher’s LSD for the 1.9 
Log cd.s/m2 comparison). INL, inner nuclear layer; ONL, outer nuclear layer; RPE, retinal 
pigment epithelium. Scale bars represent 50µm. 
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Figure 3.8. Depletion of systemic complement using cobra venom factor (CVF) at 7 days 
of photo-oxidative damage (PD). A: Complement activity in the serum was inhibited in 
CVF-injected animals compared to PBS controls as determined in a haemolytic assay using 
sheep red blood cells (SRBC), where complement inhibition in CVF-injected animals was 
comparable to C3-/- animals (N=4 animals). B: Retinal expression of complement genes 
(C3, C1s, C2, C4a, Cfb, Cfh) were not significantly affected by CVF depletion of systemic 
complement (N=9 animals). C-D: There was no difference in C3 protein deposition 
between CVF and PBS-injected animals. E: No difference in ONL thickness was observed 
between CVF and PBS-injected animals (N=6 animals). F-H: Depletion of systemic 
complement did not decrease retinal function, as there was no significant difference in the 
a-wave (F) or b-wave (G) between CVF and PBS groups (N=5 animals). Statistical 
significance was determined by an unpaired student t-test (A,B,E) or a two-way ANOVA 
(F-G, uncorrected Fisher’s LSD for the 1.9 Log cd.s/m2 comparison). ONL, outer nuclear 
layer; RPE, retinal pigment epithelium. Scale bars represent 50µm. 
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To understand the impact of CVF on complement gene expression in the retina we 
compared levels of C3, C1s, C2, C4a, Cfb, and Cfh at 7 days in animals injected with CVF, 
with PBS-injected controls. The elimination of systemic complement by CVF did not 
significantly alter the retinal expression of those complement components or regulatory 
genes (Figure 3.8B). In addition, no difference was observed in retinal C3 deposition 
between CVF- and PBS-injected animals at 7 days (Figure 3.8C-D). 
Analysis of retinal morphology showed that depletion of systemic complement 
does not protect against retinal degeneration. No difference in ONL thickness in CVF-
injected mice compared with PBS-injected mice was observed (Figure 3.8E). Similarly, 
there were no significant differences in mean a-wave or b-wave amplitudes in CVF- and 
PBS-injected animals after 7 days damage, and no significant difference in the ERG 
intensity response characteristics between groups (Figure 3.8F-H).  
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Supplementary Figure 3.1. Characterisation of dim-reared C57BL/6J wild-type (Wt) and 
C3-/- mouse retinas. A: When assessing retinal function, there was no change in the a-wave 
between Wt and C3-/- groups. B-C: There was no significant difference in the b-wave 
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across the varying flash intensities (B) except at 1.9 Log cd.s/m2, where a significant 
difference was detected (C, P<0.05, N=4-5 animals). D-G: Rhodopsin labelling in the outer 
segments (OS) was similar in the Wt and C3-/- retinas (D-F, N=5 animals), and there was no 
change in Rhod gene expression between both groups (G, N=3 animals). H-J: GFAP 
expression in the Müller cells was not significantly different in Wt and C3-/- retinas, 
however, was slightly higher in the Wt (N=5 animals). K: There was no significant change 
in the expression of neuroprotective genes (Cntf, Fgf2) between Wt and C3-/- retinas (N=4 
animals). Statistical significance was determined by an unpaired student t-test (F-G,J-K) or 
a two-way ANOVA (A-B, uncorrected Fisher’s LSD for the 1.9 Log cd.s/m2 comparison). 
GCL, ganglion cell layer; INL, inner nuclear layer; ONL, outer nuclear layer. 
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3.5. Discussion 
This is the first study to demonstrate the key importance of locally expressed 
sources of complement in driving complement-induced retinal atrophy. First, we show that 
C3 expression by macrophages in the human retina is closely linked to retinal atrophy in 
AMD. Second, we demonstrate in vivo the emergence and progression of a focal atrophic 
lesion in the rat retina over a period of 56 days, and the modulation of expression of a 
range of complement-related genes, including the persistent elevation of C3 and its 
expression by macrophages over the time-course. Third, using C3-/- mice, knockdown and 
depletion strategies we demonstrate conclusively that C3 expressed in the retina, but not 
serum C3, plays a decisive role in complement propagation in retinal degeneration. Taken 
together, these results suggest that a therapeutic approach targeting C3 could slow the 
progression of many neurodegenerative diseases including AMD. 
3.5.1. Role of complement in onset of retinal atrophy 
Complement dysregulation has been highly implicated in the progression of AMD 
[152]. Consistent with other similar findings that complement over-activation contributes 
to retinal degenerations [68, 69, 196, 200, 217, 219], our previous studies show an up-
regulation of complement genes C1s, C2, C3 and C4a in retinal degenerations [141, 144, 
211, 228]. This study extends those collective findings showing that C1s, C2, C3 and C4a 
are up-regulated during progressive lesion expansion, and that accumulation of C3-
expressing macrophages at the lesion edges is a constant feature of lesion progression. This 
complement gene expression profile is consistent with a broad scope of literature, which 
has genetically and histologically linked focal retinal atrophy, including AMD 
pathogenesis, to irregularities in the complement system [47, 62, 153, 157, 158, 160-162]. 
In particular, sustained up-regulation of C1s, C3 and C4a demonstrated in this study, is 
consistent with findings from systems-level analysis of AMD neural retinas [47].  
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C3 propagation is strongly implicated in AMD through the association of the 
Y402H variant of CFH [153, 154]. We pursued the effects of disrupting local and systemic 
C3 using a triad of C3 inhibition strategies. The results show that the retina is protected 
from atrophy in both ablation and local knockdown of C3, but not from systemic CVF 
depletion of C3. This demonstrates that only locally expressed C3 – not serum C3 – is 
linked to retinal atrophy in this study. Serum complement components are constitutively 
produced and replenished by the liver [235], and it has been reported that C3 levels are 
elevated in the peripheral blood of AMD patients [236]. Because complement components 
from serum would not be able to cross the intact blood-retinal barrier (BRB) due to their 
large size, it is unlikely that they could participate in the onset of retinal atrophy. However, 
as retinal atrophy progresses and there is breakdown of the outer BRB, there are no barriers 
to the permeation of serum constituents and this could contribute to further progression of 
atrophy. 
3.5.2. Local C3-expressing macrophages as a therapeutic target for reducing retinal 
atrophy 
Macrophage infiltration of the subretinal space is a feature of AMD histopathology 
[4, 92, 135], including at the lesion edges in geographic atrophy [135], and their 
pathogenic involvement in the disease is well-supported through findings in both laser-
induced neovascularization [237, 238] and photo-oxidative damage [92, 228, 239] models, 
where their presence is associated with photoreceptor loss. In the present study we show 
that C3 is upregulated only by retinal and subretinal macrophages, and not by RPE cells in 
AMD-affected retinas. Areas of lesion development in our experimental model of retinal 
degeneration are associated with complement activation and deposition by microglia and 
macrophages, where photoreceptor cell death may occur through membrane attack 
complex formation. Our current and previous findings [141, 144] are consistent with a 
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transcriptome-wide analysis, combining over 60 donor samples covering all forms of 
AMD, which demonstrated C3 upregulation in neural retina, but not RPE/choroid  [47].  
Despite this we do not suggest that the RPE/choroid interface plays no role in 
modulating complement, as these tissues are known to express a range of other 
complement constituents, and the membrane attack complex is abundant in the 
choriocapillaris in early AMD [164]. RPE cells have been reported in some studies as a 
local source of C3 in mouse retina in homeostasis or resulting from retinal degenerations 
[140, 181, 214]. These studies relied upon PCR of combined extracts of RPE/Choroid, or 
used cultured RPE. However, no study has confirmed that RPE expresses complement 
genes in the retinal environment in situ.  
We surmise that complement activation and deposition in the outer retina is 
dependent on the summative effects of a range of mediators and regulators, and that 
accumulation of subretinal macrophages is a key component from the perspective of C3 
synthesis and deposition. We identify retinal C3-expressing macrophages as a novel 
therapeutic target for mitigating the damaging effects of complement in retinal atrophy, 
and highlight a potential role for C3-targeted gene therapies. 
An outstanding question is whether the C3-expressing macrophages associated with 
retinal atrophy derive from the pool of resident microglia, or recruited bone-marrow 
monocytes, or both. O’Koren and colleagues have shown, using genetic lineage tracing, 
that subretinal macrophages are predominantly resident microglia [120]. On the other 
hand, their localisation of some C3-expressing macrophages adjacent to the superficial 
retinal vasculature and optic nerve suggest recruitment pattern of bone-marrow derived 
macrophages [185], suggesting that the C3-expressing population may also comprise non-
resident macrophages.  
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3.5.3. Conclusions 
Through combined observations in human donor tissue and models of retinal 
degeneration, our study illustrates a novel role of macrophages in priming the pathogenic 
activation of complement via their secretion of C3. We emphasise that this key 
contribution of subretinal macrophages does not preclude important roles for the 
RPE/choroid interface itself in influencing complement activation. However, our findings 
do reveal that the orchestration of complement-mediated pathology in AMD involves more 
elements than surmised previously [152], of which subretinal macrophages are a pivotal 
element. In demonstrating the efficacy of intravitreal C3 siRNA in mediating complement-
induced in retinal atrophy while also negating a contribution of systemic C3, we provide 
vital proof-of-principle support for locally administered gene therapy to target 
complement-induced retinal atrophy. This work lays a foundation for testing advanced 
gene-editing approaches, such as CRISPR/Cas9 technology, with the potential to 
revolutionise the therapeutic landscape for complement-mediated retinal degenerations 
including AMD. 
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4. RESULTS 
 
The broad spectrum chemokine inhibitor NR58-3.14.3 
modulates macrophage-mediated inflammation in the diseased 
retina 
 
 
This chapter is presented as the following publication (* denotes equal first author): 
Fernando, N.*, Natoli, R.*, Valter, K., Provis, J., Rutar, M. (2016) The broad spectrum 
chemokine inhibitor NR58-3.14.3 modulates macrophage-mediated inflammation in the 
diseased retina. Journal of Neuroinflammation. 13:41 
The candidate has made a major contribution as a first author to this study (generating 80% 
of all data and preparing the manuscript for publication). 
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4.1. Abstract 
Background: The activity of macrophages is implicated in the progression of retinal 
pathologies such as atrophic age-related macular degeneration (AMD), where they 
accumulate amongst the photoreceptor layer and subretinal space. This process is aided by 
the local expression of chemokines, which furnish these cells with directional cues that 
augment their migration to areas of retinal injury. While these qualities make chemokines a 
potential therapeutic target in curtailing damaging retinal inflammation, their wide variety 
and signalling redundancy pose challenges in broadly modulating their activity. Here, we 
examine the efficacy of the broad spectrum chemokine inhibitor NR58-3.14.3 – a 
suppressor of Ccl- and Cxcl- chemokine pathways – in suppressing macrophage activity 
and photoreceptor death, using a light-induced model of outer-retinal atrophy and 
inflammation.  
Methods: Photo-oxidative damage was induced in SD rats via exposure to 1000lx of light 
for 24hrs, after which animals were euthanized at 0 or 7 day post-exposure time points. 
Prior to damage, NR58-3.14.3 was injected intravitreally. Retinas were harvested and 
evaluated for the effect of NR58-3.14.3 on subretinal macrophage accumulation and 
cytokine expression profile, as well as photoreceptor degeneration.  
Results: We report that intravitreal administration of NR58-3.14.3 reduces the 
accumulation of macrophages in the outer retina following exposure to light damage, at 
both 0 and 7 days post-exposure time-points. Injection of NR58-3.14.3 also reduced the 
up-regulation of inflammatory markers including of Il6, Ccl3 and Ccl4 in infiltrating 
macrophages, which are promoters of their pathogenic activity in the retina. Finally, 
NR58-3.14.3 injected retinas displayed markedly reduced photoreceptor death following 
light damage, at both 0 and 7 days post-exposure.  
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Conclusions: Our findings indicate that NR58-3.14.3 is effective in inhibiting subretinal 
macrophage accumulation in light-induced retinal degeneration, and illustrate the potential 
of broad spectrum chemokine inhibitors as novel therapeutic agents in thwarting retinal 
inflammation. Although broad spectrum chemokine inhibitors may not be appropriate for 
all retinal inflammatory conditions, our results suggest that they may be beneficial for 
retinal dystrophies in which chemokine expression and subretinal macrophage 
accumulation are implicated, such as advanced AMD. 
 
4.2. Background 
Age-related macular degeneration (AMD) is the leading cause of irreversible 
blindness among those aged over 65 in industrialised nations [34]. It is a progressive 
retinopathy that affects the photoreceptor population, retinal pigment epithelium (RPE) and 
Bruch’s membrane, and the choroid at various stages of the disease. The advanced stages 
of AMD are classified into two forms. Exudative ‘wet’ AMD, induced by sudden choroidal 
neovascularisation (CNV), and geographic atrophy (GA) marked by a progressive 
expanding lesion of the RPE, photoreceptors, and choriocapillaris. While AMD has a 
complex aetiology involving multiple lifestyle and genetic risk factors, the significance of 
immunological processes has emerged slowly [4, 71-74, 240]. The relatively recent 
confirmation in genome wide association studies (GWAS) of the importance of the 
complement system and macrophages has placed inflammation among the forefront of 
factors influencing both the onset and progression of AMD [152, 241].  
The accumulation and activation of macrophages within the retinal tissues is a 
prominent feature of most retinopathies, and is well documented in all forms of AMD. 
Microglial cells are the resident macrophages of the retina that are derived from embryonic 
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yolk sac progenitors during development [119, 242], while non-resident bone marrow-
derived macrophages may be recruited into the retina from the vasculature in pathology [5, 
120]. In AMD lesions, macrophages form large aggregations in the photoreceptor layer, 
subretinal space, and RPE [71, 72, 74, 92, 134, 135, 243], which are typically free of these 
leukocytes in healthy individuals [244]. Despite having some beneficial properties [131], 
excessive accumulation of these cells is implicated in degeneration in animal models of 
AMD, retinal detachment [245], diabetic retinopathy [183, 246, 247], and glaucoma [248, 
249].  
Chemokines are key regulators of macrophage activation and accumulation in 
AMD [250, 251], as well as degenerations associated with retinal detachment [245] and 
diabetic retinopathy [183]. The chemokine family comprises more than 50 molecules and 
associated receptors that activate and recruit leukocytes to sites of damage. Transcriptome-
wide analysis of AMD donor retinas reports that the leukocyte chemoattractants Ccl2, 
Cxcl1, Cxcl10, Cxcl11 are up-regulated in all forms of the disease [47]. Moreover, 
intraocular Ccl2 protein levels are increased in patients with CNV or GA [92, 252, 253], 
and infiltrating microglia/monocytes in retinas with GA express the cognate Ccl2 receptor, 
Ccr2 [92]. Chemokines signalling is implicated in exacerbating the accumulation of 
macrophages and photoreceptor death in a range of animal models that demonstrate some 
features in common with AMD, including laser-induced-CNV [3], photo-oxidative stress 
[89, 91, 92], Abca4−/−Rdh8−/− mice [93], and carboxyethylpyrrole (CEP)-immunized mice 
[254].  
While these findings underscore the importance of chemokines in shaping 
inflammation in the retina, therapeutic blockade of individual chemokine ligands/receptors 
may have limited efficacy due to chemokine receptor redundancy, and the tendency toward 
compensatory increases in expression of other chemokine family members [93, 185]. 
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Broad spectrum chemokine inhibitors (BSCIs) are a class of chemokine modulators with 
the ability to inhibit signal transduction of a broad swathe of chemokine receptors [187]. 
Among these, NR58-3.14.3 is a robust cyclic peptide that specifically inhibits chemokine-
mediated migration of macrophages by blocking the signalling of Ccl- and Cxcl- pathways 
[187]. NR58-3.14.3 has been shown to effectively inhibit macrophage accumulation and 
ameliorate pathology in lung ischemia [191], obliterative bronchiolitis [190], skin 
inflammation [187], and atherosclerotic plaques [192].  
To our knowledge there are no studies which have explored the potential of BSCIs 
in retinal degeneration models. Here, we investigate the effect of NR58-3.14.3 in 
modulation of the accumulation of macrophages in the outer retina, using a light-induced 
model of oxidative stress and retinal inflammation. While acute exposure to light damage  
does not induce some of the classical features of AMD (including drusen and CNV) it 
induces focal and progressive atrophy of the outer retina and models very effectively the 
accumulation of subretinal macrophages and up-regulation of chemokines Ccl2, Cxcl1, 
Cxcl10, and Cxcl11 [87]. Furthermore, we have shown that the degenerative changes 
associated with light damage closely mimic naturally occurring degenerative changes in 
the aging rat retina [144]. 
 In the current study, we show that intravitreal delivery of NR58-3.14.3 is safely 
tolerated in experimental animals, is long-lasting in the retinal environment, suppresses 
macrophage accumulation in the outer retina, and reduces retinal pathology following light 
damage. Additionally, we demonstrate that NR58-3.14.3 reduces the expression of pro-
inflammatory factors Il6, Ccl3 and Ccl4 by macrophages, which are implicated in 
promoting their deleterious activity in retinal dystrophy. These data provide proof-of-
principle support of the value of BSCIs in thwarting deleterious macrophage activity in 
retinal degeneration. 
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4.3. Methods 
4.3.1. Animal handling and rearing 
All experiments were in accordance with the ARVO Statement for Use of Animals 
in Ophthalmic and Vision Research, and with approval from the ANU Animal 
Experimentation Ethics Committee (Ethics ID: A2014/56). Adult Sprague-Dawley (SD) 
rats were utilised in all experiments, which were born and reared under dim light 
conditions (5 lux) and aged between 90-120 post-natal days at the time of use. 
4.3.2. Preparation of NR58-3.14.3 and intravitreal injections 
Animals were anaesthetised with an intraperitoneal injection of Ketamine 
(100mg/kg; Troy Laboratories, NSW, Australia) and Xylazil (12mg/kg; Troy Laboratories, 
NSW, Australia). Intravitreal injections of consisting of 3µL were conducted as described 
previously [89]; this route was preferred over systemic administration as it minimizes the 
potential for off-target effects which may confound the data. The 3µL injection volume 
was chosen as offers good reproducibility, minimal disturbance in vitreal volume, and 
negligible cataract formation [221]. The broad spectrum chemokine inhibitor (BSCI) 
NR58-3.14.3 (Auspep, VIC, Australia) was reconstituted in endotoxin-free 0.1M PBS to a 
final concentration of 66.7µg/µl. In the treatment group, 3µl of NR58-3.14.3 in PBS was 
intravitreally injected into both eyes of each animal, so that 200µg of NR58-3.14.3 was 
delivered to each eye. The control group received an injection of 3µl PBS vehicle in each 
eye. Following intravitreal injections the animals were monitored closely throughout the 
time course of experiments. As expected, no incidences of cataract formation or other 
abnormalities were observed. 
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4.3.3. Light damage  
Immediately after administering intravitreal injections, animals were exposed to 
1000 lux light for a period of 24 hours, as described previously [209]. During light 
damage, animals were placed into transparent Perspex open-top cages under a light source 
(COLDF2, 2x36W, IHF, Thorn Lighting, Australia) with access to food and water ad 
libitum. After light damage, animals were either euthanized for tissue collection (0 day 
time point) or were placed into recovery under dim light conditions (5 lux) for 7 days.  
4.3.4. Retinal localisation of injected NR58-3.14.3 via fluorescein 
The fluorescein-labelled NR58-3.14.3 was prepared using an NHS-Fluorescein 
Antibody Labelling Kit (Pierce, Thermo Fisher Scientific, MA, USA), applied according to 
the manufacturer’s protocol. In brief, the NR58-3.14.3 was reconstituted in endotoxin-free 
PBS to a concentration of 1mg/ml. The NR58-3.14.3 was then incubated with the NHS-
Fluorescein for 1 hour at room temperature, before being purified through a column to 
remove excess dye from the final product. The fluorescein-NR58-3.14.3 was stored at 4°C. 
Using the intravitreal procedure described earlier, each animal was injected with 3µl 
fluorescein-NR58-3.14.3 in one eye only; the contralateral eye was used as either a 
fluorescein-only injected control, or a non-injected control. Following the injection, 
animals were placed under dim-light conditions to recover. Both eyes of each animal were 
collected for cryosectioning at several times after the injection (20 minutes, 3 hours, 24 
hours and 7 days). The levels of fluorescein-NR58-3.14.3 in injected retinas were 
measured on cryosections. The fluorescence was visualised with a laser-scanning A1+ 
confocal microscope (Nikon, Tokyo, Japan), and images were acquired at consistent 
regions using the NIS-Elements AR software (Nikon, Tokyo, Japan). From these images 
fluorescence intensity was quantified with ImageJ software (NIH, MD, USA), using 
integrated density for a fixed area. 
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4.3.5. Tissue collection and processing of whole retinas 
Animals were euthanized using an overdose of barbiturate, which was administered 
via intraperitoneal injection (Valabarb; Virbac, NSW, Australia). The left eye from each 
animal was marked for orientation then enucleated for cryosectioning, while the retina from 
the right eye was excised through a corneal incision for RNA extraction. Both 
cryosectioning and RNA extraction of the excised retinas were performed according to our 
previous methodology [141]. 
4.3.6. Fluorescence-activated cell sorting (FACS) of retinal macrophages 
Rats in each treatment group were euthanized immediately after light damage (0 
days) using barbiturate overdose as previously described. Retinas from both eyes were 
promptly removed through a corneal incision. Retinas from each animal were pooled and 
immediately placed in chilled Hank's balanced salt solution (HBSS), and then subjected to 
light mechanical separation using a razor blade. Samples were transferred into a 0.2% 
papain digestion cocktail as described in our previous protocol [87], with minor 
modifications. Samples were incubated at 37°C for 7 minutes then 8°C for 30 minutes. 
After neutralisation and resuspension, the resulting homogenate was incubated in staining 
buffer containing a CD11b antibody conjugated to Alexa 647 (Biolegend, San Diego, CA) 
for 30 minutes at 4°C, then washed in HBSS and resuspended in staining buffer. The 
resultant CD11b-stained samples were run through a fluorescence-activated cell sorter 
(FACS) (BD FACSAria II; BD Biosciences, Franklin Lakes, NJ). The isolated CD11b+ 
macrophages were collected in staining buffer and kept chilled on ice until RNA extraction 
could be commenced. RNA extraction was conducted via a protocol we have previously 
established [87]. Isolated total RNA was analysed for quantity and purity with a ND-1000 
spectrophotometer (Nanodrop Technologies, Wilmington, DE). 
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4.3.7. TUNEL assay and quantification of photoreceptor survival 
To quantify levels of photoreceptor cell death in the retina, retinal cryosections 
were stained for apoptosis using a terminal deoxynucleotidyl transferase dUTP nick end 
labelling (TUNEL) kit (Roche Diagnostics, NSW, Australia) as previously described [255, 
256]. TUNEL+ cells in the ONL were counted throughout the full length of each retinal 
section along the para-sagittal plane (supero-inferior), and also included the optic nerve for 
consistency. These counts were subsequently averaged for each experimental group. To 
quantify photoreceptor survival, sections were stained with bisbenzimide (Sigma-Aldrich 
Co., MO, USA), and the number of rows of photoreceptor cell bodies in the ONL were 
counted. Five counts were made for each retinal section, and then were averaged for each 
experimental group. 
4.3.8. Immunohistochemistry 
Cryosections were used for immunohistochemical analysis, using antibodies 
against IBA1 (1:500, Wako, Osaka, Japan) and GFAP (1:500, Dako, Agilent Technologies, 
CA, USA) as described in our previous study, with minor modifications [87, 209]. 
Fluorescence in retinal sections was captured with a laser-scanning A1+ confocal 
microscope (Nikon, Tokyo, Japan). Images panels were analysed and assembled using 
ImageJ (NIH, MD, USA) and Photoshop CS6 software (Adobe Systems, CA, USA).  
4.3.9. Quantification of microglia/macrophages 
Macrophages counts were performed on sections immunolabelled with the IBA1 
marker, a label for retinal microglia and macrophages. Counts of IBA1+ cells were carried 
out along the full-length of retinal sections cut in the para-sagittal plane (supero-inferior) 
within the vertical meridian, and each section also included the optic nerve to ensure 
consistency. Counts were made of all IBA1+ cells throughout the retina, which were split 
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into two groups: the inner retina (ILM-OPL), and the outer retina (ONL-RPE) where 
activated macrophages are known to aggregate during retinal degeneration [131, 245, 257]. 
4.3.10. Polymerase chain reaction (PCR) 
cDNA was prepared from 1µg of RNA of each sample using a Tetro cDNA 
Synthesis Kit (Bioline Reagents, London, UK). The quantitative real-time PCRs (qPCRs) 
were conducted using Taqman hydrolysis probes (Table 4.1) and Taqman Gene Expression 
Master Mix (Applied Biosystems, Life Technologies, CA, USA). These were applied 
following the manufacturer’s instructions, and run on a QuantStudio Flex 12K instrument 
(Applied Biosystems), at the Biomolecular Resource Facility, JCSMR, ANU. Data analysis 
was performed using Expression Suite v1.0.3 software (Life Technologies, CA, USA); the 
fold change was determined for each gene and sample using the comparative cycle 
threshold (Ct) method (ΔΔCt). All data was normalised to the GAPDH reference gene, 
which does not change in expression over the course of retinal light damage [141, 217, 
225]. ACTB was utilised as an additional reference gene in qPCRs involving the CD11b+ 
isolates. 
Table 4.1. Taqman hydrolysis probes used for qPCR 
Gene Symbol Gene Name Catalog Number Entrez Gene ID 
Ccl2 Chemokine (C-C motif) ligand 2 Rn01456716_g1 24770 
Ccl3 Chemokine (C-C motif) ligand 3 Rn00564660_m1 25542 
Ccl4 Chemokine (C-C motif) ligand 4 Rn00587826_m1 116637 
Ccl7 Chemokine (C-C motif) ligand 7 Rn01467286_m1 287561 
IL-6 Interleukin 6 Rn01410330_m1 24498 
IL-1B Interleukin 1β Rn00580432_m1 24494 
TNF  Tumor necrosis factor α Rn00562055_m1 24835 
IL-12B  Interleukin 12β Rn00575112_m1 64546 
GAPDH  Glyceraldehyde-3-phosphate 
dehydrogenase 
Rn99999916_s1 24383 
ACTB  Actin, beta Rn00667869_m1 81822 
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Standard PCR was performed on RNA samples purified from FACS-isolated 
CD11b+ microglia/macrophages, using primers specific to chemokine receptor genes 
(Ccr1, Ccr2, Ccr5, Cxcr3) which are detailed in our previous investigation [87]. First-strand 
cDNA synthesis was performed from 50 ng of RNA using the Tetro cDNA Synthesis Kit 
(Bioline), and standard PCR was then performed using MyTaq DNA polymerase (Bioline); 
negative controls had cDNA omitted from the reaction cocktail. The presence of PCR 
product and specificity of the reaction were assessed by gel electrophoresis. 
4.3.11. In situ hybridisation 
Ccl3 was cloned from a 540bp PCR product using cDNA prepared from rat retinas 
(as described in the qPCR section), and which was synthesised into a digoxigenin (DIG)-
labelled riboprobe according to our previous publication [87]. The In situ hybridisation was 
performed using our established protocol [224]; the Ccl3 riboprobe was hybridised on 
retinal cryosections overnight at 55°C, and then washed in decreasing concentrations of 
saline sodium citrate (pH 7.4) at 60°C. The bound probe was visualised with either 
NBT/BCIP, or HNPP/Fast-Red (Roche). 
4.3.12. Statistical analysis 
All graphing and statistical analysis was performed using Prism 6 (GraphPad 
Software, CA, USA). A two-way ANOVA with Tukey’s multiple comparison post-test, or 
an unpaired student t-test was utilised to determine the statistical outcome; a P-value of 
<0.05 was considered statistically significant. 
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4.4. Results 
4.4.1.  Stability and localisation of NR58-3.14.3 in injected retinas 
Localisation and persistence of NR58-3.14.3 within the retina was determined by 
intravitreal injections of fluorescein-conjugated NR58-3.14.3 (Figure 4.1). At 20 minutes 
post-injection, levels of fluorescence increased dramatically in retinas injected with NR58-
3.14.3-fluorescein, compared to fluorescein-only and non-injected controls (P<0.05, Figure 
4.1A). Fluorescence levels were maintained at 3 hours post-injection, though were reduced 
by approximately a third after 24hrs – this was not significant however compared to the 20 
minutes post-injection group (P>0.05). After 7 days, fluorescence was still present in 
NR58-3.14.3-fluorescein injected retinas at levels significantly higher than the fluorescein-
only and non-injected control groups (P<0.05).  
 At 20 minutes-post injection, NR58-3.14.3-fluorescein was distributed throughout 
the retina, spanning the ganglion cell layer (GCL) to the RPE (Figure 4.1B). This 
distribution was mostly unchanged after 3hrs, although fluorescence appeared more 
concentrated within the GCL, nerve fibre layer (NFL), inner nuclear layer (INL), and RPE 
(Figure 4.1C, arrows). After 24hrs incubation, fluorescence was localised in intense 
clusters encompassing the NFL, retinal vasculature, and RPE (Figure 4.1D, arrows). This 
localisation was maintained at 7 days post injection (Figure 4.1E, arrows), while 
fluorescein-only controls showed little fluorescence at all (Figure 4.1F). 
4.4.2. Tolerance of NR58-3.14.3 within the retinal environment 
NR58-3.14.3 was initially injected into dim-reared retinas to determine whether it 
induced any change in photoreceptor death, retinal stress, or macrophages alone (Figure 
4.2). At 24hrs following intravitreal injection with NR58-3.14.3 analyses showed no 
significant change in the number of TUNEL+ photoreceptors (P>0.05, Figure 4.2A) or in  
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Figure 4.1. Stability and localisation of intravitreally injected NR58-3.14.3. A: Levels of 
fluorescence readily increased in retinas injected with fluorescein-conjugated NR58-3.14.3 
after only 20 minutes, and remained highly elevated after 3hrs. Fluorescence was 
significantly lower at 7 days post-injection (P<0.05), but was still far higher than 
fluorescein-only and non-injected controls (P<0.05). B: NR58-3.14.3-fluorescein (green, 
arrow) was present throughout the retina at 20 minutes post-injection. C: Fluorescence 
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remained consistent in retinas after 3hrs, though was more concentrated within the GCL, 
NFL, INL, and RPE (arrows). D-E: After 24hrs and 7 days post-injection, fluorescence for 
NR58-3.14.3-fluorescein was markedly reduced, but still readily apparent around the NFL, 
retinal vasculature, and RPE (arrows). F: Retinas injected with fluorescein-only showed 
only very faint background fluorescence in comparison to NR58-3.14.3-fluorescein 
injected animals (E). GCL, ganglion cell layer; INL, inner nuclear layer; NFL, nerve fibre 
layer; ONL, outer nuclear layer; RPE, retinal pigment epithelium. Scale bars represent 
100µm. NR58-3.14.3-fluorescein n=3, fluorescein-only n=3, non-injected n=3.  
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Figure 4.2. Tolerance of NR58-3.14.3 within the retinal environment in relation to stress 
and macrophage recruitment. A: Injection of dim-reared controls with NR58-3.14.3 did not 
yield any change in TUNEL+ photoreceptors after 24hrs incubation, compared to non-
injected controls (P>0.05). B: NR58-3.14.3 alone did not induce any recruitment of IBA1+ 
macrophages to the outer retina after 24hrs incubation in dim-reared animals, and there 
was also no change in the inner retinal population (P>0.05). C-D: The integrity of the ONL 
was unchanged in animals injected with NR58-3.14.3, compared to non-injected controls. 
E-F: The morphology of IBA1+ macrophages/microglia (green) was unaltered in NR58-
3.14.3 treated retinas, and the ONL was devoid of any of these cells (arrows) in both 
groups. G-H: Immunoreactivity for stress marker GFAP was restricted to the GCL in both 
NR58-3.14.3 and non-injected groups (arrows), consistent with a normal physiological 
state. GCL, ganglion cell layer; IHC, immunohistochemistry; INL, inner nuclear layer; 
NFL, nerve fibre layer; ONL, outer nuclear layer; RPE, retinal pigment epithelium. Scale 
bars represent 100µm. NR58-3.14.3 n=3, non-injected n=3. 
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integrity of the retinal layers (Figure 4.2C-D), compared to control retinas; both parameters 
were consistent with our previous measurements in control SD retinas [209]. General 
retinal stress was assessed via immunohistochemistry for GFAP (Figure 4.2G-H), an 
accepted indicator of retinal pathology [10]. Immunoreactivity for GFAP was confined to 
the GCL (arrows) in both NR58-3.14.3- and PBS-injected retinas, consistent with a normal 
physiological retinal state [10, 209, 258]. Finally, there was no change in the distribution of 
IBA1+ microglia/macrophages in NR58-3.14.3-injected retinas compared to PBS-injected 
controls (P>0.05, Figure 4.2B, E-F). The outer nuclear layer (ONL) and subretinal space 
was devoid of macrophages in both groups (Figure 4.2E-F, arrows), while resident 
microglia/macrophages in the inner retina showed no change in number or morphology. 
4.4.3. Effect of NR58-3.14.3 on macrophage accumulation following light damage 
The accumulation of macrophages within the outer retina (including the 
photoreceptor layer and subretinal space) following NR58-3.14.3 injection was assessed 
using IBA1 immunoreactivity (Figure 4.3) to identify microglia/macrophages [259, 260]. 
Immediately following light damage (0 days recovery), we observed a substantial incursion 
of IBA1+ cells into the outer retina of PBS-injected controls (Figure 4.3A, C-D arrows). In 
animals injected with NR58-3.14.3, this accumulation was substantially less per retinal 
section (~70% reduction after NR58-3.14.3, P<0.05, Figure 4.3A, E).  
In PBS-injected animals 7 days post-light damage, the number of IBA1+ cells 
increased significantly throughout the retina, particularly in the subretinal space (Figure 
4.3A) where accumulations of swollen, amoeboid-like macrophages were observed 
amongst the degenerating photoreceptor segments (Figure 4.3F-G arrows). In animals 
injected with NR58-3.14.3 however, the number of IBA1+ cells infiltrating the outer retina 
was significantly less than in PBS controls (~60% reduction after NR58-3.14.3, P<0.05, 
Figure 4.3A), and virtually no macrophages were detected in the subretinal space (Figure  
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Figure 4.3. Macrophage/microglia recruitment to the outer retina following injection of 
NR58-3.14.3 and light damage. A-B: At 0 days post-LD, there was a substantial incursion 
of IBA1+ cells and their ramified processes into the outer retina of PBS-injected controls, 
which was substantially lower in animals injected with NR58-3.14.3 (P<0.05). During the 
chronic phase of degeneration at 7 days post-LD, the number of IBA1+ cells was further 
increased in the outer retina, although animals injected with NR58-3.14.3 had far fewer 
IBA1+ cells than in PBS controls (P<0.05). For the inner retinal counts of IBA1+ 
macrophages/microglia, there was no change at either 0 or 7 days recovery for both 
treatment groups (P >0.05). C-E: IBA1+ cells invaded ONL with their extended processes 
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in PBS-injected animals at 0 days (C-D, arrows), which was not apparent in the NR58-
3.14.3 group (E). F-H: Accumulations subretinal IBA1+ macrophages were observed in 
PBS-injected animals at 7 days (F-G, arrows), while the subretinal space was nearly devoid 
of these cells in NR injected retinas. GCL, ganglion cell layer; IHC, 
Immunohistochemistry; INL, inner nuclear layer; NFL, nerve fibre layer; ONL, outer 
nuclear layer; RPE, retinal pigment epithelium. C,E,F,H scale bars represent 100µm, D,G 
are 25µm. N=11 per group at 0 and 7 days. 
  
100 
 
4.3H). Conversely, the numbers of IBA1+ cells in the inner retina was similar in NR58-
3.14.3- and PBS-injected animals at both 0 and 7 days recovery (P>0.05, Figure 4.3B). 
4.4.4. Change in photoreceptor integrity following NR58-3.14.3 injection and light 
damage 
The effect of NR58-3.14.3 administration on photoreceptor cell death following 
light-induced damage was investigated using the TUNEL assay (Figure 4.4). Exposure to 
bright continuous light induced an increase in the number of TUNEL+ photoreceptors in 
both PBS- and NR58-3.14.3-injected groups (Figure 4.4A). However, the number of 
TUNEL+ cells in animals injected with NR58-3.14.3 was approximately half that in the 
PBS-injected control animals at 0 days recovery (P<0.05, Figure 4.4A-C). The effect of 
NR58-3.14.3 was even more pronounced during the chronic phase of degeneration at 7 
days recovery, wherein the number of TUNEL+ photoreceptors was 4 times lower in 
NR58-3.14.3-injected animals compared with the PBS-controls (P<0.05, Figure 4.4A, D-
E). In addition, the cumulative effect of NR58-3.14.3 on the number of surviving 
photoreceptors following light damage was determined via measurements of ONL 
thickness. There was no change in the number of photoreceptor rows at 0 days recovery 
compared to PBS controls (P>0.05, Figure 4.4F). At 7 days recovery however, there was in 
increased number of photoreceptor rows in NR58-3.14.3 retinas compared to PBS controls 
(P<0.05, Figure 4.4F-H).  
4.4.5. Cytokine and chemokine expression following NR58-3.14.3 injection and light 
damage 
The expression of chemokines (Ccl2, Ccl3, Ccl4, Ccl7) and cytokines (Il6, Il1b, 
TNFa, Il12) was assessed using qPCR to determine the effect of NR58-3.14.3 on 
chemokine signalling (Figure 4.5). These were selected based on their up-regulation in our 
microarray analysis conducted previously using the light damage model [87]. Expression  
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Figure 4.4. Change in photoreceptor integrity following injection of NR58-3.14.3 and light 
damage. A: At 0 days post-LD, animals injected with NR58-3.14.3 had approximately half 
the number of TUNEL+ cells per retina compared to PBS-injected controls (P<0.05). After 
7 days post-LD, where chronic retinal degeneration is most apparent, the number of 
TUNEL+ photoreceptors was roughly 3 times lower in animals injected with NR58-3.14.3 
than in the PBS-controls (P<0.05). B-E: Representative TUNEL images showcase the 
reduction in TUNEL+ photoreceptors in NR58-3.14.3 injected retinas at both 0 (C) and 7 
(E) days post-LD, compared to PBS controls (B,D). F: At 0 days post-LD, there was no 
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change in the number of rows of photoreceptor nuclei in NR58-3.14.3 injected retinas 
compared to PBS controls (P>0.05). However, at 7 days post-LD, animals injected with 
NR58-3.14.3 had a larger number of remaining photoreceptor rows than PBS controls 
(P<0.05). G-H: Representative ONL images demonstrate this reduction of photoreceptor 
loss in NR58-3.14.3 injected retinas compared to PBS controls at 7 days post-LD. INL, 
inner nuclear layer; ONL, outer nuclear layer. B-E scale bars represent 100µm, G-J are 
50µm. N=10-11 per group at 0 days, N=12 per group at 7 days. 
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Figure 4.5. Expression of chemokines (A, C) and cytokines (B, D) in whole retinas 
following injection of NR58-3.14.3 and light damage. A-B: All genes assessed exhibited 
significant up-regulation at 0 days post-LD in both treatment groups. However, Ccl3, Ccl4, 
and Il6 had significantly lower expression (P<0.05) in retinas injected with NR58-3.14.3 
compared to PBS-controls. C-D: By 7 days post-LD, up-regulation of all genes assessed 
was only 10-20% of that observed at 0 days, with no difference between NR58-3.14.3 and 
PBS injected groups (P>0.05). 0 days N=11-12 per group, 7 days N=5 per group. 
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levels of all genes were substantially upregulated immediately after bright light exposure 
(0 days) in both PBS- and NR58-3.14.3-injected animals (Figure 4.5A-B). However, 
expression levels of Ccl3, Ccl4, and Il6 were significantly less in NR58-3.14.3-injected 
compared to PBS-injected animals (Figure 4.5A-B; P<0.05). At 7 days post-light damage, 
expression levels of all cytokines/chemokines assessed had dropped by approximately 80-
90% (Figure 4.5C-D), and there was no difference between expression levels in the two 
treatment groups (P>0.05). 
4.4.6. Change in expression of inflammatory factors by macrophages following 
NR58-3.14.3 injection and light damage 
Microglia/macrophages were FACS-sorted from retinal suspensions for each 
treatment group on the basis of CD11b immunoreactivity (Figure 4.6A), which co-localises 
with IBA1 [261-263]. CD11b was preferred over IBA1 as a microglia/macrophage marker 
in this instance, because the intracellular staining required for IBA1 would prevent any 
downstream RNA analysis following FACS. We first sought to confirm whether the 
CD11b+ microglia/macrophages expressed Ccl- and Cxcl- chemokine receptors which 
correspond to the ligands up-regulated following light damage [87], as well as in AMD 
[47]. Using standard PCR (Figure 4.6B), CD11b+ microglia/macrophages from both 
treatment groups were found to express Ccr1, Ccr3, Ccr5, and Cxcr3 receptors. 
To further explore the role of microglia/macrophages in retinal inflammation we 
compared the expression of Ccl3, Ccl4, and Il6 in isolated CD11b+ microglia/macrophages 
from NR58-3.14.3-injected and PBS-injected groups using qPCR. These were chosen due 
to their differential expression in the whole-retina samples (shown in Figure 4.5) and the 
implicit roles of these genes in promoting pathogenic macrophage activity [93, 239]. After 
light damage, expression of Ccl3, Ccl4, and Il6 were significantly decreased in CD11b+ 
cells from NR58-3.14.3-injected retinas, compared to PBS control retinas (P<0.05,  
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Figure 4.6. Effect of NR58-3.14.3 on the pathogenic phenotype of the retinal macrophage 
population following light damage. A: Representative FACS plots, with gating strategies 
for the isolation of CD11b+ microglia/macrophages. Gating methodology was applied 
equally for all samples. B: Representative images of PCR products via electrophoresis for 
chemokine receptors Ccr1, Ccr2, Ccr5, Cxcr3, in samples of CD11b-sorted cells. Receptor 
expression was observed in both NR58-3.14.3 and PBS CD11b isolates. C: Following 
exposure to LD, expression of Ccl3, Ccl4, and Il6 were all decreased in CD11b+ 
microglia/macrophages isolated from NR58-3.14.3–injected retinas, compared to those 
from PBS injected retinas (P<0.05). N=5 per group at 0 days. 
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Figure 4.6C). In situ hybridisation for Ccl3 mRNA showed clusters of ramified microglia 
in the outer retina of PBS controls (Figure 4.7A-B arrows) following light damage, which 
were also immunoreactive for IBA1 (Figure 4.7E-F arrows). Ccl3-expressing macrophages 
were far less numerous in retinas from NR58-3.14.3-injected animals (Figure 4.7C-D 
arrows). 
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Figure 4.7. In situ hybridisation for Ccl3 mRNA following NR58-3.14.3 injections and 
light damage. A-B: At 0 days LD recovery in PBS-injected retinas, there was staining for 
Ccl3 mRNA (purple) in among clusters of irregularly shaped nuclei traversing the ONL 
(arrows). C-D: Retinas injected NR58-3.14.3, conversely, displayed very few Ccl3-
expressing nuclei. E-F: Ccl3-expressing nuclei (red, arrow) were correlated with 
immunofluorescence for IBA1+ macrophages/microglia (green, arrow). IHC, 
immunohistochemistry; ISH, in situ hybridisation; ONL, outer nuclear layer; OS, outer 
segments. Scale bars represent 50µm.  
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4.5. Discussion 
The findings of the current study demonstrate the efficiency of the broad spectrum 
chemokine inhibitor NR58-3.14.3 in modulating the pathogenic activity of 
macrophages/microglia and ameliorating photoreceptor death, in a model of photo-
oxidative damage and outer retinal inflammation. First, our data demonstrate that the 
intravitreal delivery of NR58-3.14.3 is tolerated within the retinal environment, and its 
persistence in the retina provides for a generous window of activity. Second, we show that 
injection of NR58-3.14.3 suppresses the chronic accumulation of macrophages/microglia 
within the photoreceptor layer and subretinal space following damage. Third, NR58-
3.14.3-treated macrophages demonstrated reduced pathogenic activation, indicated by 
decreased expression of Ccl3, Ccl4, and Il6. Finally, we show that photoreceptor 
degeneration is reduced across the time course of damage in retinas injected with NR58-
3.14.3, which is accompanied by an increase in photoreceptor survival at the site of focal 
and progressive atrophy. 
NR58-3.14.3 is thought to exert its inhibitory effect on Ccl- and Cxcl- families 
though disruption of intracellular signal transduction, which effectively renders leukocytes 
blind to directional cues provided by Ccl- and Cxcl- ligands [195, 264]. This broad 
suppression is desirable, as the blockade of singular chemokine ligands, such as Ccl2, can 
induce compensatory increases in the expression other chemokines which exacerbate 
retinal inflammation and degeneration [93, 185]. Up-regulation of Ccl2, Cxcl1, Cxcl10, 
Cxcl11 are present in all forms of AMD [47], and the Ccl2/Ccr2 axis is implicated in the 
pathogenic accumulation of macrophages to the outer retina in models that feature aspects 
of either CNV or geographic atrophy, such as light damage [3, 89, 91-93, 254]. Increases 
in ocular Ccl- and Cxcl- chemokines are also found in individuals affected by retinal 
detachment [265, 266], uveitis [267], glaucoma [268], diabetic retinopathy, and retinitis 
109 
 
pigmentosa [269], while blockade of Ccl2 signalling has proven beneficial in thwarting 
macrophage aggregation and cell death in experimental retinal detachment [245], diabetic 
retinopathy [183], and retinitis pigmentosa [184]. While the light damage paradigm does 
not model features of CNV or degenerations such as retinal detachment, our findings 
allude to the potential of BSCIs in targeting a broad swathe of chemokine activity across a 
spectrum of retinal degenerations.  
To our knowledge, this is the first study to examine the potential of BSCIs as a 
potential therapeutic agent in retinal disease. The findings from our study are consistent 
with previous investigations using NR58-3.14.3 in inflammatory models ranging from 
atherosclerotic plaques to obliterative bronchiolitis, wherein an inhibition of macrophage 
accumulation and amelioration of tissue damage were observed [189, 190, 192, 194, 195]. 
Our data own show that intravitreal NR58-3.14.3 reduces the accumulation of 
macrophages within the outer retina, including ONL and subretinal space. The proportion 
of these subretinal macrophages that are either resident microglia or recruited bone-
marrow derived monocytes is unclear, although the effect of intravitreal NR58-3.14.3 on 
these subpopulations is beyond the scope of this study. Nevertheless, we speculate that 
intravitreal NR58-3.14.3 could impact the infiltration of both subpopulations to the 
subretinal space, despite the local nature its administration. This is suggested by the 
localisation fluorescein-NR58-3.14.3 within the retinal vasculature, where blood borne 
monocytes are known to recruit into the retina following light-induced injury [185]. 
Additionally, as NR58-3.14.3 penetrates through to all layers of the retina, it may act on 
RPE and Müller cells, which are both known to secrete Ccl- and Cxcl- chemokines to 
recruit leukocytes to the site of injury [85, 87]. 
Our data indicate that NR58-3.14.3 modulates the transcriptional phenotype of 
macrophages following light damage. The expression of Ccl3, Ccl4, and Il6 were all down-
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regulated in macrophages exposed to NR58-3.14.3, and is consistent with the down 
regulation of Il6 observed in experimental obliterative bronchiolitis following 
administration of NR58-3.14.3 [190]. Ccl3, Ccl4, and Il6 are markers of M1 polarisation, 
which is typically associated with deleterious pro-inflammatory responses [113]. Although 
macrophage polarisation is considered a simplification of extremes which form part of a 
phenotypic spectrum, the suppression of these genes within the macrophage population in 
NR58-3.14.3 injected retinas do point toward a lower inflammatory state among these cells 
as a result. How NR58-3.14.3 elicits this transcriptional change is unclear, though we 
speculate it may occur via its inhibition of macrophage chemotaxis to the outer retina, 
wherein emergent photoreceptor death may stimulate up-regulation of cytokines such as 
Ccl3, Ccl4, and Il6. This is supported by our in situ hybridisation data, wherein Ccl4 
mRNA is expressed only in macrophages that have migrated to the outer retina. 
Several lines of evidence suggest that Ccl3, Ccl4, and Il6 are important mediators 
of pathogenic activity by macrophages in retinal degeneration, which may account for the 
neuroprotective action of NR58-3.14.3. Increased levels of Il6 are associated with the 
incidence and progression of AMD, and the cytokine is considered a potential therapeutic 
target [46, 96, 270]. A pathogenic role of Il6 is more recently highlighted by Levy and 
colleagues, who show that accumulation of the AMD biomarker apolipoprotein E (APOE) 
in subretinal macrophages up-regulates their expression of Il6, which in turn promotes 
their increased survival and induction of retinal pathology in light-damaged Cx3cr1−/− 
mice [239]. Additionally, a deleterious role of Il6 has been characterised in experimental 
ocular toxoplasmosis via antibody neutralisation, which considerably improved retinal 
morphology compared to controls [97].   
Ccl3 is implicated in animal models of AMD/Stargardt disease 
(Abca4−/−Rdh8−/−), retinitis pigmentosa (Mertk−/−) [93], and oxygen induced 
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retinopathy [94]. Ccl3 was expressed by macrophages/microglia as shown by Kohno and 
colleagues – consistent with our current investigation – and its ablation reduced the extent 
of photoreceptor degeneration in both aged Abca4−/−Rdh8−/− mice and young Mertk−/− 
mice [93]. In experimental oxygen induced retinopathy, mice were treated with the 
combination therapy of Ccl3 and Ccl2 neutralising antibodies, rather than a singular 
therapy. Regardless the neovascular pathology was reduced by 30% in these animals [94]. 
The precise role of Ccl4 in retinal degeneration has yet to be examined, although protein 
levels are increased in the aqueous humour of AMD patients [271], and its expression is 
up-regulated concomitantly with emergence of retinal degeneration in experimental light 
damage [87], diabetic retinopathy, and Abca4−/−Rdh8−/− and Mertk−/− mice [93]. 
Moreover, ablation of Ccl3 induced compensatory increases in Ccl4 expression in light-
damaged Abca4−/−Rdh8−/− mice, which was postulated to contribute to the increased 
pathology observed in this paradigm (rather than the age paradigm where there was 
protection). 
We speculate that NR58-3.14.3 may also confer retinal protection by inhibiting 
other macrophage processes, such as aberrant phagocytosis. This phenomenon has been 
recently demonstrated in the rd10 model of retinitis pigmentosa, in which infiltrating 
microglial cells were found to exacerbate cell death by phagocytosing non-apoptotic 
photoreceptors [116]. In suppressing the infiltration of macrophages within the outer 
retina, NR58-3.14.3 may also reduce the erratic phagocytosis of photoreceptors by 
activated macrophages. This may be a contributing factor to the increases in ONL 
thickness in NR58-3.14.3-injected retinas, however, additional investigations including 
longer-term and functional studies are required to firmly establish this in the future. 
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4.5.1. Conclusion 
Our findings showcase the efficacy of BSCIs such as NR58-3.14.3 in modulating 
macrophage/microglia responses in retinal degeneration. NR58-3.14.3 ameliorated the 
chronic aggregation of subretinal macrophages in light-induced subretinal inflammation, 
and suppressed their potentiation of Il6, Ccl3 and Ccl4 signalling. As with all current 
models, light damage does not encompass every aspect of AMD pathology; nevertheless 
our findings have implications for the treatment of inflammation in the disease. 
Chemokines are associated with the aggregation of subretinal macrophages in AMD, while 
expression of Il6, Ccl3 and Ccl4 are implicated in augmenting their survival and 
pathogenicity within the subretinal space. Together, these experiments offer proof-of-
principle for the potential of BSCIs as therapeutic agents in targeting subretinal 
inflammation in diseases such as AMD. 
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5. RESULTS 
 
Microglia-derived IL-1β promotes chemokine expression by 
Müller cells and RPE in focal retinal degeneration 
 
 
 
This chapter is presented as the following publication (* denotes equal first author): 
Natoli, R.*, Fernando, N.*, Madigan, M., Chu-Tan, J.A., Valter, K., Provis, J., Rutar, M. 
(2017) Microglia-derived IL-1β promotes chemokine expression by Müller cells and RPE 
in focal retinal degeneration. Molecular Neurodegeneration. 12:31 
The candidate has made a major contribution as a first author to this study (generating 50% 
of all data and preparing the manuscript for publication). 
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5.1. Abstract 
Background: Chemokine signalling is required for the homing of leukocytes during 
retinal inflammation, and is associated with pathogenesis of diseases such as age-related 
macular degeneration (AMD). Here, we explore the role of interleukin-1β (IL-1β) in 
modulating AMD-associated chemokines Ccl2, Cxcl1, and Cxcl10 during photo-oxidative 
retinal damage, and the effect on both the accumulation of outer-retinal macrophages, and 
death of photoreceptors.  
Methods: Inhibition of retinal IL-1β expression was performed using either siRNA or 
antibody neutralisation, which was intravitreally injected in SD rats prior to photo-
oxidative damage. Changes in the expression and localisation of Il-1β, Ccl2, Cxcl1 and 
Cxcl10 genes were assessed using qPCR and in situ hybridisation, while the recruitment of 
retinal macrophages was detected using immunohistochemistry for IBA1. Levels of 
photoreceptor cell death were determined using TUNEL. 
Results: Photo-oxidative damage elevated the expression of Il-1β and inflammasome-
related genes, and IL-1β protein was detected in microglia infiltrating the outer retina. This 
was associated with increased expression of Ccl2, Cxcl1, and Cxcl10. Intravitreal IL-1β 
inhibitors suppressed chemokine expression following damage and reduced macrophage 
accumulation and photoreceptor death. Moreover, in Müller and RPE cell cultures, and in 
vivo, Ccl2, Cxcl1 and Cxcl10 were variously upregulated when stimulated with IL-1β, with 
increased macrophage accumulation detected in vivo.  
Conclusions: IL-1β is produced by retinal microglia and macrophages and promotes 
chemokine expression by Müller cells and RPE in retinal degeneration. Targeting IL-1β 
may prove efficacious in broadly suppressing chemokine-mediated inflammation in retinal 
dystrophies such as AMD. 
115 
 
5.2. Background 
Inflammation plays a key role in the pathogenesis of age-related macular 
degeneration (AMD), which is the leading cause of blindness in the ageing population of 
the Western world [34]. One of the characteristics of atrophic or ‘dry’ AMD, is the 
accumulation of microglia/macrophages in the outer retina and subretinal space [4, 71-74]. 
Homing of leukocytes, such as macrophages, to sites of neuronal damage is orchestrated in 
part by the co-ordinated expression of chemokines (reviewed in [272]). The chemokine 
family consists of numerous ligands and receptors belonging to particular subclasses (such 
as Ccl- and Cxcl-), which act as guidance cues for leukocytes during homeostasis and 
injury [78]. Chemokine expression is prominent in many retinal degenerations, including 
AMD, wherein the up-regulation of genes encoding potent ligands such as Ccl2 and 
Cxcl10 is a characteristic of the disease [47]. The Ccl2-Ccr2 signalling axis has been well-
studied in relation to retinal disease, and genetic ablation or pharmacological inhibition of 
the ligand or receptor reduces pathology in laser-induced neovascularisation and photo-
oxidative damage models [84, 92, 238]. 
Our previous work has shown that RPE and Müller cells are the mediators of 
chemokine responses, and up-regulate the expression of Ccl2, Cxcl1 and Cxcl10 in 
response to damage [87]. Furthermore, pharmacological suppression of the Ccl- and Cxcl- 
signalling axes ameliorates subretinal macrophage infiltration and photoreceptor/RPE 
degeneration [228]. However, the factor/s that stimulate expression of these chemokines 
during retinal inflammation remain unclear. Recent in vitro studies indicate that cytokines 
such as Il-6 and Ccl2 may be stimulated in RPE or Müller cells when co-cultured with 
lipopolysaccharide (LPS)-stimulated microglia [86, 88], suggesting that similar 
interactions may promote chemokine expression by Müller cells and RPE during retinal 
degeneration.  
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 IL-1β is a pro-inflammatory cytokine whose maturation and secretion into the 
extracellular environment is mediated by assembly of the NLRP3 inflammasome 
(reviewed in [98-100]), and is associated with the progression of retinal pathologies 
including neovascular and atrophic AMD [111, 112]. Several studies have also indicated 
that IL-1β is secreted by microglia in photo-oxidative damage [113, 114], as well as in 
models of neovascular AMD [115], retinitis pigmentosa [116], and retinal detachment 
[117]. In this study, we tested the hypothesis that IL-1β promotes the up-regulation of 
chemokines in Müller cells and RPE, increasing outer-retinal macrophage accumulation 
and photoreceptor death, using a model of focal retinal degeneration. In this model, several 
inflammatory features observed in atrophic AMD are produced, including the expression 
of chemokines such as Ccl2, macrophage accumulation and outer retinal lesion 
development [85, 141, 209]. We find that inhibiting IL-1β, either via antibody 
neutralisation or targeted small interfering RNA (siRNA), suppresses the expression of 
RPE- and Müller cell-associated chemokines Ccl2, Cxcl1, and Cxcl10, reduces 
accumulation of macrophages in the outer retina, and mitigates photoreceptor death. We 
also find that IL-1β protein directly stimulates retinal chemokine up-regulation in vivo, and 
in cultured RPE and Müller cells. Targeting IL-1β as a therapeutic approach to reduce 
chemokine synthesis in the damaged retina may be beneficial in slowing the progression of 
retinal degenerations. 
 
5.3. Methods 
5.3.1. Animals and photo-oxidative damage 
All experiments were conducted in accordance with the ARVO Statement for Use 
of Animals in Ophthalmic and Vision Research, and had approval from the Australian 
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National University (ANU) Animal Experimentation Ethics Committee (Ethics ID: 
A2014/56). Adult Sprague-Dawley (SD) albino rats aged 90-120 days were used for all 
experiments. Animals were born and reared under dim light conditions (5 lux) prior to 
photo-oxidative damage. For the photo-oxidative damage paradigm, animals were placed 
into transparent Perspex open-top cages under a light source (COLD F2, 2x36W, IHF, 
Thorn Lighting, Australia) at 1000 lux for either 3, 6, 12, 17, or 24 hours (hrs), with access 
to food and water ad libitum. Following light exposure, animals were immediately 
euthanized using an overdose of barbiturate via an intraperitoneal injection (Valabarb; 
Virbac, NSW, Australia). For each animal, eyes were processed for either cryosectioning 
or RNA extraction, according to protocols detailed in our previous publications [141]. 
5.3.2. Intravitreal injections 
Intravitreal injections were performed as described in detail previously [273], 
wherein animals were anaesthetised using an intraperitoneal injection of ketamine 
(100mg/kg; Troy Laboratories, NSW, Australia) and xylazil (12mg/kg; Troy Laboratories). 
Injections consisted of either siRNA- or antibody-based IL-1β inhibitors, or IL-1β protein. 
 A neutralising antibody to IL-1β (Cat# AF-501-NA, R&D Systems, Minneapolis, 
MN) was administered intravitreally to rats immediately prior to photo-oxidative damage. 
A 3µL solution containing either anti-IL-1β or an isotype control antibody was injected 
into individual animals, which equated to a delivery of 0.6µg of antibody per eye. After 
intravitreal injections, the animals were immediately transferred to individual cages 
designed to allow light to enter unimpeded. Animals were exposed to photo-oxidative 
damage for 24hrs, during which corneal hydration was maintained though application of a 
synthetic tear gel (GenTeal Gel; Novartis, NSW, Australia) until the animals awoke.   
RNA-interference (RNAi) was conducted using Il-1β-specific siRNA (Cat# 
s127941; Thermo Fisher Scientific, Waltham, MA, USA), while a scrambled negative 
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siRNA (Cat# 12935300, Stealth RNAi Med GC; Thermo Fisher Scientific) served as a 
control, which were encapsulated using a cationic liposome-based formulation 
(Invivofectamine 3.0 Reagent; Thermo Fisher Scientific) according to the manufacturer’s 
instructions. To purify and concentrate the siRNA formulation, the samples were 
centrifuged at 4000g through an Amicon Ultra-4 Centrifugal Filter Unit (Merck Millipore, 
MA, USA). The final concentration of the encapsulated siRNA formulation was 1µg/µl in 
endotoxin-free 0.1M PBS. For injection, animals were anaesthetised in the same fashion as 
the antibody neutralisation series. 3µl of either Il-1β or negative siRNA was then 
intravitreally delivered to both eyes of each animal, which equated to a final dosage of 3µg 
siRNA per eye. Animals were then exposed to 24hrs photo-oxidative damage under the 
same parameters as the antibody neutralisation cohort. 
IL-1β protein was administered to rats following the same intravitreal methodology 
as described in the inhibition experiments. Recombinant IL-1β protein (Cat# AF-501-RL-
010, R&D Systems) was injected at final concentration of 10ng per eye, as established in a 
previous study [274]; injections with only the PBS vehicle served as controls. Animals 
were euthanized at 3, 6, or 12 days post-injection, with eyes then processed as described in 
the previous section.  
5.3.3. RPE and Müller cell cultures 
Immortalised human cell lines MIO-M1 (Müller 1 Mooreﬁelds Institute of 
Ophthalmology; Dr A. Limb, Institute of Ophthalmology, University College London) and 
ARPE-19 (ATCC CRL-2302, American Tissue Culture Collection, Manassas, VA) were 
used to study responses to IL-1β stimulation. Cell lines were authenticated by CellBank, 
Australia. The cells were grown in Dulbecco's Modified Eagle Medium (DMEM; Life 
Technologies, Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS; Life 
Technologies) and 3mM L-glutamine (Life Technologies), in a humidified atmosphere 
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consisting of 95% air and 5% CO2 at 37°C. The cells were passaged by trypsinization 
every 3 to 4 days. 
The MIO-M1 and ARPE-19 lines were incubated in IL-1β protein to assess its 
effect on their expression of chemokines. Cells were first seeded to a density of 1 × 105 
cells on 24-well plates and left to recover for at least 48hrs. 24hrs prior to experimentation, 
the cells were placed in serum-deficient DMEM containing 1% FBS. IL-1β protein (Cat# 
201-LB, R&D Systems) was then added to the culture medium at a concentrations of 
10ng/mL, as per previous literature [275, 276], and then incubated for 12hrs. The cells 
were then harvested for either RNA extraction and PCR, or an MTT assay to verify cell 
viability. RNA was extracted from each sample well using a retinal RNA extraction 
protocol that we have established previously [85], with slight modifications for cell culture. 
The MTT assay was performed with a kit supplied by Roche (Cell Proliferation Kit I, 
Roche Applied Science, Penzberg, Germany) following the supplied instructions. 
Following IL-1β stimulation, MTT reagent was added to the sample wells and left to 
incubate for 4hrs, after which a solution of 0.04M HCl in isopropanol was then added to 
each well to dissolve the resulting formazan crystals. The absorbance for each sample was 
then read at 570nm on a TECAN Infinite 200 PRO (TECAN Seestrasse, Männedorf, 
Switzerland), and quantified as a percentage relative to unstimulated culture samples. 
5.3.4. TUNEL and immunohistochemistry 
Retinal cryosections were stained for apoptotic cells using a terminal 
deoxynucleotidyl transferase dUTP nick end labelling (TUNEL) kit (Roche Applied 
Science) and following our previous methodology [255, 256]. To quantify photoreceptor 
cell death, TUNEL+ cells in the ONL were counted throughout the full length of each 
section cut in the parasagittal plane (supero-inferior). For each animal, technical duplicates 
were counted, and these counts were averaged for each experimental group. 
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Immunohistochemistry was performed on retinal cryosections according to 
previously described protocols, with minor modifications [87]. A list of primary antibodies 
used is provided in Table 5.1. Fluorescence in sections was captured using a laser-scanning 
A1+ confocal microscope (Nikon, Tokyo, Japan). Images were processed using Photoshop 
CS6 software (Adobe Systems, CA, USA). Immunolabelled IBA1+ 
microglia/macrophages were quantified across the full length of each section in the 
parasagittal plane (supero-inferior). The number of IBA1+ microglia/macrophages in the 
outer retina was quantified by counting the IBA1+ cells in the ONL and subretinal space. 
Table 5.1. Primary antibodies used for immunohistochemistry 
Primary Antibody Dilution Source 
Rabbit α-IBA1 (ionized binding 
calcium adaptor molecule 1) 
1:500 #019-19741, Wako Pure Chemical 
Industries, Osaka, Japan 
Goat α-IL-1β 1:500 #AF501, R&D Systems, Minneapolis, MN, 
USA 
Mouse α-Vimentin 1:100 #V6630, Sigma-Aldrich, St. Louis, MO, 
USA 
 
5.3.5.  Polymerase chain reaction (PCR) 
In preparation for quantitative real-time PCR (qPCR) and standard PCR, the RNA 
from retina or cell culture samples was synthesised into cDNA using a Tetro first-strand 
cDNA Synthesis Kit (Bioline Reagents, London, UK), as described in our previous 
investigation  [87]. 
qPCR was performed on cDNA samples using Taqman hydrolysis probes (Table 
5.2; Thermo Fisher Scientific), which were applied according to the manufacturer’s 
instructions with the Taqman Gene Expression Master Mix system (Thermo Fisher 
Scientific). The qPCR reactions were run on a QuantStudio Flex 12K instrument (Thermo 
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Fisher Scientific).  The resultant data were analysed according to the comparative cycle 
threshold (Ct) method (ΔΔCt), which was normalised to the expression of both Gapdh and 
Actb reference genes, as established in our previous analyses  [85, 144].  
Table 5.2. Taqman hydrolysis probes used for qPCR 
Gene 
Symbol 
Gene Name Catalog Number Entrez 
Gene ID 
Actb Actin, beta Rn00667869_m1 81822 
Casp1 Caspase 1 Rn00562724_m1 25166 
Casp8 Caspase 8 Rn00574069_m1 64044 
Ccl2 Chemokine (C-C) motif ligand 2 Rn01456716_g1 24770 
Cxcl1 Chemokine (C-X-C) motif ligand 1 Rn00578225_m1 81503 
Cxcl10 Chemokine (C-X-C) motif ligand 10 Rn01413889_g1 245920 
Gapdh Glyceraldehyde-3-phosphate 
dehydrogenase 
Rn99999916_s1 24383 
Il-1β Interleukin 1β Rn00580432_m1 24494 
Nlrp3 Nucleotide-binding domain, leucine-rich-
containing family, pyrin domain-
containing-3 
Rn04244620_m1 287362 
 
Standard PCR was conducted from cDNA synthesised from cells cultures or retinal 
homogenates, using primers specific to Il-1β receptor-related genes in human: Il-1r1 (F: 5’ 
ATCGTGATGAATGTGGCTGA 3’; R: 5’ TCTCATTAGCTGGGCTCACA 3’), Il-1rap 
(F: 5’ CGTTTCATCTCACCAGGACTC 3’; R: 5’ CCAAACCTCATTGCGAGAAT 3’), 
or rat: Il-1r1 (F: 5’ ACATTCGCAGCTGTCCTCTT 3’; R: 5’ 
TGTGCTCTTCAGCCACATTC 3’), Il-1rap (F: 5’ TCATACCGCCAAGGTACACA 3’; 
R: 5’ GGGCTCAGGACAACAATCAT 3’). The primers designed using the Primer3 web-
based design program [226]; both transverse an intron splice site to avoid genomic 
amplification. The PCR was performed using MyTaq DNA Polymerase (Bioline) as per 
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the manufacturer’s instructions, and the presence and specificity of the PCR product were 
inferred by gel electrophoresis. 
5.3.6. In situ hybridisation 
Ccl2 and Cxcl1 were cloned from PCR products (550-bp and 504-bp amplicons 
respectively) using cDNA synthesised from retinal RNA (as described above). 
Digoxigenin (DIG)-labelled riboprobes were then prepared as described in our previous 
publication  [87]. In situ hybridisation on retinal cryosections was carried out according to 
our established methodology [224]; briefly, each riboprobe was hybridised to sections 
overnight at 55˚C, then was washed in decreasing concentrations of saline sodium citrate 
(pH 7.4) at 60˚C. The bound probe was visualised with either NBT/BCIP or HNPP/Fast-
Red (Roche Applied Science). 
5.3.7. Quantitative and statistical analysis 
Graphing and statistical analysis for this study was performed using Prism 7 
(GraphPad Software, CA, USA). Statistical analysis was conducted using a Students t-test 
for instances of single comparisons. For assessing trends or multiple comparisons over 
protracted time-courses, a Kruskal–Wallis one-way analysis of variance (ANOVA) with 
Dunn’s multiple comparison post-test was applied, as per our previous investigation [87]. 
A P value of < 0.05 was considered statistically significant. 
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5.4. Results 
5.4.1. Expression of retinal IL-1β in relation to chemokine up-regulation and 
macrophage infiltration following photo-oxidative damage 
 Retinal expression of Il-1β and genes associated with inflammasome assembly and 
activation (Casp1, Casp8, and Nlrp3) were assessed by qPCR following 24hrs photo-
oxidative damage (Figure 5.1A). Il-1β was dramatically up-regulated after 24hrs photo-
oxidative damage, consistent with our prior reports [87], and in concert with expression of 
Casp1, Casp8, and Nlrp3 (P<0.05, Figure 5.1A). Immunoreactivity for IL-1β was not 
detected in dim-reared control retinas, but after photo-oxidative damage IL-1β 
immunoreactivity was evident on some ramified IBA1+ microglia/macrophages in the 
ONL and subretinal space (Figure 5.1B-C, yellow). IBA1+ cells located in the choroid did 
not exhibit IL-1β immunoreactivity (Figure 5.1C). 
Comparison of Il-1β expression with changes in retinal Ccl2, Cxcl1 and Cxcl10 
(Figure 5.1D) shows a correlation between Il-1β and chemokine expression. Over the 24hr 
time-course of photo-oxidative damage (3, 6, 12, 17, and 24hrs), Il-1β expression was 
markedly upregulated after 6hrs, and increasing Il-1β expression was associated with an 
upregulation of Ccl2, Cxcl1, and Cxcl10, with all markers reaching peak expression at 
24hrs (P<0.05; one-way ANOVA). Consistent with previous reports [85, 141] we also 
observed incursions of IBA1+ macrophages into the ONL and subretinal space by 24hrs of 
photo-oxidative damage (P<0.05, Figure 5.1E-G).  
5.4.2. Effect of IL-1β suppression on photoreceptor death, macrophage 
accumulation, and chemokine expression  
Inhibition of IL-1β and its effect on photo-oxidative retinal damage was ascertained using 
both siRNA and antibody neutralisation approaches (Figures 5.2 and 5.3). Intravitreal  
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Figure 5.1. Temporal relation of IL-1β to chemokine expression and macrophage 
infiltration following photo-oxidative damage (PD). A: After 24hrs of light exposure, a 
number of inflammasome activation markers were significantly upregulated (Casp1, 
Casp8, Nlrp3, P<0.05), in addition to Il-1β (P<0.05). B-C: Representative images show 
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immunoreactivity for IL-1β (red) in the outer retina following 24hrs of photo-oxidative 
damage, particularly in the ONL, subretinal space and RPE (B; arrows), and which co-
localised to IBA1+ microglia (green) (C; arrows). D: Up-regulation of IL-1β was 
documented over a 24hr time-course of photo-oxidative damage (P<0.05), which was 
found to align closely with up-regulation of Ccl2, Cxcl1 and Cxcl10 over the same period 
(P<0.05). E: A large increase in the number of IBA1-immunoreactive macrophages was 
quantified within the outer retina (ONL and subretinal space) following photo-oxidative 
damage (P<0.05) compared to dim-reared controls. F-G: Representative images showcase 
the infiltration of IBA1-immunolabelled macrophages (green) within the ONL and 
subretinal space (arrows) in retinal sections following photo-oxidative damage (G), in 
contrast to the absence of these cell in sections from dim-reared retinas (F). C, choroid; 
INL, inner nuclear layer; ONL, outer nuclear layer; OS, outer segments. N=4-6 per group. 
Asterisks denote a significant change, where P<0.05. Scale bars equate to 50µm. 
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injection of the Il-1β-specific siRNA induced a 1.8 fold reduction in the expression of 
retinal Il-1β at 24hrs photo-oxidative damage, compared to negative control siRNA 
(P<0.05, Figure 5.2A). Animals injected with Il-1β siRNA had ~60% fewer TUNEL+ 
photoreceptors 24hrs post-exposure to photo-oxidative damage compared to controls 
(P<0.05, Figure 5.2B). In experiments where IL-1β was neutralised using the antibody, 
injected intravitreally prior to photo-oxidative damage, there was an 80% reduction in the 
number of TUNEL+ photoreceptors in the retina, compared to those injected with an 
isotype antibody control (P<0.05, Figure 5.2C-E). Counts of IBA1+ macrophages confirm 
that inhibition of IL-1β with either siRNA or neutralising antibody reduces the number of 
IBA1+ macrophages in the outer retina (ONL and subretinal space), compared with the 
respective controls (P<0.05, Figure 5.2F-H). 
 We then sought to determine the effect of IL-1β suppression on the retinal 
expression of chemokines Ccl2, Cxcl1, and Cxcl10 (Figure 5.3A). In both modes of IL-1β 
inhibition, there was a significant reduction in the expression of Ccl2 and Cxcl1 compared 
to controls (P<0.05, Figure 5.3A). While Il-1β-specific siRNA did not modify expression 
of Cxcl10, antibody neutralisation of IL-1β was effective in reducing Cxcl10 expression 
(P<0.05). By use of in situ hybridisation, we also confirmed that Ccl2 mRNA was present 
in vimentin-immunoreactive Müller cell processes after 24hrs photo-oxidative damage 
(Figure 5.3D-E; arrows), and that Ccl2 mRNA labelling was reduced in IL-1β-inhibited 
retinas compared to controls (Figure 5.3B-C; arrows). Ccl2 mRNA was not detected in 
RPE cells (Figure 5.3B-C), consistent with our previous findings [85, 87]. We detected 
Cxcl1 mRNA labelling in the INL (Figure 5.3F; arrows) and RPE layer (Figure 5.3H; 
arrows) after photo-oxidative damage, which was reduced in retinas where IL-1β had been 
inhibited via neutralising antibody (Figure 5.3G, I). INL staining for Cxcl1 mRNA 
correlated with vimentin-immunoreactive Müller cells (Figure 5.3J-K; arrows), consistent 
with our previous report [87].  
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Figure 5.2. Effect of IL-1β inhibition on photoreceptor apoptosis and macrophage 
infiltration following photo-oxidative damage (PD). A: A significant knockdown of Il-1β 
expression in the retina was achieved in retinas injected with an Il-1β-specific siRNA, 
compared to the negative control siRNA group (P<0.05). B: The number of TUNEL+ cells 
in the ONL was reduced in Il-1β siRNA-injected retinas after photo-oxidative damage, 
compared to controls (P<0.05) C: A reduction in the number of TUNEL+ cells in the ONL 
was also documented in animals that had been intravitreally injected with an IL-1β 
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neutralising antibody prior to photo-oxidative damage, in comparison to an isotype control 
antibody (P<0.05). D-E: Representative images showcase a decrease in TUNEL+ profiles 
(red) in retinal section from the IL-1β neutralisation group (E), compared to a section from 
the isotype control group (D). F: The infiltration of IBA1-immunolabelled macrophages 
into the outer retina (ONL and subretinal space) following photo-oxidative damage was 
significantly decreased in animals injected with either Il-1β-specific siRNA or an IL-1β-
specific neutralising antibody, compared to their respective controls (P<0.05). G-H: 
Representative images of IBA1-immunolabelled macrophages demonstrate the reduction in 
IBA1+ cells in the outer retina in the IL-1β antibody neutralisation retinas compared to 
controls (green). INL, inner nuclear layer; ONL, outer nuclear layer. N=4-5 per group. 
Asterisks denote a significant change, where P<0.05. Scale bars equate to 25µm. 
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Figure 5.3. Effect of IL-1β inhibition on chemokine expression following photo-oxidative 
damage (PD). A: In animals that were intravitreally injected with Il-1β-specific siRNA, 
there was significantly lower expression of Ccl2 and Cxcl1 compared to control siRNA 
after photo-oxidative damage (P<0.05). In the group injected with IL-1β neutralising 
antibody however, the expression of Ccl2, Cxcl1 and Cxcl10 were all significantly down-
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regulated in comparison to the isotype control group (P<0.05). B-K: In situ hybridisation 
was used to examine the localisation of Ccl2 and Cxcl1 mRNA transcripts following IL-1β 
inhibition and photo-oxidative damage, as shown in representative images. Staining for 
Ccl2 mRNA (purple/red) was decreased in IL-1β antibody-injected retinas compared to 
control IgG retinas (B-C; arrows), and was co-localised to vimentin–immunoreactive 
Müller cells (green) (D-E; arrows). Staining for Cxcl1 mRNA was observed within INL (F-
G) and RPE layers (H-I), which was decreased in the IL-1β neutralising antibody group. 
The INL staining correlated with Müller cell processes that were immunolabelled with 
vimentin (J-K). INL, inner nuclear layer; ONL, outer nuclear layer; OS, outer segments. 
N=5 per group. Asterisks denote a significant change, where P<0.05. 
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5.4.3. Effect of IL-1β stimulation on chemokine expression in Müller and RPE cell 
cultures 
 The capacity for IL-1β to stimulate chemokine up-regulation in Müller cells and 
RPE cells was assessed in MIO-M1 and ARPE-19 cell cultures, respectively (Figure 5.4). 
Both cultures were incubated with 10ng/mL IL-1β protein for 12hrs, at which point we 
observed dramatic increases in the expression of Ccl2, Cxcl1 and Cxcl10 in MIO-M1 cells 
compared to unstimulated control wells (P<0.05, Figure 5.4A). To discount the possibility 
that the IL-1β-induced up-regulation of chemokines was a result of cell stress/death, we 
conducted an MTT assay on the cultures after IL-1β stimulation (Figure 5.4B). We 
determined that both cultures exhibited no reduction in viability as a result of IL-1β 
stimulation compared to controls (P>0.05). We also found that both MIO-M1 and ARPE-
19 cells express Il-1r1 and Il-1rap receptor genes necessary for IL-1β signal transduction 
(Figure 5.4C-D).  
5.4.4. Changes in chemokine expression and macrophage infiltration following 
intravitreal delivery of IL-1β protein 
Finally, we investigated the effect of IL-1β protein administered intravitreally on 
the expression of chemokines and the accumulation of macrophages over a 24hr period 
(Figure 5.5). The data show a broad up-regulation of retinal Ccl2, Cxcl1, and Cxcl10 
(Figure 5.5A), up to 24hrs post-injection compared to PBS-injected controls. This was 
particularly evident for Cxcl1, which by 6 hrs-post-injection increased ~22 fold (P<0.05), 
although was somewhat reduced by 12 and 24hrs. The localisation and number of IBA1+ 
macrophages at 24hrs after the injection of IL-1β protein (Figure 5.5B-F) demonstrated a 
significant increase in the total number of retinal macrophages present compared to the 
PBS-control group (P<0.05; Figure 5.5B). IBA1+ cells were observed predominantly in 
the GCL and optic nerve head (Figure 5.5E-F; arrows), and comprised a population with a  
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Figure 5.4. Chemokine expression in RPE and Müller cell cultures stimulated with IL-1β. 
A: MIO-M1 and ARPE-19 cells were incubated with IL-1β protein for 12hrs, after which 
MIO-M1 cultures were found to up-regulate expression of Ccl2, Cxcl1 and Cxcl10 
(P<0.05), while ARPE-19 cells had significantly increased expression of Cxcl1 and Cxcl10 
(P<0.05), compared to unstimulated controls. B: MTT assays were conducted on MIO-M1 
and ARPE-19 cultures, which showed no difference in cell viability between IL-1β and 
control groups. C-D: Representative images of Il-1r1 and Il-rap PCR products indicate 
that MIO-M1 and ARPE-19 express the receptor genes necessary for Il-1β signal 
transduction. N=5 per group. Asterisks denote a significant change, where P<0.05. 
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Figure 5.5. Change in retinal chemokine expression and macrophage infiltration in retinas 
following intravitreal injection of IL-1β protein. A: Injection of IL-1β protein increased the 
expression of Ccl2, Cxcl1 and Cxcl10 in retinas over a time-course of 6, 12, and 24hrs 
post-injection, compared to PBS-injected controls (P<0.05). B: There was a significant 
increase in the number of IBA1+ cells throughout retinal sections in the IL-1β group at 
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24hrs post-injection, compared to the PBS control group (P<0.05). C-F: Representative 
images of IBA1-immunolabelled retinal sections show increased clusters of IBA1+ 
macrophages amongst the GCL and optic nerve head of the IL-1β-injected group (E-F; 
arrows) compared to PBS controls (C-D). G-H: Representative images show positive 
expression of PCR products for Il-1r1 and Il-rap in control rat retinas. GCL, ganglion cell 
layer; INL, inner nuclear layer; ONL, outer nuclear layer. N=3-6 per group. Asterisks 
denote a significant change, where P<0.05. Scale bars equate to 50µm. 
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rounded (activated) rather than ramified (resting) morphology. PCR conducted on isolates 
of control rat retinal tissue confirmed the presence of Il-1r1 and Il-1rap genes (Figure 
5.5G-H). 
 
5.5. Discussion 
 These findings describe for the first time a key role for IL-1β in mediating the 
accumulation of outer-retinal macrophages by modulating the expression of chemokines by 
Müller cells and RPE. First, we demonstrate that Il-1β is up-regulated in concert with the 
Müller and RPE cell-expressed chemokines (Ccl2, Cxcl1 and Cxcl10), and with the influx 
of macrophages into the outer retina following photo-oxidative damage. Second, we 
showed that therapeutic suppression of retinal IL-1β using either siRNA or antibody 
neutralisation curtails chemokine expression, accumulation of outer-retinal macrophages 
and photoreceptor degeneration. Finally, we show that Müller and RPE cell cultures up-
regulate Ccl2 (Müller cells only), Cxcl1 and Cxcl10 in response to IL-1β stimulation, and 
that intravitreal delivery of IL-1β induces up-regulation of these same chemokines in the 
retina, coinciding with increases in the population of retinal macrophages. The data from 
this study supports the use of IL-1β inhibition strategies as a therapeutic approach to 
reduce chemokine synthesis, and subsequent macrophage accumulation and photoreceptor 
death in retinal degenerations. 
Previous studies using injections of recombinant IL-1ra, an endogenous antagonist 
for IL-1r1, have suggested a role for IL-1β in propagating retinal degeneration, using 
models of photo-oxidative damage in Cx3cr1-deficient mice [114, 277], laser-induced 
CNV [115], and retinitis pigmentosa [116]. However, a short-coming of that approach is 
that IL-1ra does not suppress IL-1β signalling specifically, as the inflammatory cytokine 
136 
 
IL-1α also competes for binding and is equally as effective in activating Il-1r1 as IL-1β 
[98, 278, 279]. In this study, we have used Il-1β-specific siRNA, as well as IL-1β antibody 
inhibition methodologies to target IL-1β directly, circumventing any possibility of off-
target inhibition of IL-1α-mediated signalling. Our data clearly show that decreased IL-1β 
correlates with decreased chemokine production by RPE and Müller cells, reduced 
macrophage recruitment and increased photoreceptor survivability. Excluding the effect of 
IL-1α signalling is an important consideration, as IL-1α released from dying cells promotes 
sterile inflammation and leukocyte recruitment [279, 280], and ablation of IL-1α alleviates 
inflammation in myocardial infarction [281]. Moreover, our previous microarray analysis 
(gene expression omnibus GSE22818) indicates that IL-1α is up-regulated following 
photo-oxidative damage [141].  
Our previous investigations have indicated that RPE and Müller cells are 
potentiators of Ccl- and Cxcl- expression during photo-oxidative damage [85-87]. Several 
of these chemokines, including CCL2, CXCL1 and CXCL10 are involved in leukocyte 
recruitment in CNS diseases and in retinal degeneration [84, 85, 87, 272]. The significance 
of the expression of such chemokines is underscored by our finding that the broad 
spectrum chemokine inhibitor NR58-3.14.3 – a suppressor of Ccl- and Cxcl- signalling – 
ameliorates macrophage recruitment and photoreceptor degeneration resulting from photo-
oxidative damage [228]. The involvement of IL-1β signalling in chemokine expression 
shown in the current study is consistent with its known influence outside the retina, 
including its ability to induce CCL2 in pancreatic β-cells [282, 283], and spur up-
regulation of CXCL1 in intestinal tissue during infection with Clostridium difficile [284]. 
Precisely how IL-1β induces the up-regulation of chemokines in RPE and Müller cells is 
uncertain, though it has been demonstrated in pancreatic β-cells that IL-1β signalling 
mediates nuclear localisation of the transcription factor NF-κB, which then promote the 
expression of chemokines such as CCL2 [285]. 
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While the data generated in these investigations was generally consistent between 
the IL-1β inhibition strategies employed, it is noted that expression of Cxcl10 was not 
inhibited by Il-1β siRNA, in contrast to the findings using antibody neutralisation. This 
difference may be due to delayed efficacy of the siRNA resulting from the time required 
for adequate transfection and mRNA suppression. Consistent with this idea, comparison of 
the data indicate that the neutralising antibody had a more potent effect on Ccl2 and Cxcl1 
expression compared with siRNA. However, given the reduction in macrophage infiltration 
identified in both treatment groups (siRNA and antibody), despite the discordant 
suppression of Cxcl10, it is possible that Cxcl10 does not play a crucial role in macrophage 
recruitment in the retina compared to Ccl2 and Cxcl1. While indeed plausible, other studies 
have shown that CXCL10 specifically elicits macrophage recruitment in experimental 
nonalcoholic steatohepatitis [286], and is also implicated in macrophage infiltration in 
kidney during puromycin aminonucleoside nephrosis [287]. 
Though our investigation focused on the effect of IL-1β on expression of 
RPE/Müller cell-associated chemokines and macrophage recruitment, the potential 
contribution of other leukocyte populations should not be overlooked. Peripheral 
neutrophils and T-cells, as well as macrophages, express the receptors for CXCL1 and 
CXCL10 [288-291]. These leukocyte populations are poorly characterised in sterile retinal 
inflammation, although are understood to comprise a small proportion amongst the 
predominantly macrophage-led response in AMD and models such as photo-oxidative 
damage [3, 170]. Nonetheless, the contribution of these cell types to pathology in sterile 
retinal inflammation is unclear, and identifies neutrophils and T-cells as candidates for 
investigation in future studies. 
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5.5.1. Conclusions 
 Our study identifies a key role for IL-1β in orchestrating the infiltration of 
macrophages to the outer retina, by inducing the up-regulation of chemokines in RPE and 
Müller cells following retinal damage. Moreover, we confirm the potential of specific IL-
1β inhibitors in dampening inflammation and ameliorating photoreceptor degeneration. 
Consequently, their application may have value in the treatment of retinal dystrophies in 
which chemokine expression and subretinal macrophage accumulation are implicated, such 
as AMD. 
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6. SUMMARY 
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 These studies collectively build upon previous findings in our research group that 
C3 is expressed by macrophages in models of retinal degeneration and ageing [141, 144] 
as well as the finding that Ccl2 siRNA reduces macrophage recruitment in the retina [89]. 
This thesis presents data which strongly indicates that retinal microglia and macrophages 
contribute to photoreceptor degeneration, and have a sustained effect on atrophic lesion 
development in the degenerating retina. This supports the use of therapeutic molecules to 
target inflammatory activation by retinal microglia and macrophages, as a strategy for 
slowing the progression of retinal degenerative diseases. 
 The work described in this thesis provides a deeper understanding of how microglia 
and macrophages propagate the inflammatory response in retinal degeneration. First, it is 
demonstrated that microglia and macrophages play a critical role in activating complement, 
leading to increased photoreceptor loss and further accumulation of inflammatory cells in 
the damaged retina [292]. It is shown, in both human atrophic age-related macular 
degeneration (AMD) and in rodent photo-oxidative damage, that complement component 3 
(C3), a central component of the complement system, is synthesised and deposited in the 
photoreceptor layer by retinal microglia and macrophages. Using intravitreally-delivered 
C3 siRNA to inhibit retinal sources of C3, it is demonstrated that locally-derived C3, not 
systemic C3, contributes to the onset of retinal degeneration implicating complement-
expressing retinal microglia and macrophages in prolonged disease progression. 
 The findings from Chapter 3 using C3 siRNA demonstrates a potential role for 
gene therapies to knockdown the expression of specific inflammatory genes, particularly 
C3. The strong association between polymorphisms in complement genes, and the 
prevalence of AMD gives further weight to the potential use of gene therapies to combat 
retinal diseases. Using locally-delivered C3 siRNA via lipid-based transfection, we 
demonstrated that C3 expression in the retina was knocked down efficiently. However, the 
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delivery of siRNA to the retina may only be for a short duration, as other research from our 
group suggests it may be cleared within 3-4 days of delivery. Gene therapies that exert a 
prolonged effect within the retina are therefore warranted, such as the use of vectors 
including AAV2, which have proven useful in the treatment of Leber Congenital 
Amaurosis (RPE65 mutation) [310]. The use of clustered, regularly interspaced, short 
palindromic repeat (CRISPR)/Cas9 technology (reviewed in [293]) would allow sustained 
C3 knockout to occur within the retina, and has been performed in several models of 
retinal disease [294-296]. Most recently, one group demonstrated the use of Vegfa Cas9 
ribonucleoproteins (RNPs) in a choroidal neovascularisation (CNV) model of wet AMD to 
reduce Vegfa-associated retinal damage [297, 298]. Alternatively, conditional ablation of 
C3 from retinal microglia using Cre-loxP could be useful in further determining the 
contribution of the local microglia/macrophages to complement activation in retinal 
degeneration. Utilisation of these technologies may lead to valuable insights into the 
reduction of deleterious complement gene activation in AMD. 
Second, the work highlights the therapeutic potential of broad spectrum chemokine 
inhibition as a strategy to prevent retinal degeneration [228]. It was demonstrated that an 
intravitreal injection of NR58-3.14.3 reduced the recruitment of microglia and 
macrophages into the outer retina, and ameliorated photoreceptor cell death in rodent 
photo-oxidative damage. This indicates its potential for the treatment of retinal 
degenerations such as atrophic AMD, where chemokine secretion and macrophage 
recruitment to the outer retina are key features of disease progression. This study also 
shows that targeting chemokine production to inhibit macrophage recruitment and activity 
may be an optimal therapeutic strategy for slowing the progression of retinal degeneration. 
Third, it has been shown that the pro-inflammatory cytokine interleukin-1β (IL-1β) 
plays a key role in contributing to retinal degeneration in rodent photo-oxidative damage 
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[299]. This study shows that retinal microglia and macrophages are the primary expressers 
of IL-1β, promoting the expression of chemokines by Müller cells and RPE, leading to the 
further recruitment of macrophages to the degenerating retina. This study also 
demonstrates the value of targeting cell signalling mechanisms upstream of complement, 
further highlighting the key roles of microglia and macrophages in retinal degeneration. 
Here we demonstrate that Il-1β knockdown is also an effective method for reducing 
chemokine-mediated macrophage recruitment in the retina. However, the inflammasome 
signalling pathway is largely responsible for Il-1β production, which is primarily expressed 
by macrophage cells [100]. The role of the NLRP3 inflammasome has been controversial 
in the literature, with research suggesting that blocking NLRP3 inflammasome activation is 
beneficial in dry AMD [103], but detrimental in wet AMD [106]. Current work in our 
research group is being undertaken to understand the role of the NLRP3 inflammasome in 
the photo-oxidative damage model. Additionally, as we have shown that gene therapies to 
target Il-1β and inflammasome activation may be useful, our research group is focused on 
the use of microRNAs (miRNAs), ‘master gene regulators’ [300], to regulate inflammation 
in retinal degeneration [301]. By identifying miRNAs that may regulate Il-1β and 
inflammasome signalling [302-305] in the retina, this may lead to the development of 
novel gene therapies to target macrophage-derived inflammation in retinal degeneration. 
 The next critical question, beyond the scope of the studies reported here is do 
retinal microglia and blood-borne macrophages contribute similarly to the progression of 
retinal degeneration? A limitation of the studies presented in this thesis is that thus far it 
has not been possible to differentiate these two cell populations. However, two recent 
advances now make this distinction possible. First, studies indicate that a TMEM119 
antibody is able to differentiate resident microglia from blood-borne macrophages in the 
brain, using flow cytometry and immunohistochemistry [306-308]. Second, a fate mapping 
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technique to endogenously label the two cell types with fluorescent reporters can 
distinguish cells as either resident or recruited, using tamoxifen-inducible Cre 
recombinases [120], and suggests that these populations are phenotypically distinguishable 
by a specific set of markers. Characterising the inflammatory profiles of these two separate 
populations will assist in understanding how microglia and macrophages each contribute to 
pro-inflammatory cytokine production, complement activation and photoreceptor cell 
death. This will allow for further development of therapeutic interventions for retinal 
diseases including AMD.  
 The photo-oxidative damage model recapitulates many features of atrophic AMD, 
including oxidative stress, pro-inflammatory cytokine production, the recruitment of 
microglia and macrophages, the synthesis of complement system components and the 
progression of an expanding photoreceptor lesion. However, further investigation to 
identify the translational potential of the therapeutic molecules described in this thesis is 
warranted, using additional models that reproduce other features of AMD not modelled in 
photo-oxidative damage including the CEP model [63, 68, 69] and the laser-induced CNV 
model [196, 197]. Additionally, a model of early AMD, such as ageing, could be used to 
further investigate the thickening of Bruch’s membrane, drusen and RPE disruption. 
 This thesis provides further understanding of the role of microglia and 
macrophages in amplifying the inflammatory response and their contribution to the 
progression of retinal degeneration. It also demonstrates that the inhibition of factors that 
drive the recruitment of these cells into the degenerating retina reduces their accumulation 
and ameliorates photoreceptor damage. Further studies that delineate resident microglia 
and blood-borne macrophages to elucidate their individual contributions will be valuable in 
developing more effective therapeutic strategies to manage photoreceptor loss in AMD. 
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